chembl_id,drug_name,SMILES,from_protein,from_pathway,from_moa,protein_row_indices,pathway_row_indices,moa_row_indices,phase,status,gene_symbols,pathways,pathway_ids,mechanisms,disease_ids,disease_names,support_sources_count,n_genes,n_pathways,n_moas
CHEMBL1000,CETIRIZINE,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,True,True,False,977,6607,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL1004,DOXYLAMINE,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,True,True,False,1034,6664,,3.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0002017,Nausea and vomiting,2,1,1,0
CHEMBL1005,REMIFENTANIL,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,True,True,False,325,295;1329;7242,,3.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL1008,BEPRIDIL,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,True,False,False,1905;2489,,,4.0,,CACNA1A;CACNA2D1,,,,EFO_0000319,cardiovascular disease,1,2,0,0
CHEMBL101,PHENYLBUTAZONE,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,True,True,True,127;921,350;4468;5561;5621;5677;6061;6135;6209;6283;6357;6431,142,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL101253,VATALANIB,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,True,True,False,1125;1165,570;6982;7023;7516,,3.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0004288,colonic neoplasm,2,2,3,0
CHEMBL1014,CANDESARTAN CILEXETIL,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,True,True,True,584,6538;7157;7268;7288,4,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000400,diabetes mellitus,3,1,4,1
CHEMBL1016,CANDESARTAN,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,True,True,True,591,6545;7164;7275;7295,5,3.0,Unknown status,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000266,aortic stenosis,3,1,4,1
CHEMBL1017,TELMISARTAN,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,True,True,True,585,6539;7158;7269;7289,6,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000400,diabetes mellitus,3,1,4,1
CHEMBL1020,TOLMETIN,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1,True,True,False,141;922,364;4482;5562;5622;5691;6075;6149;6223;6297;6371;6445,,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005755,rheumatic disease,2,2,10,0
CHEMBL1021,NEPAFENAC,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,True,True,True,118;902,341;4459;5542;5602;5668;6052;6126;6200;6274;6348;6422,127,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL10316,IDAZOXAN,c1ccc2c(c1)OCC(C1=NCCN1)O2,True,True,False,1346;1399;2546,917;970;1021;1074;1125;1177;1230;1409;1462;1513,,3.0,Withdrawn,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,MONDO_0002009,major depressive disorder,2,3,6,0
CHEMBL1034,DICLOFENAC SODIUM,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],True,True,True,96;893,319;4437;5533;5593;5646;6030;6104;6178;6252;6326;6400,103,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL103667,DORAMAPIMOD,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,False,False,True,,,89,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1040,CALCIFEDIOL ANHYDROUS,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12,True,True,False,246,5999;7776;7894,,3.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,,EFO_0000612,myocardial infarction,2,1,3,0
CHEMBL1042,CHOLECALCIFEROL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12,True,True,True,240,5993;7770;7888,7,4.0,Recruiting,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0003882,osteoporosis,3,1,3,1
CHEMBL1046,AMINOCAPROIC ACID,NCCCCCC(=O)O,True,True,True,683,76;107;134;457,723,4.0,Unknown status,PLG,Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Platelet degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-114608;R-HSA-1474228;R-HSA-1592389;R-HSA-381426,Plasminogen inhibitor,MP_0001914,hemorrhage,3,1,4,1
CHEMBL105060,DNK333,CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1,False,False,True,,,529,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL1059,PREGABALIN,CC(C)C[C@H](CN)CC(=O)O,True,False,False,2491,,,4.0,Completed,CACNA2D1,,,,EFO_0000474,epilepsy,1,1,0,0
CHEMBL1064,SIMVASTATIN,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,True,True,True,735,7614;7629;7644;7659,44,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL1069,VALSARTAN,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,True,True,True,578,6532;7151;7262;7282,8,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL107,COLCHICINE,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,True,True,True,821;1554;1989;2228;2333;2397;2704;2768;2832,1534;1598;1662;1726;1790;1854;1918;2083;2147;2211;2275;2339;2403;2467;2531;2595;2659;2723;2787;2851;2915;2979;3049;3113;3177;3241;3305;3369;3433;3497;3561;3652;3716;3780;3844;3908;3972;4039,39,4.0,Completed;Recruiting,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0004274,gout,3,9,38,1
CHEMBL1070,NABUMETONE,COc1ccc2cc(CCC(C)=O)ccc2c1,True,True,False,97,320;4438;5647;6031;6105;6179;6253;6327;6401,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL1071,OXAPROZIN,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,True,True,True,107;894,330;4448;5534;5594;5657;6041;6115;6189;6263;6337;6411,151,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL107430,NRX195183,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl,True,False,False,1769,,,2.0,Withdrawn,RARA,,,,EFO_0000224,acute promyelocytic leukemia,1,1,0,0
CHEMBL1076263,SETROBUVIR,CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2,False,False,True,,,430,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL1076903,VARENICLINE,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,True,True,False,435;2131,7915;7929;7943,,4.0,Terminated,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0003768,nicotine dependence,2,2,3,0
CHEMBL1077,BROMFENAC,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,True,True,False,123;908,346;4464;5548;5608;5673;6057;6131;6205;6279;6353;6427,,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005752,eye inflammation,2,2,10,0
CHEMBL1078178,MOMELOTINIB,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,True,True,True,768;792,193;217;655;679;4245;4424;4565;4589;4644;4668;4723;4747;4792;4830;4854;4899;4923;4965;4989;5031;5055;5099;5141;5165;5219;5269;5307;5331;5373;5397;5467;6920;6944;7478;8307;8335;8363;8397;8425;8453,476,3.0,Completed,JAK1;JAK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,EFO_0002430,primary myelofibrosis,3,2,27,1
CHEMBL1079,TIZANIDINE,Clc1ccc2nsnc2c1NC1=NCCN1,True,True,False,1347;1398;2545,918;969;1022;1073;1126;1178;1229;1410;1461;1514,,3.0,Completed,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,HP_0003419,Low back pain,2,3,6,0
CHEMBL1082407,ENZALUTAMIDE,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,True,True,True,543,1966;5881;7785,79,4.0,Unknown status,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000196,metastatic prostate cancer,3,1,3,1
CHEMBL1082462,DBPR-108,CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N,True,False,True,674,,535,3.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL1083385,CLOPIDOGREL BISULFATE,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O,True,True,False,464,1349,,4.0,,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0000556,ischemia,2,1,1,0
CHEMBL1088750,ARRY-797,CC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(C(=O)NCCN(C)C)cc21,False,False,True,,,92,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1088751,PH-797804,CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,False,False,True,,,109,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1088752,LOSMAPIMOD,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,False,False,True,,,110,,,,,,MAP kinase p38 alpha inhibitor | MAP kinase p38 beta inhibitor,,,1,0,0,1
CHEMBL1089636,ANG1005,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,True,True,False,838;1573;2008;2244;2349;2413;2724;2784;2848,1551;1615;1679;1743;1807;1871;1935;2100;2164;2228;2292;2356;2420;2484;2548;2612;2676;2740;2804;2868;2932;2996;3066;3130;3194;3258;3322;3386;3450;3514;3578;3669;3733;3797;3861;3925;3989;4056,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000519,glioblastoma multiforme,2,9,38,0
CHEMBL1090089,PAMAPIMOD,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21,False,False,True,,,107,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1090090,VX-702,NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,False,False,True,,,108,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1090173,SD-0006,O=C(CO)N1CCC(c2n[nH]c(-c3ccc(Cl)cc3)c2-c2ccncn2)CC1,False,False,True,,,93,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1091,HYDROCORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,21,713;2022;5937;7841;7978;8044;8115;8181;8247,199,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1092581,NESBUVIR,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(CCO)S(C)(=O)=O)c(C3CC3)cc12,False,False,True,,,431,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL1094,FELBAMATE,NC(=O)OCC(COC(N)=O)c1ccccc1,True,True,True,703;1602;1948;2175;2596;2639;2665,3609;6793;6820;6847;6880;7038;7065;7092;7119,391,4.0,,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,EFO_0000474,epilepsy,3,7,9,1
CHEMBL109480,TANESPIMYCIN,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,False,False,True,,,578,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL1095032,LETAXABAN,O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1,True,True,True,463,7543;7572,467,2.0,Completed,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,Coagulation factor X inhibitor,EFO_0005672,acute coronary syndrome,3,1,2,1
CHEMBL1096,AMLEXANOX,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1,True,True,True,414;1048;1075;2152,4326;5736;5765;5792;5831;5859,598,4.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,HP_0006536,Airway obstruction,3,4,3,1
CHEMBL1096380,PLINABULIN,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,True,True,True,830;1563;2000;2239;2342;2406;2713;2777;2842,1543;1607;1671;1735;1799;1863;1927;2092;2156;2220;2284;2348;2412;2476;2540;2604;2668;2732;2796;2860;2924;2988;3058;3122;3186;3250;3314;3378;3442;3506;3570;3661;3725;3789;3853;3917;3981;4048,61,3.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0003060,non-small cell lung carcinoma,3,9,38,1
CHEMBL109648,CLAZOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO,True,False,False,1920,,,3.0,Terminated,EDNRA,,,,EFO_0000713,subarachnoid hemorrhage,1,1,0,0
CHEMBL1097279,CANGRELOR TETRASODIUM,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(Cl)(Cl)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Na+].[Na+].[Na+].[Na+],True,True,False,465,1350,,4.0,,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0000612,myocardial infarction,2,1,1,0
CHEMBL11,IMIPRAMINE,CN(C)CCCN1c2ccccc2CCc2ccccc21,True,False,False,1252,,,4.0,Terminated,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL1106,EPINASTINE,NC1=NCC2c3ccccc3Cc3ccccc3N12,True,True,False,967,6597,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL1108,DROPERIDOL,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,False,False,True,,,660,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1111,AMBRISENTAN,COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,True,False,False,1911,,,4.0,,EDNRA,,,,EFO_0000537,hypertension,1,1,0,0
CHEMBL1112,ARIPIPRAZOLE,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,False,False,True,,,681,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1113,AMOXAPINE,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,True,False,False,1255,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL111659,ALTINICLINE,C#Cc1cncc([C@@H]2CCCN2C)c1,False,False,True,,,530,,,,,,Neuronal acetylcholine receptor; alpha4/beta2 agonist,,,1,0,0,2
CHEMBL1118,DESVENLAFAXINE,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,True,False,False,1253,,,4.0,Completed,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL112,ACETAMINOPHEN,CC(=O)Nc1ccc(O)cc1,True,True,True,119;687;690;903,342;4460;5543;5603;5669;5716;6053;6127;6201;6275;6349;6423,101,4.0,,FAAH;PTGS1;PTGS2;TRPV1,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX);TRP channels,R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-3295583;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Anandamide amidohydrolase inhibitor | Cyclooxygenase inhibitor | Vanilloid receptor opener,EFO_0003843,pain,3,4,11,1
CHEMBL1120,BISMUTH SUBSALICYLATE,N/A,True,True,True,149;931,372;4490;5571;5631;5699;6083;6157;6231;6305;6379;6453,128,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,HP_0002018,Nausea,3,2,10,1
CHEMBL1131,ACITRETIN,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,True,True,False,183;1765;1891,5985;6011;6020,,4.0,,RARA;RARB;RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,,EFO_0000676,psoriasis,2,3,3,0
CHEMBL1136,TELITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,False,False,True,,,298,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL114,SAQUINAVIR,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,False,False,True,,,386,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL1144,PRAVASTATIN,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,True,True,False,730,7609;7624;7639;7654,,4.0,Completed,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL1152,PREDNISOLONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,43,735;2044;5959;7863;8000;8066;8137;8203;8269,220,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0007141,allergic conjunctivitis,3,1,9,1
CHEMBL1159650,CLOBETASOL PROPIONATE,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,19,711;2020;5935;7839;7976;8042;8113;8179;8245,171,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000676,psoriasis,3,1,9,1
CHEMBL116,AMPRENAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,False,False,True,,,387,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL1161,MOMETASONE FUROATE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,True,True,True,28,720;2029;5944;7848;7985;8051;8122;8188;8254,200,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1162175,REGRELOR,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21,True,True,False,475,1360,,2.0,Terminated,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0001645,coronary artery disease,2,1,1,0
CHEMBL1165,MOEXIPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O,True,True,False,637,433,,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL1168,RAMIPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,True,True,True,638,434,368,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL1170,TESTOSTERONE PROPIONATE,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,True,True,False,574,1997;5912;7816,,1.0,Suspended,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_1001271,Atrophic Vaginitis,2,1,3,0
CHEMBL1171837,PONATINIB,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,True,True,False,1210;2206,4301,,3.0,"Active, not recruiting;Recruiting",ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000220,acute lymphoblastic leukemia,2,2,1,0
CHEMBL1172,DESLORATADINE,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,True,True,False,964,6594,,4.0,Terminated,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005531,urticaria,2,1,1,0
CHEMBL1175,DULOXETINE,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,True,False,False,1285,,,3.0,Completed,SLC6A4,,,,EFO_0003843,pain,1,1,0,0
CHEMBL118,CELECOXIB,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,True,True,False,95,318;4436;5645;6029;6103;6177;6251;6325;6399,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000616,neoplasm,2,1,9,0
CHEMBL1186579,METHYLNALTREXONE,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,True,True,False,326,296;1330;7243,,3.0,Withdrawn,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0002618,pancreatic carcinoma,2,1,3,0
CHEMBL1189432,OLOPATADINE,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,True,True,False,978,6608,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL1193,PHENIRAMINE,CN(C)CCC(c1ccccc1)c1ccccn1,True,True,False,984,6614,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL119385,NEFLAMAPIMOD,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,False,False,True,,,104,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1195136,SNX 5422,CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1,False,False,True,,,583,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL1197051,ISOXSUPRINE,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1,True,True,False,402;1502;1862,865;6527;6727,,2.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000319,cardiovascular disease,2,3,3,0
CHEMBL12,DIAZEPAM,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,True,False,True,477;1412;1629;1675;2041;2087;2445,,239,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000474,epilepsy,2,7,0,2
CHEMBL1200322,ESCITALOPRAM OXALATE,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,True,False,False,1251,,,4.0,,SLC6A4,,,,EFO_0006788,anxiety disorder,1,1,0,0
CHEMBL1200323,LABETALOL HYDROCHLORIDE,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl,True,True,False,373;1316;1366;1476;1835;2514,836;887;937;991;1041;1095;1147;1197;1379;1429;1483;6498;6698,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,6,8,0
CHEMBL1200328,DULOXETINE HYDROCHLORIDE,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl,True,False,False,1246,,,4.0,,SLC6A4,,,,EFO_0002970,muscular disease,1,1,0,0
CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,Cl.Clc1ccc2nsnc2c1NC1=NCCN1,True,True,False,1335;1387;2535,906;958;1010;1062;1114;1166;1218;1398;1450;1502,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,HP_0001257,Spasticity,2,3,6,0
CHEMBL1200332,PROTRIPTYLINE HYDROCHLORIDE,CNCCCC1c2ccccc2C=Cc2ccccc21.Cl,True,False,False,1281,,,4.0,,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL1200335,TESTOSTERONE ENANTHATE,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,True,True,False,547,1970;5885;7789,,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL1200339,PHENYLEPHRINE HYDROCHLORIDE,CNC[C@H](O)c1cccc(O)c1.Cl,True,True,False,386;1482;1842,849;6511;6711,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0003956;EFO_0005251;EFO_0006834,hypotension;seasonal allergic rhinitis;septic shock,2,3,3,0
CHEMBL1200342,PARAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,False,False,True,,,180,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200343,PERINDOPRIL ERBUMINE,CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,True,True,True,649,445,375,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000537,hypertension,3,1,1,1
CHEMBL1200376,BETAMETHASONE BENZOATE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccccc1)C(=O)CO,False,False,True,,,206,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200384,BETAMETHASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,14,706;2015;5930;7834;7971;8037;8108;8174;8240,181,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000544,infection,3,1,9,1
CHEMBL1200386,PREDNICARBATE,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,22,714;2023;5938;7842;7979;8045;8116;8182;8248,182,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1200392,DOXYLAMINE SUCCINATE,CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O,True,True,False,1035,6665,,3.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0002017,Nausea and vomiting,2,1,1,0
CHEMBL1200395,ORPHENADRINE CITRATE,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,True,True,705;953;1604;1950;2177;2598;2641;2667,3611;6583;6795;6822;6849;6882;7040;7067;7094;7121,376,4.0,,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;HRH1,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;G alpha (q) signalling events;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-416476;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,EFO_0003843,pain,3,8,10,1
CHEMBL1200406,DIMENHYDRINATE,CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O,True,True,False,1014,6644,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,Cl.c1ccc2c(c1)CCCC2C1=NCCN1,True,True,False,397;1341;1394;1499;1857;2540,860;912;965;1016;1069;1120;1172;1225;1404;1457;1508;6522;6722,,3.0,Unknown status,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000678,pterygium,2,6,8,0
CHEMBL1200419,MOLINDONE HYDROCHLORIDE,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl,False,False,True,,,684,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1200420,MIDAZOLAM HYDROCHLORIDE,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.Cl,True,False,True,503;1431;1656;1702;2063;2106;2470,,269,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_1001454,amnesia,2,7,0,2
CHEMBL1200430,ESTRADIOL ACETATE,CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,True,False,False,2292,,,4.0,,ESR1,,,,EFO_1000096,Atrophy,1,1,0,0
CHEMBL1200434,OXTRIPHYLLINE,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O,True,True,True,416;1047;1077;2153,4328;5738;5764;5794;5833;5861,606,4.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,HP_0006536,Airway obstruction,3,4,3,1
CHEMBL1200436,OXANDROLONE,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,True,True,False,558,1981;5896;7800,,3.0,Withdrawn,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000546,injury,2,1,3,0
CHEMBL1200449,TRIAMCINOLONE DIACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](OC(C)=O)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,False,False,True,,,207,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200461,MIDODRINE HYDROCHLORIDE,COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl,True,True,False,399;1501;1859,862;6524;6724,,3.0,Terminated,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0006834,septic shock,2,3,3,0
CHEMBL1200463,OXAPROZIN POTASSIUM,O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+],False,False,True,,,129,,,,,,Cyclooxygenase inhibitor,,,1,0,0,1
CHEMBL1200467,HYDROXYZINE PAMOATE,O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,True,True,False,952,6582,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000701,skin disease,2,1,1,0
CHEMBL1200469,PROMAZINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2Sc2ccccc21.Cl,False,False,True,,,665,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1200472,QUAZEPAM,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,True,False,True,495;1427;1638;1694;2045;2102;2462,,270,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004698,insomnia,2,7,0,2
CHEMBL1200474,DEMECLOCYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12.Cl,False,False,True,,,304,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200485,SORAFENIB TOSYLATE,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,True,True,False,1103;1152,557;6969;7001;7503,,4.0,,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000681,renal cell carcinoma,2,2,3,0
CHEMBL1200491,EPINASTINE HYDROCHLORIDE,Cl.NC1=NCC2c3ccccc3Cc3ccccc3N12,True,True,False,982,6612,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0007141,allergic conjunctivitis,2,1,1,0
CHEMBL1200492,NEFAZODONE HYDROCHLORIDE,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl,True,False,True,1278,,685,4.0,,SLC6A4,,,Serotonin 2a (5-HT2a) receptor antagonist,MONDO_0002009,major depressive disorder,2,1,0,1
CHEMBL1200494,GUANFACINE HYDROCHLORIDE,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,True,True,False,1314;1367;2516,885;938;989;1042;1093;1145;1198;1377;1430;1481,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,3,6,0
CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+],True,True,True,45,737;2046;5961;7865;8002;8068;8139;8205;8271,183,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,MONDO_0004979,asthma,3,1,9,1
CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,True,True,True,40,732;2041;5956;7860;7997;8063;8134;8200;8266,184,4.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0003956,seasonal allergic rhinitis,3,1,9,1
CHEMBL1200506,ERYTHROMYCIN LACTOBIONATE,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,False,False,True,,,305,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200510,ERYTHROMYCIN STEARATE,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,False,False,True,,,306,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200531,ALFENTANIL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl,False,False,True,,,626,,,,,,Mu opioid receptor agonist,,,1,0,0,1
CHEMBL1200534,MOEXIPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl,True,True,True,650,446,377,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000537,hypertension,3,1,1,1
CHEMBL1200538,BETAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,32,724;2033;5948;7852;7989;8055;8126;8192;8258,185,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000729,ulcerative colitis,3,1,9,1
CHEMBL1200542,DESOXYCORTICOSTERONE ACETATE,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,False,False,True,,,359,,,,,,Mineralocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200543,ANILERIDINE PHOSPHATE,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.O=P(O)(O)O,False,False,True,,,640,,,,,,Mu opioid receptor agonist,,,1,0,0,1
CHEMBL1200545,DIFLORASONE DIACETATE,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,23,715;2024;5939;7843;7980;8046;8117;8183;8249,186,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1200561,DOXAZOSIN MESYLATE,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O,True,True,False,357;1450;1819,820;6482;6682,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,3,3,0
CHEMBL1200562,HYDROCORTISONE VALERATE,CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,False,False,True,,,208,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200563,CERIVASTATIN SODIUM,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c1-c1ccc(F)cc1.[Na+],False,False,True,,,22,,,,,,HMG-CoA reductase inhibitor,,,1,0,0,1
CHEMBL1200578,THEOPHYLLINE SODIUM GLYCINATE,Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCC(=O)[O-].[Na+],False,False,True,,,607,,,,,,Phosphodiesterase 4 inhibitor,,,1,0,0,1
CHEMBL1200588,CLINDAMYCIN HYDROCHLORIDE,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1.Cl,False,False,True,,,307,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200592,DESOXYCORTICOSTERONE PIVALATE,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,False,False,True,,,360,,,,,,Mineralocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200598,DIETHYLSTILBESTROL DIPHOSPHATE,CC/C(=C(/CC)c1ccc(OP(=O)(O)O)cc1)c1ccc(OP(=O)(O)O)cc1,True,False,False,2282,,,4.0,,ESR1,,,,EFO_0000616,neoplasm,1,1,0,0
CHEMBL1200599,DIFENOXIN HYDROCHLORIDE,Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1,False,False,True,,,627,,,,,,Mu opioid receptor agonist,,,1,0,0,1
CHEMBL1200600,FLUOROMETHOLONE,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,35,727;2036;5951;7855;7992;8058;8129;8195;8261,187,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0003894,acne,3,1,9,1
CHEMBL1200609,PAROXETINE MESYLATE,CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,True,False,False,1237,,,4.0,,SLC6A4,,,,EFO_0001358,post-traumatic stress disorder,1,1,0,0
CHEMBL1200613,TOLMETIN SODIUM,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+],True,True,True,109;896,332;4450;5536;5596;5659;6043;6117;6191;6265;6339;6413,130,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL1200617,RIMEXOLONE,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,36,728;2037;5952;7856;7993;8059;8130;8196;8262,226,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0005752,eye inflammation,3,1,9,1
CHEMBL1200618,FEXOFENADINE HYDROCHLORIDE,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl,True,True,False,955,6585,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1200622,PARICALCITOL,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C,True,True,True,241,5994;7771;7889,23,4.0,Terminated,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0003884,chronic kidney disease,3,1,3,1
CHEMBL1200632,CLINDAMYCIN PALMITATE HYDROCHLORIDE,CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl)O[C@@H]1SC.Cl,False,False,True,,,308,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200635,HYDROCORTAMATE HYDROCHLORIDE,CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C.Cl,False,False,True,,,188,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200636,CYCLOBENZAPRINE HYDROCHLORIDE,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21.Cl,False,False,True,,,686,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1200638,DEXBROMPHENIRAMINE MALEATE,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,True,True,False,974,6604,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1200644,FONDAPARINUX SODIUM,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],True,True,False,168,140;7546;7575;7597,,4.0,,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0000612,myocardial infarction,2,1,4,0
CHEMBL1200649,QUINUPRISTIN,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,False,False,True,,,323,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200659,ENALAPRIL MALEATE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O,True,True,True,646,442,378,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000373,congestive heart failure,3,1,1,1
CHEMBL1200665,DIPHENOXYLATE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl,True,True,True,333,303;1337;7250,641,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0000304,breast adenocarcinoma,3,1,3,1
CHEMBL1200666,CALCIPOTRIENE,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,239,5992;7769;7887,24,4.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000676,psoriasis,3,1,3,1
CHEMBL1200675,TOREMIFENE CITRATE,CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,False,False,2276,,,4.0,,ESR1,,,,EFO_0000305,breast carcinoma,1,1,0,0
CHEMBL1200678,ATAZANAVIR SULFATE,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C.O=S(=O)(O)O,False,False,True,,,417,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL1200681,MONTELUKAST SODIUM,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],True,True,False,1229,619;6576,,4.0,,CYSLTR1,G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-416476;R-HSA-9679191,,EFO_0005854,allergic rhinitis,2,1,2,0
CHEMBL1200688,ERYTHROMYCIN ETHYLSUCCINATE,CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,False,False,True,,,324,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200689,NITRIC OXIDE,[N]=O,True,True,True,74,7690,227,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000684,respiratory system disease,3,1,1,1
CHEMBL1200692,OLMESARTAN MEDOXOMIL,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,True,True,True,579,6533;7152;7263;7283,13,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL1200694,SEVOFLURANE,FCOC(C(F)(F)F)C(F)(F)F,True,True,True,509;524;527;532;537;540;1404;1438;1523;1662;1708;1749;1782;1803;1876;1937;2069;2115;2476;2562;2585;2633,0;3;6;9;12;17;22;7724;7729;7904,271,3.0,Completed;Not yet recruiting,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;KCNK10;KCNK18;KCNK2;KCNK3;KCNK9,Neurotransmitter receptors and postsynaptic signal transmission;Phase 4 - resting membrane potential;TWIK related potassium channel (TREK);TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-112314;R-HSA-1299316;R-HSA-1299503;R-HSA-5576886,GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,EFO_0000694,severe acute respiratory syndrome,3,22,4,2
CHEMBL1200699,DOXYCYCLINE,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,True,True,True,609;614;620;627,25;31;38;43;49;55;62;67;80;86;93;98;111;125;230;3027,325,4.0,,MMP1;MMP13;MMP7;MMP8,Activation of Matrix Metalloproteinases;Basigin interactions;Collagen degradation;Degradation of the extracellular matrix;Interleukin-4 and Interleukin-13 signaling;Neutrophil degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1442490;R-HSA-1474228;R-HSA-1592389;R-HSA-381426;R-HSA-6785807;R-HSA-6798695,Bacterial 70S ribosome inhibitor | Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 7 inhibitor | Matrix metalloproteinase 8 inhibitor | Matrix metalloproteinase-1 inhibitor,DOID_7551,gonorrhea,3,4,7,1
CHEMBL1200703,CHLORDIAZEPOXIDE HYDROCHLORIDE,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1.Cl,False,False,True,,,251,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL1200710,CLOMIPRAMINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21.Cl,True,False,False,1243,,,4.0,,SLC6A4,,,,EFO_0004242,obsessive-compulsive disorder,1,1,0,0
CHEMBL1200729,CHLORAMPHENICOL SODIUM SUCCINATE,O=C([O-])CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1.[Na+],False,False,True,,,309,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200732,AMCINONIDE,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,False,False,True,,,209,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200733,DESFLURANE,FC(F)OC(F)C(F)(F)F,True,True,True,521;526;529;534;539;542;1406;1446;1531;1671;1719;1758;1788;1807;1880;1943;2080;2126;2485;2566;2593;2637,2;5;8;11;14;19;24;7726;7731;7906,272,2.0,Completed,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;KCNK10;KCNK18;KCNK2;KCNK3;KCNK9,Neurotransmitter receptors and postsynaptic signal transmission;Phase 4 - resting membrane potential;TWIK related potassium channel (TREK);TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-112314;R-HSA-1299316;R-HSA-1299503;R-HSA-5576886,GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,EFO_1002048,kidney failure,3,22,4,2
CHEMBL1200734,FOSAMPRENAVIR CALCIUM,CC(C)CN(C[C@@H](OP(=O)([O-])[O-])[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1.[Ca+2],False,False,True,,,395,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL1200750,PROMETHAZINE HYDROCHLORIDE,CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl,True,True,False,950,6580,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000274,atopic eczema,2,1,1,0
CHEMBL1200760,BALSALAZIDE DISODIUM,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+],True,True,True,105;892,328;4446;5532;5592;5655;6039;6113;6187;6261;6335;6409,131,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000729,ulcerative colitis,3,2,10,1
CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],True,True,True,33,725;2034;5949;7853;7990;8056;8127;8193;8259,189,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000729,ulcerative colitis,3,1,9,1
CHEMBL1200774,FLUPREDNISOLONE,C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,False,False,True,,,210,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200781,CITALOPRAM HYDROBROMIDE,Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,True,False,False,1256,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl,True,True,True,363;1307;1351;1456;1826;2498,826;878;922;982;1026;1086;1138;1182;1370;1414;1474;6488;6688,459,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,Adrenergic receptor alpha antagonist,EFO_0000239,adrenal gland pheochromocytoma,3,6,8,1
CHEMBL1200790,METHYPRYLON,CCC1(CC)C(=O)NCC(C)C1=O,False,False,True,,,273,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl,True,True,False,387;1323;1376;1489;1844;2522,850;894;947;998;1051;1102;1154;1207;1386;1439;1490;6512;6712,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0003956;EFO_0007214,common cold;seasonal allergic rhinitis,2,6,8,0
CHEMBL1200794,OXYMORPHONE HYDROCHLORIDE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,True,True,False,274,244;1278;7191,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1200795,CLEMASTINE FUMARATE,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O,True,True,False,956,6586,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1200798,TRAZODONE HYDROCHLORIDE,Cl.O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,True,False,True,1257,,687,4.0,,SLC6A4,,,Serotonin 2a (5-HT2a) receptor antagonist,MONDO_0002009,major depressive disorder,2,1,0,1
CHEMBL1200802,TALBUTAL,C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O,False,False,True,,,274,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL1200804,DICLOFENAC POTASSIUM,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],True,True,True,98;885,321;4439;5525;5585;5648;6032;6106;6180;6254;6328;6402,132,4.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL1200806,NAPROXEN SODIUM,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],True,True,True,110;897,333;4451;5537;5597;5660;6044;6118;6192;6266;6340;6414,111,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL1200809,AZELASTINE HYDROCHLORIDE,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,True,True,False,972,6602,,4.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005854,allergic rhinitis,2,1,1,0
CHEMBL1200810,DOXERCALCIFEROL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,243,5996;7773;7891,25,4.0,,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0003884,chronic kidney disease,3,1,3,1
CHEMBL1200817,LEVOMETHADYL ACETATE HYDROCHLORIDE,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1.Cl,False,False,True,,,642,,,,,,Mu opioid receptor agonist,,,1,0,0,1
CHEMBL1200825,METHADONE HYDROCHLORIDE,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl,True,True,True,275,245;1279;7192,643,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1200826,LITHIUM CARBONATE,O=C([O-])[O-].[Li+].[Li+],True,True,False,1178;1225,5492;5495;5500;5503;5506;5511;5514;5517;8089,,4.0,,GSK3A;GSK3B,AKT phosphorylates targets in the cytosol;Constitutive Signaling by AKT1 E17K in Cancer;Maturation of nucleoprotein;Regulation of RUNX2 expression and activity;Suppression of apoptosis;XBP1(S) activates chaperone genes,R-HSA-198323;R-HSA-381038;R-HSA-5674400;R-HSA-8939902;R-HSA-9635465;R-HSA-9683610,,EFO_0009963,bipolar I disorder,2,2,6,0
CHEMBL1200831,SPIRAPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2.Cl,False,False,True,,,379,,,,,,Angiotensin-converting enzyme inhibitor,,,1,0,0,1
CHEMBL1200845,HALCINONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1,True,True,True,29,721;2030;5945;7849;7986;8052;8123;8189;8255,172,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1200865,LOTEPREDNOL ETABONATE,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,39,731;2040;5955;7859;7996;8062;8133;8199;8265,190,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0007141,allergic conjunctivitis,3,1,9,1
CHEMBL1200873,PHENTOLAMINE MESYLATE,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,True,True,True,364;1299;1352;1457;1811;2506,827;870;923;974;1027;1078;1130;1183;1362;1415;1466;6489;6689,460,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,Adrenergic receptor alpha antagonist,EFO_0000239,adrenal gland pheochromocytoma,3,6,8,1
CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl,True,True,True,412;1045;1073;2150,4324;5734;5762;5790;5829;5857,608,4.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0003830;EFO_0003901,dysuria;prostatitis,3,4,3,1
CHEMBL1200877,FLUMETHASONE PIVALATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,False,False,True,,,191,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,True,True,True,46,738;2047;5962;7866;8003;8069;8140;8206;8272,211,4.0,Unknown status,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,MONDO_0005178,osteoarthritis,3,1,9,1
CHEMBL1200881,MINOCYCLINE HYDROCHLORIDE,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl,False,False,True,,,326,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200890,OXYCODONE HYDROCHLORIDE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,True,True,True,276,246;1280;7193,644,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1200901,HALOFANTRINE HYDROCHLORIDE,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12.Cl,False,False,True,,,432,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL1200903,SECOBARBITAL SODIUM,C=CCC1(C(C)CCC)C(=O)[N-]C(=O)NC1=O.[Na+],False,False,True,,,275,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL1200908,HALOBETASOL PROPIONATE,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,20,712;2021;5936;7840;7977;8043;8114;8180;8246,192,4.0,Terminated,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000676,psoriasis,3,1,9,1
CHEMBL1200909,PREDNISOLONE TEBUTATE,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,False,False,True,,,193,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200914,TAMSULOSIN HYDROCHLORIDE,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl,True,True,False,345;1451;1809,808;6470;6670,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,3,3,0
CHEMBL1200916,THIORIDAZINE HYDROCHLORIDE,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2.Cl,False,False,True,,,666,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1200927,DEXCHLORPHENIRAMINE MALEATE,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,True,True,False,966,6596,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005532,angioedema,2,1,1,0
CHEMBL1200937,DALFOPRISTIN,CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12,False,False,True,,,310,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1200946,NANDROLONE DECANOATE,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,True,True,False,568,1991;5906;7810,,2.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0003964,hip fracture,2,1,3,0
CHEMBL1200948,TRIMIPRAMINE MALEATE,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21.O=C(O)/C=C\C(=O)O,False,False,True,,,699,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1200952,METHAMPHETAMINE HYDROCHLORIDE,CN[C@@H](C)Cc1ccccc1.Cl,True,False,False,1240,,,4.0,,SLC6A4,,,,EFO_0003888,attention deficit hyperactivity disorder,1,1,0,0
CHEMBL1200953,HYDROCORTISONE PROBUTATE,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,24,716;2025;5940;7844;7981;8047;8118;8184;8250,228,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1200959,METHDILAZINE,CN1CCC(CN2c3ccccc3Sc3ccccc32)C1,True,True,False,995,6625,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1200961,BROMPHENIRAMINE MALEATE,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,True,True,False,957,6587,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1200964,AMITRIPTYLINE HYDROCHLORIDE,CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl,True,False,False,1279,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL1200968,HYDROCORTISONE SODIUM PHOSPHATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],False,False,True,,,194,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200974,CARBINOXAMINE MALEATE,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,True,True,False,975,6605,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1200975,CLOCORTOLONE PIVALATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,False,False,True,,,212,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1200980,ESTROPIPATE,C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O,True,False,False,2288,,,4.0,,ESR1,,,,EFO_0004266,primary ovarian insufficiency,1,1,0,0
CHEMBL1200982,BUTABARBITAL SODIUM,CCC(C)C1(CC)C(=O)[N-]C(=O)NC1=O.[Na+],False,False,True,,,276,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL1200986,HALOPERIDOL DECANOATE,CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,False,False,True,,,700,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1200987,EPROSARTAN MESYLATE,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O,True,True,True,587,6541;7160;7271;7291,14,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000537,hypertension,3,1,4,1
CHEMBL1200988,METHANTHELINE BROMIDE,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21.[Br-],True,True,True,754,5823,726,1.0,Completed,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,HP_0000011,Neurogenic bladder,3,1,1,1
CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl,True,True,True,25,717;2026;5941;7845;7982;8048;8119;8185;8251,213,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1201,THIOTHIXENE,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,False,False,True,,,697,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1201006,PYRILAMINE MALEATE,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1.O=C(O)/C=C\C(=O)O,True,True,False,958,6588,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1201010,FLUDROCORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,False,False,True,,,361,,,,,,Mineralocorticoid receptor agonist,,,1,0,0,1
CHEMBL1201011,QUINAPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.Cl,True,True,True,648,444,380,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000400,diabetes mellitus,3,1,1,1
CHEMBL1201012,FLURANDRENOLIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,True,True,True,30,722;2031;5946;7850;7987;8053;8124;8190;8256,229,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1201013,OLSALAZINE SODIUM,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+],True,True,True,106;901,329;4447;5541;5601;5656;6040;6114;6188;6262;6336;6410,133,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000729,ulcerative colitis,3,2,10,1
CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],True,True,True,8,700;2009;5924;7828;7965;8031;8102;8168;8234,214,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000341,chronic obstructive pulmonary disease,3,1,9,1
CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl,True,True,True,710;1013;1612;1955;2182;2602;2651;2675,3616;6643;6800;6827;6854;6887;7045;7072;7099;7126,396,4.0,,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;HRH1,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;G alpha (q) signalling events;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-416476;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,MONDO_0005180,Parkinson disease,3,8,10,1
CHEMBL1201044,DAPIPRAZOLE HYDROCHLORIDE,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl,True,True,False,378,841;6503;6703,,4.0,,ADRA1A,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0004190,open-angle glaucoma,2,1,3,0
CHEMBL1201047,ANILERIDINE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.Cl,False,False,True,,,645,,,,,,Mu opioid receptor agonist,,,1,0,0,1
CHEMBL1201051,CIMETIDINE HYDROCHLORIDE,CN/C(=N\CCSCc1nc[nH]c1C)NC#N.Cl,False,False,True,,,727,,,,,,Histamine H2 receptor antagonist,,,1,0,0,1
CHEMBL1201052,MESORIDAZINE BESYLATE,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21.O=S(=O)(O)c1ccccc1,False,False,True,,,688,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1201060,LOXAPINE HYDROCHLORIDE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.Cl,False,False,True,,,667,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1201064,FLUOROMETHOLONE ACETATE,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,False,False,True,,,215,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL1201065,THIAMYLAL SODIUM,C=CCC1(C(C)CCC)C(=O)[N-]C(=S)NC1=O.[Na+],False,False,True,,,277,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL1201066,VENLAFAXINE HYDROCHLORIDE,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.Cl,True,False,False,1250,,,4.0,,SLC6A4,,,,EFO_0004262,panic disorder,1,1,0,0
CHEMBL1201071,TETRACYCLINE PHOSPHATE COMPLEX,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.O=P(O)(O)O,False,False,True,,,327,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+],True,True,True,16,708;2017;5932;7836;7973;8039;8110;8176;8242,195,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000574,lymphoma,3,1,9,1
CHEMBL1201082,FLUOXETINE HYDROCHLORIDE,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl,True,False,False,1244,,,4.0,,SLC6A4,,,,EFO_0004242,obsessive-compulsive disorder,1,1,0,0
CHEMBL1201089,DIPHENHYDRAMINE CITRATE,CN(C)CCOC(c1ccccc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,True,False,1036,6666,,3.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005277,migraine disorder,2,1,1,0
CHEMBL1201099,CODEINE PHOSPHATE,N/A,True,True,False,299,269;1303;7216,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003890,drug dependence,2,1,3,0
CHEMBL1201101,TESTOSTERONE CYPIONATE,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,True,True,False,548,1971;5886;7790,,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL1201103,METHOXAMINE HYDROCHLORIDE,COc1ccc(OC)c(C(O)C(C)N)c1.Cl,True,True,False,404;1505;1863,867;6529;6729,,2.0,Completed,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0009523,fecal incontinence,2,3,3,0
CHEMBL1201109,DESONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,True,True,True,0,692;2001;5916;7820;7957;8023;8094;8160;8226,196,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL1201120,REMIFENTANIL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1.Cl,False,False,True,,,646,,,,,,Mu opioid receptor agonist,,,1,0,0,1
CHEMBL1201124,KETOROLAC TROMETHAMINE,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,True,True,True,137;904,360;4478;5544;5604;5687;6071;6145;6219;6293;6367;6441,134,4.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL1201127,DARUNAVIR ETHANOLATE,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1.CCO,False,False,True,,,418,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL1201132,NALBUPHINE HYDROCHLORIDE,Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,True,True,False,277,247;1281;7194,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1201141,IBUPROFEN LYSINE,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O,True,True,True,150;930,373;4491;5570;5630;5700;6084;6158;6232;6306;6380;6454,156,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,HP_0001643,Patent ductus arteriosus,3,2,10,1
CHEMBL1201148,MEPREDNISONE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,True,True,True,62,754;2063;5978;7882;8019;8085;8156;8222;8288,216,2.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000756,melanoma,3,1,9,1
CHEMBL1201149,NALTREXONE HYDROCHLORIDE,Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,True,True,False,278,248;1282;7195,,4.0,Terminated,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1201155,LOXAPINE SUCCINATE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.O=C(O)CCC(=O)O,False,False,True,,,668,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1201156,NORTRIPTYLINE HYDROCHLORIDE,CNCCC=C1c2ccccc2CCc2ccccc21.Cl,True,False,False,1258,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL1201159,FENTANYL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl,True,True,True,330,300;1334;7247,647,3.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1201163,SUFENTANIL CITRATE,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,True,True,279,249;1283;7196,648,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1201167,CARVEDILOL PHOSPHATE,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O,True,True,False,372;1477;1837,835;6497;6697,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000537,hypertension,2,3,3,0
CHEMBL1201173,MEDRYSONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,True,True,True,37,729;2038;5953;7857;7994;8060;8131;8197;8263,173,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0005752,eye inflammation,3,1,9,1
CHEMBL1201174,SITAGLIPTIN PHOSPHATE,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O,True,False,True,660,,518,4.0,,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0000612,myocardial infarction,2,1,0,1
CHEMBL1201180,DICLOFENAC EPOLAMINE,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1,True,True,True,120;917,343;4461;5557;5617;5670;6054;6128;6202;6276;6350;6424,112,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL1201187,MARAVIROC,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,True,True,False,214,1256;4373;6755;6779,,4.0,Completed,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000180,HIV-1 infection,2,1,4,0
CHEMBL1201190,LEVOCETIRIZINE DIHYDROCHLORIDE,Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,True,True,False,951,6581,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000701,skin disease,2,1,1,0
CHEMBL1201191,LEVOCETIRIZINE,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,True,True,False,996,6626,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1201201,METHAMPHETAMINE,CN[C@@H](C)Cc1ccccc1,True,False,False,1242,,,4.0,,SLC6A4,,,,EFO_0003888,attention deficit hyperactivity disorder,1,1,0,0
CHEMBL1201202,FONDAPARINUX,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,True,True,False,171,143;7549;7578;7600,,4.0,,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,HP_0004419,Recurrent thrombophlebitis,2,1,4,0
CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,True,True,False,56,748;2057;5972;7876;8013;8079;8150;8216;8282,,3.0,Terminated,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_1001097,periarthritis,2,1,9,0
CHEMBL1201212,MIDODRINE,COc1ccc(OC)c(C(O)CNC(=O)CN)c1,True,True,False,349;1466;1827,812;6474;6674,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000319,cardiovascular disease,2,3,3,0
CHEMBL1201216,DAPIPRAZOLE,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1,True,True,False,393,856;6518;6718,,4.0,,ADRA1A,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,MONDO_0005041,glaucoma,2,1,3,0
CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,True,True,False,55,747;2056;5971;7875;8012;8078;8149;8215;8281,,3.0,Unknown status,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0007308,Herpes simplex virus keratitis,2,1,9,0
CHEMBL1201234,MEPHENTERMINE,CNC(C)(C)Cc1ccccc1,True,True,False,350;1300;1357;1467;1812;2507,813;871;928;975;1032;1079;1131;1188;1363;1420;1467;6475;6675,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL1201245,BROMODIPHENHYDRAMINE,CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1,True,True,False,997,6627,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1201262,DIPIVEFRIN,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,True,True,False,394;1338;1389;1496;1855;2537,857;909;960;1013;1064;1117;1169;1220;1401;1452;1505;6519;6719,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,MONDO_0005041,glaucoma,2,6,8,0
CHEMBL1201264,METHANTHELINE,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21,True,True,False,752,5821,,4.0,,HRH2,G alpha (s) signalling events,R-HSA-418555,,EFO_0010282,gastrointestinal disease,2,1,1,0
CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12,True,True,False,49,741;2050;5965;7869;8006;8072;8143;8209;8275,,3.0,Terminated,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0000222,acute myeloid leukemia,2,1,9,0
CHEMBL1201271,BUCLIZINE,CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1,True,True,False,998,6628,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1201287,DEXBROMPHENIRAMINE,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,True,True,False,999,6629,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1201293,ACAMPROSATE,CC(=O)NCCCS(=O)(=O)O,True,True,False,504;712;1433;1518;1610;1657;1703;1745;1778;1799;1872;1933;1956;2064;2110;2184;2471;2558;2580;2605;2630;2649;2673,3618;6802;6829;6856;6889;7047;7074;7101;7128,,4.0,Completed;Not yet recruiting;Terminated,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0007079,alcohol dependence,2,23,9,0
CHEMBL1201294,DIPHENOXYLATE,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1,True,True,False,334,304;1338;7251,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0000304,breast adenocarcinoma,2,1,3,0
CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,True,True,False,54,746;2055;5970;7874;8011;8077;8148;8214;8280,,3.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_1000811,anterior uveitis,2,1,9,0
CHEMBL1201319,METARAMINOL,C[C@H](N)[C@H](O)c1cccc(O)c1,True,True,False,351;1468;1828,814;6476;6676,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000319,cardiovascular disease,2,3,3,0
CHEMBL1201346,BALSALAZIDE,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1,True,True,False,153;932,376;4494;5572;5632;5703;6087;6161;6235;6309;6383;6457,,3.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000729,ulcerative colitis,2,2,10,0
CHEMBL1201353,DEXCHLORPHENIRAMINE,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,True,True,False,1029,6659,,3.0,Unknown status,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003958,sunburn,2,1,1,0
CHEMBL1201414,TINZAPARIN SODIUM,N/A,True,True,False,169,141;7547;7576;7598,,4.0,Completed,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0003907,deep vein thrombosis,2,1,4,0
CHEMBL1201421,PEGAPTANIB SODIUM,N/A,False,True,False,,422;466;478;490;502;514;526;538;588;801,,4.0,,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0004683,wet macular degeneration,1,1,10,0
CHEMBL1201460,DALTEPARIN SODIUM,N/A,True,True,False,170,142;7548;7577;7599,,4.0,,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0004286,venous thromboembolism,2,1,4,0
CHEMBL1201461,DEXTROMETHORPHAN POLISTIREX,N/A,True,False,False,2662,,,2.0,Withdrawn,GRIN2A,,,,EFO_0003756,autism spectrum disorder,1,1,0,0
CHEMBL1201466,"ESTROGENS, CONJUGATED SYNTHETIC A",N/A,True,False,False,2293,,,4.0,,ESR1,,,,EFO_1000096,Atrophy,1,1,0,0
CHEMBL1201467,"SYNTHETIC CONJUGATED ESTROGENS, B",N/A,True,False,False,2296,,,4.0,,ESR1,,,,EFO_1000096,Atrophy,1,1,0,0
CHEMBL1201468,"ESTROGENS, ESTERIFIED",N/A,True,False,False,2294,,,4.0,,ESR1,,,,EFO_0004266,primary ovarian insufficiency,1,1,0,0
CHEMBL1201476,ENOXAPARIN SODIUM,N/A,True,True,False,167,139;7545;7574;7596,,4.0,,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0000612,myocardial infarction,2,1,4,0
CHEMBL1201477,POLYESTRADIOL PHOSPHATE,N/A,True,False,False,2283,,,4.0,,ESR1,,,,EFO_0000616,neoplasm,1,1,0,0
CHEMBL1201513,HEPARIN CALCIUM,N/A,True,True,False,179,151;7557;7586;7608,,2.0,Completed,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_1000954,habitual abortion,2,1,4,0
CHEMBL1201534,DANAPAROID SODIUM,N/A,True,True,False,172,144;7550;7579;7601,,4.0,,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,HP_0004419,Recurrent thrombophlebitis,2,1,4,0
CHEMBL1201536,NICOTINE POLACRILEX,N/A,True,True,False,440;2133,7920;7934;7948,,3.0,Completed;Recruiting,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0003768,nicotine dependence,2,2,3,0
CHEMBL1201554,ANTITHROMBIN ALFA,N/A,True,True,False,455,7535;7564,,4.0,,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,HP_0001976,Reduced antithrombin III activity,2,1,2,0
CHEMBL1201556,BECAPLERMIN,N/A,True,True,False,1108,7006,,4.0,,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,HP_0200042,Skin ulcer,2,1,1,0
CHEMBL1201557,INTERFERON ALFACON-1,N/A,False,True,False,,624;4209;5196;5246;5444,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL1201558,INTERFERON ALFA-2B,N/A,False,True,False,,623;4208;5195;5245;5443,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000558,Kaposi's sarcoma,1,1,5,0
CHEMBL1201560,PEGINTERFERON ALFA-2A,N/A,False,True,False,,627;4212;5199;5249;5447,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL1201561,PEGINTERFERON ALFA-2B,N/A,False,True,False,,625;4210;5197;5247;5445,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL1201562,INTERFERON BETA-1A,N/A,False,True,False,,626;4211;5198;5248;5446,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL1201563,INTERFERON BETA-1B,N/A,False,True,False,,628;4213;5200;5250;5448,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL1201570,ANAKINRA,N/A,False,True,False,,634;4192;4400,,4.0,,IL1R1,Interleukin-1 signaling;Interleukin-10 signaling;Potential therapeutics for SARS,R-HSA-6783783;R-HSA-9020702;R-HSA-9679191,,EFO_0000540,immune system disease,1,1,3,0
CHEMBL1201572,ETANERCEPT,N/A,True,True,False,83,392;4146;4161;4510,,4.0,,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000540,immune system disease,2,1,4,0
CHEMBL1201580,ADALIMUMAB,N/A,True,True,False,80,389;4143;4158;4507,,4.0,Completed,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000384,Crohn's disease,2,1,4,0
CHEMBL1201581,INFLIXIMAB,N/A,True,True,False,81,390;4144;4159;4508,,4.0,,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000384,Crohn's disease,2,1,4,0
CHEMBL1201583,BEVACIZUMAB,N/A,False,True,False,,417;461;473;485;497;509;521;533;583;796,,4.0,Completed,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0000305,breast carcinoma,1,1,10,0
CHEMBL1201619,APROTININ,N/A,True,True,False,684,77;108;135;458,,4.0,Completed,PLG,Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Platelet degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-114608;R-HSA-1474228;R-HSA-1592389;R-HSA-381426,,MP_0001914,hemorrhage,2,1,4,0
CHEMBL1201649,"ESTROGENS, CONJUGATED",N/A,True,False,False,2284,,,4.0,,ESR1,,,,EFO_0003854,postmenopausal osteoporosis,1,1,0,0
CHEMBL1201657,HEPARIN SODIUM,N/A,True,True,False,166,138;7544;7573;7595,,4.0,,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0000275,atrial fibrillation,2,1,4,0
CHEMBL1201728,DESVENLAFAXINE SUCCINATE,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O=C(O)CCC(=O)O,True,False,False,1259,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl,True,True,False,1106;1149,554;6966;7004;7500,,4.0,,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000681;EFO_0000691,renal cell carcinoma;sarcoma,2,2,3,0
CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O,True,True,False,1202;2203,4293,,4.0,,ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000339,chronic myelogenous leukemia,2,2,1,0
CHEMBL1201743,SAXAGLIPTIN HYDROCHLORIDE,Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,True,False,True,661,,519,4.0,,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL1201747,ALCAFTADINE,CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,True,True,False,968,6598,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL1201748,CABAZITAXEL,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,True,True,True,813;1546;1981;2220;2328;2392;2701;2763;2827,1526;1590;1654;1718;1782;1846;1910;2075;2139;2203;2267;2331;2395;2459;2523;2587;2651;2715;2779;2843;2907;2971;3041;3105;3169;3233;3297;3361;3425;3489;3553;3644;3708;3772;3836;3900;3964;4031,49,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000616,neoplasm,3,9,38,1
CHEMBL1201749,DIFLUPREDNATE,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,42,734;2043;5958;7862;7999;8065;8136;8202;8268,174,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_1000811,anterior uveitis,3,1,9,1
CHEMBL1201752,IXABEPILONE,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,True,True,True,808;1540;1975;2217;2319;2385;2692;2756;2820,1521;1585;1649;1713;1777;1841;1905;2070;2134;2198;2262;2326;2390;2454;2518;2582;2646;2710;2774;2838;2902;2966;3036;3100;3164;3228;3292;3356;3420;3484;3548;3639;3703;3767;3831;3895;3959;4026,50,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000305,breast carcinoma,3,9,38,1
CHEMBL1201753,PITAVASTATIN,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,True,True,False,736,7615;7630;7645;7660,,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL1201758,BEPOTASTINE,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1,True,True,False,1031,6661,,3.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_1001417,"Rhinitis, Allergic, Perennial",2,1,1,0
CHEMBL1201759,BEPOTASTINE BESYLATE,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1,True,True,False,973,6603,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0007141,allergic conjunctivitis,2,1,1,0
CHEMBL1201770,METHYLNALTREXONE BROMIDE,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-],True,True,False,301,271;1305;7218,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0005611,opioid dependence,2,1,3,0
CHEMBL1201772,PRASUGREL,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,True,True,False,471,1356,,3.0,Completed,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0000275,atrial fibrillation,2,1,1,0
CHEMBL1201773,PRASUGREL HYDROCHLORIDE,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl,True,True,False,466,1351,,4.0,,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0000612,myocardial infarction,2,1,1,0
CHEMBL1201776,TAPENTADOL,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,True,True,False,303,273;1307;7220,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1201777,TAPENTADOL HYDROCHLORIDE,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl,True,True,True,304,274;1308;7221,649,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1201782,FOSAPREPITANT DIMEGLUMINE,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,False,False,True,,,536,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL1201825,RANIBIZUMAB,N/A,False,True,False,,419;463;475;487;499;511;523;535;585;798,,4.0,,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0003770,diabetic retinopathy,1,1,10,0
CHEMBL1201828,ECULIZUMAB,N/A,False,True,False,,1234;7171;7732;7744;7756,,4.0,,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0000540,immune system disease,1,1,5,0
CHEMBL1201830,RILONACEPT,N/A,False,True,False,,163;4188;4351;4355;4359;4396;4535,,4.0,,IL1B,CLEC7A/inflammasome pathway;Interleukin-1 processing;Interleukin-1 signaling;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Purinergic signaling in leishmaniasis infection;Pyroptosis,R-HSA-448706;R-HSA-5620971;R-HSA-5660668;R-HSA-6783783;R-HSA-6785807;R-HSA-9020702;R-HSA-9660826,,EFO_0000540,immune system disease,1,1,7,0
CHEMBL1201831,CERTOLIZUMAB PEGOL,N/A,True,True,False,82,391;4145;4160;4509,,4.0,,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000384,Crohn's disease,2,1,4,0
CHEMBL1201833,GOLIMUMAB,N/A,True,True,False,84,393;4147;4162;4511,,4.0,,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000540,immune system disease,2,1,4,0
CHEMBL1201834,CANAKINUMAB,N/A,False,True,False,,164;4189;4352;4356;4360;4397;4536,,4.0,,IL1B,CLEC7A/inflammasome pathway;Interleukin-1 processing;Interleukin-1 signaling;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Purinergic signaling in leishmaniasis infection;Pyroptosis,R-HSA-448706;R-HSA-5620971;R-HSA-5660668;R-HSA-6783783;R-HSA-6785807;R-HSA-9020702;R-HSA-9660826,,EFO_0000540,immune system disease,1,1,7,0
CHEMBL1201891,DEFLAZACORT,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,True,True,True,47,739;2048;5963;7867;8004;8070;8141;8207;8273,230,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,MONDO_0010679,Duchenne muscular dystrophy,3,1,9,1
CHEMBL1205,NELFINAVIR MESYLATE,CS(=O)(=O)O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,False,False,True,,,392,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL1206232,FOSBRETABULIN,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,True,True,False,834;1567;2002;2242;2347;2411;2718;2782;2846,1547;1611;1675;1739;1803;1867;1931;2096;2160;2224;2288;2352;2416;2480;2544;2608;2672;2736;2800;2864;2928;2992;3062;3126;3190;3254;3318;3382;3446;3510;3574;3665;3729;3793;3857;3921;3985;4052,,3.0,Withdrawn,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,MONDO_0002108,thyroid cancer,2,9,38,0
CHEMBL1206690,PARECOXIB,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,True,True,False,142,365;4483;5692;6076;6150;6224;6298;6372;6446,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005755,rheumatic disease,2,1,9,0
CHEMBL1207366,GW468816,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1,True,True,True,723;1621;1967;2195;2618;2660;2684,3629;6813;6840;6867;6900;7058;7085;7112;7139,397,2.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,EFO_0003768,nicotine dependence,3,7,9,1
CHEMBL1209734,BMS-986094,COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)Oc2cccc3ccccc23)[C@@H](O)[C@@]1(C)O,False,False,True,,,433,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL1213351,PROPOXYPHENE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,True,True,False,305,275;1309;7222,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1214827,ONALESPIB,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,False,False,True,,,584,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL1215,PHENYLEPHRINE,CNC[C@H](O)c1cccc(O)c1,True,True,False,365;1458;1813,828;6490;6690,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000319,cardiovascular disease,2,3,3,0
CHEMBL1215661,PRUVANSERIN,N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12,False,False,True,,,701,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL122,ROFECOXIB,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,True,True,False,128,351;4469;5678;6062;6136;6210;6284;6358;6432,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005755,rheumatic disease,2,1,9,0
CHEMBL1224,ACRIVASTINE,Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1,True,True,False,1000,6630,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1230065,BMS-582949,CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C,False,False,True,,,94,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1230314,ESTETROL,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,True,False,False,2290,,,4.0,,ESR1,,,,EFO_0002950,pregnancy,1,1,0,0
CHEMBL1230609,FORETINIB,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,True,True,False,1128;1171,576;6988;7026;7522,,2.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,2,3,0
CHEMBL1231124,AZD-1480,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,True,True,True,799,224;686;4596;4675;4754;4861;4930;4996;5062;5106;5172;5338;5404;6951;7485;8314;8342;8370;8404;8432;8460,477,1.0,Terminated,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000182,hepatocellular carcinoma,3,1,21,1
CHEMBL1236936,CINACIGUAT,O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1,True,True,True,76,7692,252,2.0,Terminated,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000373,congestive heart failure,3,1,1,1
CHEMBL1237,LISINOPRIL ANHYDROUS,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,True,True,False,653,449,,3.0,Withdrawn,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL1237022,TOCILIZUMAB,N/A,False,True,False,,177;639;4549;4628;4707;7148,,4.0,,IL6R,Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Transcriptional regulation of granulopoiesis,R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-6785807;R-HSA-9616222;R-HSA-9679191,,EFO_0000540,immune system disease,1,1,6,0
CHEMBL1237044,TRAMADOL,COc1cccc(C2(O)CCCCC2CN(C)C)c1,True,True,False,280,250;1284;7197,,4.0,Recruiting,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1237055,HYDROMORPHONE HYDROCHLORIDE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl,True,True,True,281,251;1285;7198,628,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1237061,PITAVASTATIN CALCIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2],True,True,True,742,7621;7636;7651;7666,26,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,EFO_0004911,familial hypercholesterolemia,3,1,4,1
CHEMBL1237065,TRAMADOL HYDROCHLORIDE,COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,True,True,True,282,252;1286;7199,629,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1237072,DIRITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,False,False,True,,,311,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1237102,LEVOCABASTINE HYDROCHLORIDE,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl,True,True,False,1032,6662,,3.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_1001417,"Rhinitis, Allergic, Perennial",2,1,1,0
CHEMBL1237104,PROPOXYPHENE HYDROCHLORIDE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl,True,True,True,283,253;1287;7200,650,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1241,TRIPELENNAMINE,CN(C)CCN(Cc1ccccc1)c1ccccn1,True,True,False,985,6615,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL124660,TANDUTINIB,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,True,True,False,1127;1170,575;6987;7025;7521,,2.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000349,clear cell renal carcinoma,2,2,3,0
CHEMBL1255582,FIPAMEZOLE,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1,True,True,False,1349;1401;2549,920;972;1024;1076;1128;1180;1232;1412;1464;1516,,2.0,Completed,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,MONDO_0005180,Parkinson disease,2,3,6,0
CHEMBL1255794,APLAVIROC,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2,True,True,False,215,1257;4374;6756;6780,,3.0,Terminated,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000764,HIV infection,2,1,4,0
CHEMBL1256,ISOFLURANE,FC(F)OC(Cl)C(F)(F)F,True,True,True,515;525;528;533;538;541;1405;1441;1528;1665;1712;1756;1786;1805;1878;1941;2072;2120;2479;2564;2589;2634,1;4;7;10;13;18;23;7725;7730;7905,285,3.0,Recruiting;Terminated;Withdrawn,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;KCNK10;KCNK18;KCNK2;KCNK3;KCNK9,Neurotransmitter receptors and postsynaptic signal transmission;Phase 4 - resting membrane potential;TWIK related potassium channel (TREK);TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-112314;R-HSA-1299316;R-HSA-1299503;R-HSA-5576886,GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,EFO_0009686;EFO_0011061;HP_0000023,Inguinal hernia;respiratory failure;toxicity,3,22,4,2
CHEMBL1256818,DEXTROMETHORPHAN HYDROBROMIDE,Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O,True,False,False,2642,,,4.0,,GRIN2A,,,,EFO_0007486,sinusitis,1,1,0,0
CHEMBL1256958,EPINEPHRINE BITARTRATE,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O,True,True,False,377;1322;1374;1481;1847;2528,840;893;945;997;1049;1101;1153;1205;1385;1437;1489;6502;6702,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0003843,pain,2,6,8,0
CHEMBL1257,ENFLURANE,FC(F)OC(F)(F)C(F)Cl,False,False,True,,,286,,,,,,Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,,,1,0,0,1
CHEMBL1257040,TRIFLUOPERAZINE HYDROCHLORIDE,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl,False,False,True,,,689,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1257051,TEDIZOLID,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1,False,False,True,,,343,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1259059,SOFOSBUVIR,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,False,False,True,,,419,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL126,LINEZOLID,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,False,False,True,,,320,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL12610,BENZYDAMINE,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,True,True,True,129;916,352;4470;5556;5616;5679;6063;6137;6211;6285;6359;6433,160,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755;EFO_0005757,rheumatic disease;vaginal inflammation,3,2,10,1
CHEMBL1265,ADAPALENE,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,True,True,True,185;1766;1893,5987;6013;6022,620,4.0,Completed;Terminated,RARA;RARB;RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,Retinoic acid receptor agonist,EFO_0003894,acne,3,3,3,1
CHEMBL1266,TETRAHYDROZOLINE,c1ccc2c(c1)CCCC2C1=NCCN1,True,True,False,383;1327;1381;1487;1843;2524,846;898;952;1002;1056;1106;1158;1212;1390;1444;1494;6508;6708,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0005751,eye allergy,2,6,8,0
CHEMBL1269025,EDOXABAN,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,True,True,False,453,7533;7562,,4.0,,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,HP_0004419,Recurrent thrombophlebitis,2,1,2,0
CHEMBL1269102,BQ-123,N/A,True,False,False,1925,,,2.0,Unknown status,EDNRA,,,,EFO_0001645,coronary artery disease,1,1,0,0
CHEMBL127071,POZANICLINE,Cc1ncccc1OC[C@@H]1CCCN1,True,True,False,445;2141,7925;7939;7953,,2.0,Terminated,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0003768,nicotine dependence,2,2,3,0
CHEMBL12713,SERTINDOLE,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,True,True,False,388;1490;1849,851;6513;6713,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0005407,psychosis,2,3,3,0
CHEMBL1274,NILUTAMIDE,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,True,True,True,549,1972;5887;7791,76,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000616,neoplasm,3,1,3,1
CHEMBL1276308,MIFEPRISTONE,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,True,True,False,34,726;2035;5950;7854;7991;8057;8128;8194;8260,,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0003099,Cushing syndrome,2,1,9,0
CHEMBL1278146,FAMITINIB,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,True,True,False,1117;1159,564;6976;7015;7510,,3.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000365,colorectal adenocarcinoma,2,2,3,0
CHEMBL1282,IMIQUIMOD,CC(C)Cn1cnc2c(N)nc3ccccc3c21,True,True,False,600,760;4256;7322;7344;7355;7366;7377;7399;7421;7443;7454,,4.0,,TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0000763,viral disease,2,1,11,0
CHEMBL128748,DIMETHYLCURCUMIN,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC,True,True,False,570,1993;5908;7812,,2.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0003894,acne,2,1,3,0
CHEMBL1287853,FEDRATINIB,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,True,True,True,781,206;668;4578;4657;4736;4843;4912;4978;5044;5088;5154;5320;5386;6933;7467;8296;8324;8352;8386;8414;8442,495,4.0,,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000616,neoplasm,3,1,21,1
CHEMBL1289494,TIVOZANIB,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,True,True,False,1119;1161,566;6978;7017;7512,,3.0,,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,2,3,0
CHEMBL1297,FENOPROFEN,CC(C(=O)O)c1cccc(Oc2ccccc2)c1,True,True,False,130;923,353;4471;5563;5623;5680;6064;6138;6212;6286;6360;6434,,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005755,rheumatic disease,2,2,10,0
CHEMBL130,CHLORAMPHENICOL,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,False,False,True,,,280,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1305,ANTAZOLINE,c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,True,True,False,1026,6656,,3.0,Unknown status,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000678,pterygium,2,1,1,0
CHEMBL131,PREDNISOLONE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,True,True,True,1,693;2002;5917;7821;7958;8024;8095;8161;8227,178,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL1311,ISOSORBIDE MONONITRATE,O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,True,True,True,68,7684,248,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL1323,DARUNAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,False,False,True,,,408,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL13280,FLUNITRAZEPAM,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,False,False,True,,,278,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL1336,SORAFENIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,True,True,False,1109;1154,559;6971;7007;7505,,3.0,Completed;Not yet recruiting,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000182,hepatocellular carcinoma,2,2,3,0
CHEMBL13376,CLOMETACIN,COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1,False,False,True,,,140,,,,,,Cyclooxygenase inhibitor,,,1,0,0,1
CHEMBL1339,VARDENAFIL HYDROCHLORIDE,CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl,True,True,True,873,7673;7700;7713,447,4.0,,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,EFO_0004234,erectile dysfunction,3,1,3,1
CHEMBL134,CLONIDINE,Clc1cccc(Cl)c1NC1=NCCN1,True,True,False,1315;1368;2513,886;939;990;1043;1094;1146;1199;1378;1431;1482,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,3,6,0
CHEMBL1341,METHOXYFLURANE,COC(F)(F)C(Cl)Cl,True,True,False,483;1403;1423;1513;1635;1681;1737;1775;1796;1869;1929;2043;2089;2459;2555;2575;2626,7903,,4.0,Completed;Unknown status,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1,Neurotransmitter receptors and postsynaptic signal transmission,R-HSA-112314,,EFO_0003843,pain,2,17,1,0
CHEMBL135,ESTRADIOL,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,True,False,False,2286,,,4.0,,ESR1,,,,EFO_0003882,osteoporosis,1,1,0,0
CHEMBL135400,ZOPICLONE,CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,True,False,False,510;1524;1709;1750;1783;1938;2070;2116;2586,,,3.0,Completed;Terminated,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3,,,,EFO_0003918;EFO_0005230,anxiety;obstructive sleep apnea,1,9,0,0
CHEMBL1357648,AMODIAQUINE HYDROCHLORIDE,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl.Cl.O.O,False,False,True,,,434,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL1358,FULVESTRANT,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,True,False,False,2277,,,4.0,,ESR1,,,,EFO_0000305,breast carcinoma,1,1,0,0
CHEMBL1364144,METHYLPREDNISOLONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,17,709;2018;5933;7837;7974;8040;8111;8177;8243,231,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000565,leukemia,3,1,9,1
CHEMBL136478,SODIUM NITROPRUSSIDE,N/A,True,True,True,71,7687,247,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000373,congestive heart failure,3,1,1,1
CHEMBL1366933,ESMIRTAZAPINE,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,True,True,False,1030;1345;1397;2543,916;968;1020;1072;1124;1176;1228;1408;1460;1512;6660,,3.0,Completed,ADRA2A;ADRA2B;ADRA2C;HRH1,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0004698,insomnia,2,4,7,0
CHEMBL1370,BUDESONIDE,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,True,True,True,9,701;2010;5925;7829;7966;8032;8103;8169;8235,221,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000341,chronic obstructive pulmonary disease,3,1,9,1
CHEMBL1370561,AMINOPHYLLINE,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN,True,True,False,417;1049;1076;2154,4327;5739;5766;5793;5834;5860,,4.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,,HP_0006536;MONDO_0004979,Airway obstruction;asthma,2,4,3,0
CHEMBL1375743,ZIPRASIDONE HYDROCHLORIDE,Cl.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,False,False,True,,,702,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL13828,OXATOMIDE,O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,True,True,False,1001,6631,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL139,DICLOFENAC,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,True,True,True,99;886,322;4440;5526;5586;5649;6033;6107;6181;6255;6329;6403,146,4.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL1395,METHYLTESTOSTERONE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,True,True,False,557,1980;5895;7799,,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,MONDO_0002146,hypogonadism,2,1,3,0
CHEMBL139835,CYPROTERONE ACETATE,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,True,True,True,51;559,743;1982;2052;5897;5967;7801;7871;8008;8074;8145;8211;8277,75,3.0,Completed,AR;NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Androgen Receptor antagonist,EFO_0000673,prostate adenocarcinoma,3,2,9,1
CHEMBL1405,ESTRONE,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,True,False,False,2309,,,3.0,Unknown status,ESR1,,,,MONDO_0004169,premenstrual tension,1,1,0,0
CHEMBL1409,FLUVOXAMINE MALEATE,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O,True,False,False,1245,,,4.0,,SLC6A4,,,,EFO_0004242,obsessive-compulsive disorder,1,1,0,0
CHEMBL1411979,METHAPYRILENE,CN(C)CCN(Cc1cccs1)c1ccccn1,True,True,False,1002,6632,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1419,SIBUTRAMINE,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,True,False,False,1236,,,4.0,,SLC6A4,,,,EFO_0001073,obesity,1,1,0,0
CHEMBL1421,DASATINIB,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,True,True,False,942;1097;1140;1199;2199,545;4290;6957;6995;7491,,4.0,Unknown status,ABL1;BCR;BLK;KIT;PDGFRB,"RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-1433557;R-HSA-5673001;R-HSA-8866910;R-HSA-9860927,,EFO_0000220,acute lymphoblastic leukemia,2,5,4,0
CHEMBL1422,SITAGLIPTIN,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,True,False,False,664,,,3.0,Completed,DPP4,,,,EFO_0000400,diabetes mellitus,1,1,0,0
CHEMBL1423,PIMOZIDE,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,False,False,True,,,682,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL142635,NAFTOPIDIL,COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,True,False,False,1498,,,3.0,Withdrawn,ADRA1D,,,,EFO_0000536,hyperplasia,1,1,0,0
CHEMBL142703,VILDAGLIPTIN,N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,True,False,True,658,,513,4.0,,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0000400,diabetes mellitus,2,1,0,1
CHEMBL1431,METFORMIN,CN(C)C(=N)NC(=N)N,True,False,False,1535;1945;2173,,,4.0,Completed;Recruiting,GPD2;MT-ND4;NDUFA4,,,,EFO_0000400,diabetes mellitus,1,3,0,0
CHEMBL1433,DOXYCYCLINE ANHYDROUS,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,True,True,False,611;616;622;629,27;33;40;45;51;57;64;69;82;88;95;100;113;127;232;3029,,3.0,Completed;Unknown status,MMP1;MMP13;MMP7;MMP8,Activation of Matrix Metalloproteinases;Basigin interactions;Collagen degradation;Degradation of the extracellular matrix;Interleukin-4 and Interleukin-13 signaling;Neutrophil degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1442490;R-HSA-1474228;R-HSA-1592389;R-HSA-381426;R-HSA-6785807;R-HSA-6798695,,EFO_0000341,chronic obstructive pulmonary disease,2,4,7,0
CHEMBL1434513,NOREPINEPHRINE BITARTRATE,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O,True,True,False,381;1321;1373;1485;1841;2520,844;892;944;996;1048;1100;1152;1204;1384;1436;1488;6506;6706,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0002497,acute hypotension,2,6,8,0
CHEMBL1437,NOREPINEPHRINE,NC[C@H](O)c1ccc(O)c(O)c1,True,True,False,366;1308;1358;1469;1829;2499,829;879;929;983;1033;1087;1139;1189;1371;1421;1475;6491;6691,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL14376,ILOPERIDONE,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,False,False,True,,,695,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1440,TETRACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,False,False,True,,,300,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1442422,DIBENZEPIN,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21,True,True,False,1012,6642,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0002009,major depressive disorder,2,1,1,0
CHEMBL1445,FLUOXYMESTERONE,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,False,550,1973;5888;7792,,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL1446,KANAMYCIN SULFATE,NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,False,False,True,,,301,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1447,LINCOMYCIN,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1,False,False,True,,,340,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1451,TRIAMCINOLONE,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F,True,True,True,31,723;2032;5947;7851;7988;8054;8125;8191;8257,201,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1457,HYDROCODONE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,True,True,False,320,290;1324;7237,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0012735,Cough,2,1,3,0
CHEMBL146095,GLAFENINE,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,True,True,True,121;918,344;4462;5558;5618;5671;6055;6129;6203;6277;6351;6425,153,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL1471,APREPITANT,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,False,False,True,,,532,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL1473,FLUTICASONE PROPIONATE,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,2,694;2003;5918;7822;7959;8025;8096;8162;8228,223,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL1477,CERIVASTATIN,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,True,True,False,731,7610;7625;7640;7655,,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL1479,DANAZOL,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,True,True,False,555,1978;5893;7797,,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0001065,endometriosis,2,1,3,0
CHEMBL1483,ALBENDAZOLE,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,False,False,True,,,59,,,,,,Tubulin inhibitor,,,1,0,0,1
CHEMBL1487,ATORVASTATIN,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,True,True,False,732,7611;7626;7641;7656,,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL1489,AZACITIDINE,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,False,False,True,,,413,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL1492,DIPHENYLPYRALINE,CN1CCC(OC(c2ccccc2)c2ccccc2)CC1,True,True,False,1003,6633,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1492500,DOTHIEPIN,CN(C)CC/C=C1\c2ccccc2CSc2ccccc21,True,False,False,1260,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL1493,FLAVOXATE,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O,True,True,False,433;1066;1095;2171,4346;5755;5783;5812;5850;5879,,2.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,,HP_0000020;HP_0000103,Polyuria;Urinary incontinence,2,4,3,0
CHEMBL1496,ROSUVASTATIN,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,True,True,False,733,7612;7627;7642;7657,,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL1497,BETAMETHASONE VALERATE,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,26,718;2027;5942;7846;7983;8049;8120;8186;8252,224,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1501,FLUOCINONIDE,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,True,True,True,27,719;2028;5943;7847;7984;8050;8121;8187;8253,202,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000701,skin disease,3,1,9,1
CHEMBL1504,TRIAMCINOLONE ACETONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,True,True,True,15,707;2016;5931;7835;7972;8038;8109;8175;8241,169,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000546,injury,3,1,9,1
CHEMBL1508,ESCITALOPRAM,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,True,False,False,1254,,,4.0,Completed,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL1511,ESTRADIOL VALERATE,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,True,False,False,2289,,,4.0,,ESR1,,,,EFO_0004266,primary ovarian insufficiency,1,1,0,0
CHEMBL1512,FLUNISOLIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,True,True,True,44,736;2045;5960;7864;8001;8067;8138;8204;8270,179,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0008521,rhinitis,3,1,9,1
CHEMBL1513,IRBESARTAN,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,True,True,True,580,6534;7153;7264;7284,10,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL1514,LEVOMETHADYL ACETATE,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,True,True,True,302,272;1306;7219,661,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0005611,opioid dependence,3,1,3,1
CHEMBL1516,OLMESARTAN,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,True,True,True,594,6548;7167;7278;7298,11,3.0,Completed,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000275,atrial fibrillation,3,1,4,1
CHEMBL1517,OXYTETRACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12,False,False,True,,,302,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1519,TRANDOLAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,True,True,True,633,429,370,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL1520,VARDENAFIL,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,True,True,False,874,7674;7701;7714,,4.0,Completed,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,,EFO_0004234,erectile dysfunction,2,1,3,0
CHEMBL1521,ZALEPLON,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,True,False,False,1639;1743,,,4.0,,GABRB1;GABRG2,,,,EFO_0004698,insomnia,1,2,0,0
CHEMBL1522,ESZOPICLONE,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,True,False,True,486;1416;1641;1686;2048;2093;2454,,249,4.0,"Active, not recruiting;Completed",GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004698,insomnia,2,7,0,2
CHEMBL1523964,EPHEDRINE SULFATE,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O,True,True,False,382;1326;1380;1486;1848;2531,845;897;951;1001;1055;1105;1157;1211;1389;1443;1493;6507;6707,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0005251,hypotension,2,6,8,0
CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,True,True,True,159;937,382;4500;5577;5637;5709;6093;6167;6241;6315;6389;6463,175,3.0,Not yet recruiting,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_1001904,oral mucositis,3,2,10,1
CHEMBL1530428,DEXAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,True,True,True,50,742;2051;5966;7870;8007;8073;8144;8210;8276,217,3.0,Unknown status,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000565,leukemia,3,1,9,1
CHEMBL1535,HYDROXYCHLOROQUINE,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,True,True,False,256;599,759;770;4255;7321;7332;7343;7354;7365;7376;7387;7398;7409;7420;7431;7442;7453,,4.0,,TLR7;TLR9,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0001068,malaria,2,2,11,0
CHEMBL1536,ERGOCALCIFEROL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12,True,True,True,244,5997;7774;7892,12,4.0,,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0009451,hypoparathyroidism,3,1,3,1
CHEMBL154,NAPROXEN,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,True,True,True,100;887,323;4441;5527;5587;5650;6034;6108;6182;6256;6330;6404,102,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL1549,HYDROCORTISONE CYPIONATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,True,True,True,65,757;2066;5981;7885;8022;8088;8159;8225;8291,170,2.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,MONDO_0015129,chronic primary adrenal insufficiency,3,1,9,1
CHEMBL1558,PRAZOSIN HYDROCHLORIDE,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl,True,True,False,371;1475;1834,834;6496;6696,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000400,diabetes mellitus,2,3,3,0
CHEMBL1560,CAPTOPRIL,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,True,True,True,639,435,371,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL1562610,MECLOFENAMATE SODIUM,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+],True,True,True,101;888,324;4442;5528;5588;5651;6035;6109;6183;6257;6331;6405,135,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL1565476,APAZONE,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,True,True,True,143;911,366;4484;5551;5611;5693;6077;6151;6225;6299;6373;6447,176,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL1567,SUNITINIB MALATE,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,True,True,False,1104;1150,555;6967;7002;7501,,4.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000681,renal cell carcinoma,2,2,3,0
CHEMBL15677,FENCLOFENAC,O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl,False,False,True,,,143,,,,,,Cyclooxygenase inhibitor,,,1,0,0,1
CHEMBL1568698,GANAXOLONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,True,False,True,478;1407;1509;1632;1676;1732;1772;1793;1867;1926;2037;2088;2446;2552;2571;2623,,288,4.0,,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000474,epilepsy,2,16,0,2
CHEMBL1569,AMANTADINE HYDROCHLORIDE,Cl.NC12CC3CC(CC(C3)C1)C2,True,True,True,704;1603;1949;2176;2597;2640;2666,3610;6794;6821;6848;6881;7039;7066;7093;7120,393,4.0,,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist | Matrix protein 2 inhibitor,EFO_0000544,infection,3,7,9,1
CHEMBL1569487,LORNOXICAM,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,True,True,True,144;924,367;4485;5564;5624;5694;6078;6152;6226;6300;6374;6448,177,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL15770,SULINDAC,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1,True,True,True,111;889,334;4452;5529;5589;5661;6045;6119;6193;6267;6341;6415,125,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL1581,PERINDOPRIL,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,True,True,False,640,436,,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL15870,INDOPROFEN,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,True,True,True,131;912,354;4472;5552;5612;5681;6065;6139;6213;6287;6361;6435,145,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL159,VINBLASTINE,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,True,True,False,816;1552;1984;2223;2327;2391;2700;2761;2825,1529;1593;1657;1721;1785;1849;1913;2078;2142;2206;2270;2334;2398;2462;2526;2590;2654;2718;2782;2846;2910;2974;3044;3108;3172;3236;3300;3364;3428;3492;3556;3647;3711;3775;3839;3903;3967;4034,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL1592,QUINAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,True,True,False,641,437,,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL159226,MOXISYLYTE,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,True,True,True,367;1309;1359;1459;1814;2508,830;880;930;984;1034;1088;1140;1190;1372;1422;1476;6492;6692,462,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,Adrenergic receptor alpha antagonist,EFO_0000319,cardiovascular disease,3,6,8,1
CHEMBL1595,DIHYDROCODEINE,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341,True,True,False,284,254;1288;7201,,4.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1601669,ALFACALCIDOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,248,6001;7778;7896,27,3.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0003882,osteoporosis,3,1,3,1
CHEMBL1607273,CETIRIZINE HYDROCHLORIDE,Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,True,True,False,965,6595,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005531,urticaria,2,1,1,0
CHEMBL1607480,OXYTETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.Cl,False,False,True,,,328,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1614702,SCIO-323,COc1cc2c(cc1C(=O)N1CCC(Cc3ccc(F)cc3)CC1)c(C(=O)C(=O)N(C)C)cn2C,False,False,True,,,95,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1614710,OSI-930,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,True,True,False,1176,581;6993;7527,,1.0,Completed,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL1615372,LURASIDONE HYDROCHLORIDE,Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,False,False,True,,,690,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1615374,VILAZODONE HYDROCHLORIDE,Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,True,False,False,1261,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL1615438,LEVOCABASTINE,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1,True,True,False,979,6609,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL1620,DIPHENHYDRAMINE HYDROCHLORIDE,CN(C)CCOC(c1ccccc1)c1ccccc1.Cl,True,True,False,963,6593,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003958,sunburn,2,1,1,0
CHEMBL1621,PALIPERIDONE,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,False,False,True,,,683,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1623,MECLIZINE,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1,True,True,False,1004,6634,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1626,CLEMASTINE,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,True,True,False,992,6622,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL1628502,GABAPENTIN ENACARBIL,CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C,True,False,False,2492,,,4.0,Completed,CACNA2D1,,,,EFO_0004270,restless legs syndrome,1,1,0,0
CHEMBL1628688,ZIBOTENTAN,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1,True,False,False,1923,,,3.0,Completed,EDNRA,,,,MONDO_0008315,prostate cancer,1,1,0,0
CHEMBL163,RITONAVIR,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,True,True,True,212;948;1625;1902,7907;7910;7911;7914,390,4.0,Completed,CYP3A4;CYP3A43;CYP3A5;CYP3A7,Aflatoxin activation and detoxification;Xenobiotics,R-HSA-211981;R-HSA-5423646,Cytochrome P450 3A inhibitor | Human immunodeficiency virus type 1 protease inhibitor,EFO_0000180,HIV-1 infection,3,4,2,1
CHEMBL1631540,GSK163090,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,True,False,False,1298,,,2.0,Completed,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL1633,KETOTIFEN FUMARATE,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O,True,True,False,1027,6657,,3.0,"Active, not recruiting",HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003931,bone fracture,2,1,1,0
CHEMBL1642,IMATINIB MESYLATE,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,True,True,False,1099;1142;1201;2200,547;4292;6959;6997;7493,,4.0,Completed,ABL1;BCR;KIT;PDGFRB,"RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-1433557;R-HSA-5673001;R-HSA-8866910;R-HSA-9860927,,EFO_0000339,chronic myelogenous leukemia,2,4,4,0
CHEMBL1643,RIBAVIRIN,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,False,False,True,,,414,,,,,,Inosine-5'-monophosphate dehydrogenase 1 inhibitor | RNA inhibitor | RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL1649931,PF-232798,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1,True,True,False,223,1265;4382;6764;6788,,2.0,Completed,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000764,HIV infection,2,1,4,0
CHEMBL1650,CORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C,True,True,True,3,695;2004;5919;7823;7960;8026;8097;8163;8229,225,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL1650443,TRELAGLIPTIN,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,True,False,False,668,,,3.0,Completed,DPP4,,,,EFO_0000400,diabetes mellitus,1,1,0,0
CHEMBL1650595,AR-12,NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1,True,False,False,1628,,,1.0,Completed,PDPK1,,,,EFO_0000574,lymphoma,1,1,0,0
CHEMBL1651534,REDAFAMDASTAT,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,True,False,True,688,,113,2.0,Terminated,FAAH,,,Anandamide amidohydrolase inhibitor,EFO_0001358,post-traumatic stress disorder,2,1,0,1
CHEMBL1653,PHENIRAMINE MALEATE,CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O,True,True,False,1025,6655,,3.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000684,respiratory system disease,2,1,1,0
CHEMBL1655,TOREMIFENE,CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,True,False,False,2299,,,3.0,,ESR1,,,,EFO_0000616,neoplasm,1,1,0,0
CHEMBL1657,TAZAROTENE,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,True,True,True,182;1763;1890,5984;6010;6019,623,4.0,Completed,RARA;RARB;RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,Retinoic acid receptor agonist,EFO_0000676,psoriasis,3,3,3,1
CHEMBL1659,CHLORPHENIRAMINE MALEATE,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,True,True,False,954,6584,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003843,pain,2,1,1,0
CHEMBL1668019,APLAVIROC HYDROCHLORIDE,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,True,True,True,216,1258;4375;6757;6781,501,3.0,Terminated,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 5 antagonist,EFO_0000764,HIV infection,3,1,4,1
CHEMBL166863,POLMACOXIB,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O,True,True,False,158,381;4499;5708;6092;6166;6240;6314;6388;6462,,3.0,Completed,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_1000786,"osteoarthritis, hip",2,1,9,0
CHEMBL1672054,CASOPITANT,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,False,False,True,,,549,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL1673408,DELPAZOLID,CN1CCN(c2ccc(N3C[C@H](CO)OC3=O)cc2F)C=N1,False,False,True,,,344,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1676,FLUTICASONE FUROATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,True,True,True,10,702;2011;5926;7830;7967;8033;8104;8170;8236,203,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000341,chronic obstructive pulmonary disease,3,1,9,1
CHEMBL1683,HYDROCORTISONE BUTYRATE,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,4,696;2005;5920;7824;7961;8027;8098;8164;8230,204,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL1683544,ERIBULIN MESYLATE,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O,True,True,True,811;1541;1976;2214;2320;2386;2693;2757;2821,1524;1588;1652;1716;1780;1844;1908;2073;2137;2201;2265;2329;2393;2457;2521;2585;2649;2713;2777;2841;2905;2969;3039;3103;3167;3231;3295;3359;3423;3487;3551;3642;3706;3770;3834;3898;3962;4029,51,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000305,breast carcinoma,3,9,38,1
CHEMBL1683590,ERIBULIN,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C,True,True,False,815;1550;1988;2226;2329;2393;2698;2762;2828,1528;1592;1656;1720;1784;1848;1912;2077;2141;2205;2269;2333;2397;2461;2525;2589;2653;2717;2781;2845;2909;2973;3043;3107;3171;3235;3299;3363;3427;3491;3555;3646;3710;3774;3838;3902;3966;4033,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL1685,DEZOCINE,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N,True,True,False,285,255;1289;7202,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1688243,INCB-9471,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,True,True,True,225,1267;4384;6766;6790,502,2.0,Completed,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 5 antagonist,EFO_0000764,HIV infection,3,1,4,1
CHEMBL1689,TOLAZOLINE HYDROCHLORIDE,Cl.c1ccc(CC2=NCCN2)cc1,False,False,True,,,466,,,,,,Adrenergic receptor alpha antagonist,,,1,0,0,1
CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,True,True,True,255;598,758;769;4254;7320;7331;7342;7353;7364;7375;7386;7397;7408;7419;7430;7441;7452,448,4.0,,TLR7;TLR9,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,Ferriprotoporphyrin IX inhibitor | Toll-like receptor 7 antagonist | Toll-like receptor 9 antagonist,EFO_0000685,rheumatoid arthritis,3,2,11,1
CHEMBL1692,IMIPRAMINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl,True,False,False,1282,,,4.0,,SLC6A4,,,,MONDO_0024290,enuresis,1,1,0,0
CHEMBL1694,BENAZEPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O.Cl,True,True,True,647,443,373,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000400,diabetes mellitus,3,1,1,1
CHEMBL1697737,CLOTIAZEPAM,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,True,False,True,499;1430;1637;1699;2060;2091;2452,,289,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230,anxiety,2,7,0,2
CHEMBL1699,MEMANTINE HYDROCHLORIDE,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,True,True,False,706;1605;1951;2178;2599;2643;2668,3612;6796;6823;6850;6883;7041;7068;7095;7122,,4.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,HP_0000726,Dementia,2,7,9,0
CHEMBL1701,MEPERIDINE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl,True,True,True,286,256;1290;7203,639,4.0,Unknown status,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL1703,METFORMIN HYDROCHLORIDE,CN(C)C(=N)NC(=N)N.Cl,True,False,False,1536;1946;2174,,,4.0,Completed,GPD2;MT-ND4;NDUFA4,,,,EFO_0000400,diabetes mellitus,1,3,0,0
CHEMBL1705,CLONIDINE HYDROCHLORIDE,Cl.Clc1cccc(Cl)c1NC1=NCCN1,True,True,False,1317;1369;2515,888;940;992;1044;1096;1148;1200;1380;1432;1484,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,3,6,0
CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,Cl.c1ccc2c(CC3=NCCN3)cccc2c1,True,True,False,379;1324;1377;1483;1845;2529,842;895;948;999;1052;1103;1155;1208;1387;1440;1491;6504;6704,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0003956;EFO_0007214,common cold;seasonal allergic rhinitis,2,6,8,0
CHEMBL1707,LOPERAMIDE HYDROCHLORIDE,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl,True,True,True,317,287;1321;7234,625,4.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,HP_0002014,Diarrhea,3,1,3,1
CHEMBL1708,PAROXETINE HYDROCHLORIDE,Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,True,False,False,1238,,,4.0,,SLC6A4,,,,EFO_0001358,post-traumatic stress disorder,1,1,0,0
CHEMBL1709,SERTRALINE HYDROCHLORIDE,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21.Cl,True,False,False,1241,,,4.0,,SLC6A4,,,,EFO_0001358,post-traumatic stress disorder,1,1,0,0
CHEMBL1713,CHLORPROMAZINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl,False,False,True,,,663,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1714,KETAMINE HYDROCHLORIDE,CNC1(c2ccccc2Cl)CCCCC1=O.Cl,True,True,False,714;1613;1960;2187;2608;2652;2676,3620;6804;6831;6858;6891;7049;7076;7103;7130,,3.0,"Active, not recruiting;Recruiting",GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,EFO_0000546,injury,2,7,9,0
CHEMBL17157,TERFENADINE,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,True,True,False,1015,6645,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL1716,CYPROHEPTADINE HYDROCHLORIDE,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,True,True,False,959,6589,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1717,TICLOPIDINE HYDROCHLORIDE,Cl.Clc1ccccc1CN1CCc2sccc2C1,True,True,False,468,1353,,4.0,,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0000712,stroke,2,1,1,0
CHEMBL1718,NALOXONE HYDROCHLORIDE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,True,True,False,287,257;1291;7204,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL1719,OLOPATADINE HYDROCHLORIDE,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,True,True,False,960,6590,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1721885,SU-014813,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,True,True,False,1130;1173,578;6990;7028;7524,,2.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0003869,breast neoplasm,2,2,3,0
CHEMBL1723,ALFUZOSIN HYDROCHLORIDE,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl,True,True,False,360;1452;1822,823;6485;6685,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,3,3,0
CHEMBL1735,INDINAVIR SULFATE,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O,False,False,True,,,415,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL17350,TRAXOPRODIL,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,True,True,False,722;2615,3628;6812;6839;6866;6899;7057;7084;7111;7138,,2.0,Terminated,GRIN1;GRIN2B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,EFO_0000712,stroke,2,2,9,0
CHEMBL1737,SILDENAFIL CITRATE,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,True,True,872,7672;7699;7712,449,4.0,,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,EFO_0001361,pulmonary arterial hypertension,3,1,3,1
CHEMBL1738757,REBASTINIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,True,True,False,1223,4314,,1.0,Terminated,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000304,breast adenocarcinoma,2,1,1,0
CHEMBL1738889,ENOBOSARM,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,True,True,False,561,1984;5899;7803,,3.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0003060,non-small cell lung carcinoma,2,1,3,0
CHEMBL1741,CLARITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,False,False,True,,,322,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1742423,BILASTINE,CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,True,True,False,969,6599,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL1742461,LAFUTIDINE,O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,True,True,True,753,5822,728,3.0,Completed,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,EFO_0003948,gastroesophageal reflux disease,3,1,1,1
CHEMBL1742471,EBROTIDINE,NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1,False,False,True,,,729,,,,,,Histamine H2 receptor antagonist,,,1,0,0,1
CHEMBL1742982,AFLIBERCEPT,N/A,False,True,False,,418;462;474;486;498;510;522;534;584;797,,4.0,,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0000365,colorectal adenocarcinoma,1,1,10,0
CHEMBL1742994,BRENTUXIMAB VEDOTIN,N/A,True,True,False,805;1538;1973;2212;2317;2381;2688;2753;2816,1518;1582;1646;1710;1774;1838;1902;2067;2131;2195;2259;2323;2387;2451;2515;2579;2643;2707;2771;2835;2899;2963;3033;3097;3161;3225;3289;3353;3417;3481;3545;3636;3700;3764;3828;3892;3956;4023,,4.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000183,Hodgkins lymphoma,2,9,38,0
CHEMBL1743026,GEVOKIZUMAB,N/A,False,True,False,,165;4190;4353;4357;4361;4398;4537,,3.0,Terminated,IL1B,CLEC7A/inflammasome pathway;Interleukin-1 processing;Interleukin-1 signaling;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Purinergic signaling in leishmaniasis infection;Pyroptosis,R-HSA-448706;R-HSA-5620971;R-HSA-5660668;R-HSA-6783783;R-HSA-6785807;R-HSA-9020702;R-HSA-9660826,,EFO_0003780,Behcet's syndrome,1,1,7,0
CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,N/A,True,True,False,848;1577;2012;2255;2359;2421;2728;2795;2858,1561;1625;1689;1753;1817;1881;1945;2110;2174;2238;2302;2366;2430;2494;2558;2622;2686;2750;2814;2878;2942;3006;3076;3140;3204;3268;3332;3396;3460;3524;3588;3679;3743;3807;3871;3935;3999;4066,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000637,osteosarcoma,2,9,38,0
CHEMBL1743034,IXEKIZUMAB,N/A,False,True,False,,153;4222;7302,,4.0,,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_0000540,immune system disease,1,1,3,0
CHEMBL1743037,LORVOTUZUMAB MERTANSINE,N/A,True,True,False,842;1575;2010;2247;2352;2415;2725;2786;2850,1555;1619;1683;1747;1811;1875;1939;2104;2168;2232;2296;2360;2424;2488;2552;2616;2680;2744;2808;2872;2936;3000;3070;3134;3198;3262;3326;3390;3454;3518;3582;3673;3737;3801;3865;3929;3993;4060,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000565,leukemia,2,9,38,0
CHEMBL1743044,NAMILUMAB,N/A,False,True,False,,4390;6877;8379,,2.0,Terminated,CSF2,"Interleukin-10 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;RAF/MAP kinase cascade",R-HSA-512988;R-HSA-5673001;R-HSA-6783783,,EFO_0000685,rheumatoid arthritis,1,1,3,0
CHEMBL1743050,OLOKIZUMAB,N/A,False,True,False,,119;169;4405;4541;4620;4699;7589,,3.0,,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,EFO_0000540,immune system disease,1,1,7,0
CHEMBL1743054,OZORALIZUMAB,N/A,True,True,False,89,398;4152;4167;4516,,2.0,Completed,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000685,rheumatoid arthritis,2,1,4,0
CHEMBL1743057,PEGSUNERCEPT,N/A,True,True,False,87,396;4150;4165;4514,,2.0,Completed,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000685,rheumatoid arthritis,2,1,4,0
CHEMBL1743068,SECUKINUMAB,N/A,False,True,False,,154;4223;7303,,4.0,,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_0000540,immune system disease,1,1,3,0
CHEMBL1743070,SILTUXIMAB,N/A,False,True,False,,117;167;4403;4539;4618;4697;7587,,4.0,,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,EFO_0000540,immune system disease,1,1,7,0
CHEMBL1743071,SIRUKUMAB,N/A,False,True,False,,118;168;4404;4540;4619;4698;7588,,3.0,,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,EFO_0000540,immune system disease,1,1,7,0
CHEMBL1743082,TRASTUZUMAB EMTANSINE,N/A,True,True,False,809;1542;1979;2215;2323;2387;2694;2755;2822,1522;1586;1650;1714;1778;1842;1906;2071;2135;2199;2263;2327;2391;2455;2519;2583;2647;2711;2775;2839;2903;2967;3037;3101;3165;3229;3293;3357;3421;3485;3549;3640;3704;3768;3832;3896;3960;4027,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000305,breast carcinoma,2,9,38,0
CHEMBL1744447,ROSUVASTATIN CALCIUM,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],True,True,True,740,7619;7634;7649;7664,52,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,EFO_0003914,atherosclerosis,3,1,4,1
CHEMBL175,DEXIBUPROFEN,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,True,True,True,132;925,355;4473;5565;5625;5682;6066;6140;6214;6288;6362;6436,155,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL1752,DYPHYLLINE,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O,True,True,True,415;1050;1078;2155,4329;5737;5767;5795;5832;5862,605,4.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,HP_0006536,Airway obstruction,3,4,3,1
CHEMBL1754,DOXAPRAM,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,True,True,False,530;535,15;20;7722;7727,,4.0,,KCNK3;KCNK9,Phase 4 - resting membrane potential;TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316;R-HSA-5576886,,EFO_0000684,respiratory system disease,2,2,2,0
CHEMBL176,BEKANAMYCIN,NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O,False,False,True,,,337,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1762621,BARDOXOLONE METHYL,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,True,True,False,1232,4020;4087;4113;4116;4119;4122;4125;4128;4131;4134;4137;4140;4155;4170;4173;4176;4179;4182;4185;4195;4198;4201;4204;4219;4281;4284;4287;4316;4348,,3.0,Terminated,IKBKB,"Activation of NF-kappaB in B cells;CLEC7A (Dectin-1) signaling;Downstream TCR signaling;ER-Phagosome pathway;FCERI mediated NF-kB activation;IKBKB deficiency causes SCID;IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR);IKK complex recruitment mediated by RIP1;IRAK1 recruits IKK complex;IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation;IkBA variant leads to EDA-ID;Interleukin-1 signaling;MAP3K8 (TPL2)-dependent MAPK1/3 activation;Modulation of host responses by IFN-stimulated genes;NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10;NF-kB is activated and signals survival;NOD1/2 Signaling Pathway;PKR-mediated signaling;RIP-mediated NFkB activation via ZBP1;Regulation of NF-kappa B signaling;Regulation of TNFR1 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;SLC15A4:TASL-dependent IRF5 activation;TAK1-dependent IKK and NF-kappa-B activation;TICAM1, RIP1-mediated IKK complex recruitment;TNFR1-induced NF-kappa-B signaling pathway;TRAF6 mediated NF-kB activation;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;p75NTR recruits signalling complexes",R-HSA-112409;R-HSA-1169091;R-HSA-1236974;R-HSA-168638;R-HSA-168927;R-HSA-1810476;R-HSA-202424;R-HSA-209543;R-HSA-209560;R-HSA-2871837;R-HSA-445989;R-HSA-5357905;R-HSA-5357956;R-HSA-5602636;R-HSA-5603027;R-HSA-5603029;R-HSA-5607764;R-HSA-9020702;R-HSA-933542;R-HSA-937039;R-HSA-937041;R-HSA-9705671;R-HSA-975144;R-HSA-9758274;R-HSA-9833482;R-HSA-9860276;R-HSA-9860927;R-HSA-9909505,,EFO_0000401,diabetic nephropathy,2,1,29,0
CHEMBL1764,LEVOMEPROMAZINE,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,False,False,True,,,664,,,,,,D2-like dopamine receptor antagonist,,,1,0,0,1
CHEMBL1766,DESOXIMETASONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,True,True,True,18,710;2019;5934;7838;7975;8041;8112;8178;8244,205,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000676,psoriasis,3,1,9,1
CHEMBL1766582,R-1487 HYDROCHLORIDE,Cl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,False,False,True,,,96,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1767164,GSK-1004723,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1,True,True,False,1038,6668,,2.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL1770248,ERTUGLIFLOZIN,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,False,False,True,,,588,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL1771,CLOPIDOGREL,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,True,True,False,469,1354,,4.0,,P2RY12,G alpha (i) signalling events,R-HSA-418594,,HP_0004419,Recurrent thrombophlebitis,2,1,1,0
CHEMBL1773,CAPECITABINE,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,False,False,True,,,416,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL1779710,EVOGLIPTIN,CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,True,False,True,665,,520,3.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0000400,diabetes mellitus,2,1,0,1
CHEMBL1783256,AZD6280,CCCNC(=O)c1nnc2c(-c3cc(OC)ccc3OC)cccc2c1N,True,False,False,1723;2130,,,1.0,Completed,GABRA2;GABRA3,,,,EFO_0005230,anxiety,1,2,0,0
CHEMBL1783282,AZD7325,CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,True,False,False,1716;2124,,,2.0,Completed,GABRA2;GABRA3,,,,EFO_0005230,anxiety,1,2,0,0
CHEMBL17860,LOFEXIDINE,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,True,True,False,1331;1375;2521,902;946;1006;1050;1110;1162;1206;1394;1438;1498,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0003890,drug dependence,2,3,6,0
CHEMBL178803,BLONANSERIN,CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1,False,False,True,,,724,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl,True,True,False,1333;1384;2527,904;955;1008;1059;1112;1164;1215;1396;1447;1500,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0005800,substance withdrawal syndrome,2,3,6,0
CHEMBL1789941,RUXOLITINIB,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,True,True,False,758;780,183;205;645;667;4235;4414;4555;4577;4634;4656;4713;4735;4782;4820;4842;4889;4911;4955;4977;5021;5043;5087;5131;5153;5209;5259;5297;5319;5363;5385;5457;6910;6932;7466;8295;8323;8351;8385;8413;8441,,4.0,,JAK1;JAK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,2,2,27,0
CHEMBL1790041,RANITIDINE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,True,True,True,750,5819,730,4.0,,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,EFO_0003948,gastroesophageal reflux disease,3,1,1,1
CHEMBL1795071,RUXOLITINIB PHOSPHATE,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,True,True,True,762;786,187;211;649;673;4239;4418;4559;4583;4638;4662;4717;4741;4786;4824;4848;4893;4917;4959;4983;5025;5049;5093;5135;5159;5213;5263;5301;5325;5367;5391;5461;6914;6938;7472;8301;8329;8357;8391;8419;8447,468,4.0,,JAK1;JAK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,EFO_0002429,polycythemia vera,3,2,27,1
CHEMBL17976,RESINIFERATOXIN,C=C(C)[C@]12C[C@@H](C)[C@@]34O[C@](Cc5ccccc5)(O[C@@H]1[C@@H]3C=C(COC(=O)Cc1ccc(O)c(OC)c1)C[C@]1(O)C(=O)C(C)=C[C@@H]41)O2,True,True,False,701,5727,,1.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0004616,"osteoarthritis, knee",2,1,1,0
CHEMBL1800807,ANACETRAPIB,COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,True,False,False,1900,,,3.0,Completed,CETP,,,,EFO_0001645,coronary artery disease,1,1,0,0
CHEMBL1808388,BEXAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,False,False,True,,,589,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL182066,RADIPRODIL,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,True,True,False,724;2616,3630;6814;6841;6868;6901;7059;7086;7113;7140,,2.0,Completed,GRIN1;GRIN2B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,EFO_0005762,neuropathic pain,2,2,9,0
CHEMBL1835207,APRICOXIB,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1,True,True,False,161,384;4502;5711;6095;6169;6243;6317;6391;6465,,2.0,Completed,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0002618,pancreatic carcinoma,2,1,9,0
CHEMBL185,FLUOROURACIL,O=c1[nH]cc(F)c(=O)[nH]1,False,False,True,,,410,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL1873475,IBRUTINIB,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,True,True,True,189,595;4090;6552;6732,550,4.0,,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000095,chronic lymphocytic leukemia,3,1,4,1
CHEMBL187927,DIANICLINE,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3,True,True,False,437;2134,7917;7931;7945,,3.0,Completed,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0003768,nicotine dependence,2,2,3,0
CHEMBL188462,ISPRONICLINE,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1,True,True,False,444;2140,7924;7938;7952,,2.0,Completed,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0001072,memory impairment,2,2,3,0
CHEMBL188952,PIRPROFEN,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,True,True,True,145;926,368;4486;5566;5626;5695;6079;6153;6227;6301;6375;6449,154,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL189171,ACEMETACIN,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,True,True,True,133;927,356;4474;5567;5627;5683;6067;6141;6215;6289;6363;6437,166,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL189475,LADARIXIN,C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,False,False,True,,,458,,,,,,Interleukin-8 receptor A modulator | Interleukin-8 receptor B modulator,,,1,0,0,1
CHEMBL190,THEOPHYLLINE,Cn1c(=O)c2[nH]cnc2n(C)c1=O,True,True,False,413;1046;1074;2151,4325;5735;5763;5791;5830;5858,,4.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,,EFO_0006505,chronic bronchitis,2,4,3,0
CHEMBL19019,NALTREXONE,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,True,True,False,321,291;1325;7238,,4.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,MONDO_0002046,alcohol abuse,2,1,3,0
CHEMBL190333,RWJ-67657,OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1,False,False,True,,,90,,,,,,MAP kinase p38 alpha inhibitor | MAP kinase p38 beta inhibitor,,,1,0,0,1
CHEMBL1908376,SEOCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,245,5998;7775;7893,28,3.0,Terminated,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000182,hepatocellular carcinoma,3,1,3,1
CHEMBL1908391,MASITINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,True,True,False,1102;1147,552;6964;7000;7498,,4.0,,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,2,3,0
CHEMBL1908397,KW-2449,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,True,True,False,1222,4313,,1.0,Terminated,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000222,acute myeloid leukemia,2,1,1,0
CHEMBL191,LOSARTAN,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,True,True,False,583,6537;7156;7267;7287,,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL191413,REPARIXIN,CC(C)Cc1ccc([C@@H](C)C(=O)NS(C)(=O)=O)cc1,False,False,True,,,457,,,,,,Interleukin-8 receptor A modulator | Interleukin-8 receptor B modulator,,,1,0,0,1
CHEMBL192,SILDENAFIL,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,True,True,False,875,7675;7702;7715,,4.0,Unknown status,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,,EFO_0004234,erectile dysfunction,2,1,3,0
CHEMBL1922235,DAREXABAN,COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1,True,True,True,461,7541;7570,469,3.0,Completed,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,Coagulation factor X inhibitor,EFO_0004286,venous thromboembolism,3,1,2,1
CHEMBL1928262,GISADENAFIL,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1,True,True,True,879,7679;7706;7719,451,2.0,Completed,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,EFO_0000284,benign prostatic hyperplasia,3,1,3,1
CHEMBL1929396,ANAGLIPTIN,Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,True,False,True,675,,521,3.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL19299,LOXOPROFEN,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,True,True,True,157;933,380;4498;5573;5633;5707;6091;6165;6239;6313;6387;6461,161,3.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL193240,ROFLUMILAST,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,True,True,True,408;1041;1069;2147,4320;5730;5758;5786;5825;5853,599,4.0,Completed;Recruiting,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL193482,ESTRIOL,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,True,False,False,2304,,,3.0,Completed,ESR1,,,,EFO_1001271,Atrophic Vaginitis,1,1,0,0
CHEMBL1938400,PF-03715455,CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,False,False,True,,,97,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL1944698,ZOTIRACICLIB,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,True,True,True,798,223;685;4595;4674;4753;4860;4929;4995;5061;5105;5171;5337;5403;6950;7484;8313;8341;8369;8403;8431;8459,478,1.0,Completed,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000095,chronic lymphocytic leukemia,3,1,21,1
CHEMBL19449,IBUDILAST,CC(C)C(=O)c1c(C(C)C)nn2ccccc12,True,True,True,423;878;1056;1085;2162,4336;5745;5773;5802;5840;5869;7678;7705;7718,443,3.0,Recruiting,PDE4A;PDE4B;PDE4C;PDE4D;PDE5A,"DARPP-32 events;G alpha (s) signalling events;RHOBTB1 GTPase cycle;Smooth Muscle Contraction;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;cGMP effects",R-HSA-180024;R-HSA-418457;R-HSA-418555;R-HSA-445355;R-HSA-9013422;R-HSA-9860927,Phosphodiesterase 4 inhibitor | Phosphodiesterase 5A inhibitor,HP_0002196,Myelopathy,3,5,6,1
CHEMBL1946170,REGORAFENIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,True,True,True,1101;1148;1207,553;4298;6965;6999;7499,114,4.0,,ABL1;KIT;PDGFRB,"RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-1433557;R-HSA-5673001;R-HSA-8866910;R-HSA-9860927,MAP kinase p38 beta inhibitor,EFO_0000616,neoplasm,3,3,4,1
CHEMBL1951095,ERAVACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,False,False,True,,,362,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL1951143,FIMASARTAN,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,True,True,True,593,6547;7166;7277;7297,15,3.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL1951914,AZD5672,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,True,True,True,222,1264;4381;6763;6787,503,2.0,Completed,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 5 antagonist,EFO_0000685,rheumatoid arthritis,3,1,4,1
CHEMBL1956285,DSM-265,Cc1cc(Nc2ccc(S(F)(F)(F)(F)F)cc2)n2nc(C(C)(F)F)nc2n1,False,False,True,,,736,,,,,,Dihydroorotate dehydrogenase inhibitor,,,1,0,0,1
CHEMBL1957287,TEGOBUVIR,Fc1ccccc1-c1nc2ccn(Cc3ccc(-c4ccc(C(F)(F)F)cc4C(F)(F)F)nn3)cc-2n1,False,False,True,,,435,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL1963681,AVANAFIL,COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl,True,True,True,876,7676;7703;7716,452,4.0,,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,EFO_0004234,erectile dysfunction,3,1,3,1
CHEMBL197194,VIDOFLUDIMUS,COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1,False,False,True,,,725,,,,,,Dihydroorotate dehydrogenase inhibitor,,,1,0,0,1
CHEMBL1980297,ILORASERTIB,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,True,True,False,945;1135,7033,,2.0,Terminated,BLK;PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,MONDO_0004992,cancer,2,2,1,0
CHEMBL1980391,RG-1530,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,True,True,False,1137,7035,,1.0,Completed,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000616,neoplasm,2,1,1,0
CHEMBL1981592,AVIPTADIL,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O,True,True,False,398;1342;1393;1500;1858;2541,861;913;964;1017;1068;1121;1173;1224;1405;1456;1509;6523;6723,,3.0,Withdrawn,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000694,severe acute respiratory syndrome,2,6,8,0
CHEMBL198362,RIVAROXABAN,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,True,True,True,449,7529;7558,463,4.0,,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,Coagulation factor X inhibitor,EFO_0000275,atrial fibrillation,3,1,2,1
CHEMBL2,PRAZOSIN,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,True,True,False,374;1478;1836,837;6499;6699,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000537,hypertension,2,3,3,0
CHEMBL2017179,EVACETRAPIB,Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1,True,False,False,1897,,,3.0,Terminated,CETP,,,,EFO_0000319,cardiovascular disease,1,1,0,0
CHEMBL2018096,IPRAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,False,False,True,,,609,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],True,True,True,11,703;2012;5927;7831;7968;8034;8105;8171;8237,197,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL2023895,HYDROXYSTILBAMIDINE ISETHIONATE,N=C(N)c1ccc(/C=C/c2ccc(C(=N)N)cc2O)cc1.O=S(=O)(O)CCO.O=S(=O)(O)CCO,False,False,True,,,420,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL2028661,AZILSARTAN MEDOXOMIL,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,True,True,False,592,6546;7165;7276;7296,,3.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL2028665,REMOGLIFLOZIN ETABONATE,CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O,False,False,True,,,590,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL2029422,PF-4136309,O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1,False,False,True,,,504,,,,,,C-C chemokine receptor type 2 antagonist,,,1,0,0,1
CHEMBL2031465,AZD-6703,Cc1ccc(C(=O)NC2CC2)cc1-n1cnc2ccc(N3CCN(C)CC3)cc2c1=O,False,False,True,,,80,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL2035185,CT-1578,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,False,False,True,,,479,,,,,,Tyrosine-protein kinase JAK2 inhibitor,,,1,0,0,1
CHEMBL2035187,PACRITINIB,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2,True,True,True,779,204;666;4576;4655;4734;4841;4910;4976;5042;5086;5152;5318;5384;6931;7465;8294;8322;8350;8384;8412;8440,496,4.0,,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000616,neoplasm,3,1,21,1
CHEMBL203567,RO-3201195,Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1,False,False,True,,,91,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL2040682,CICLESONIDE,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,True,True,True,41,733;2042;5957;7861;7998;8064;8135;8201;8267,232,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0003956,seasonal allergic rhinitis,3,1,9,1
CHEMBL2043025,TMC-647055,COc1ccc2c(c1)C=C1Cn3c-2c(C2CCCCC2)c2ccc(cc23)C(=O)NS(=O)(=O)N(C)CCOCCN(C)C1=O,False,False,True,,,436,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL206031,BRECANAVIR,Cc1nc(COc2ccc(C[C@H](NC(=O)O[C@H]3CO[C@H]4OCC[C@H]43)[C@H](O)CN(CC(C)C)S(=O)(=O)c3ccc4c(c3)OCO4)cc2)cs1,False,False,True,,,409,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL2062257,BRIMONIDINE TARTRATE,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,True,True,False,1318;1370;2517,889;941;993;1045;1097;1149;1201;1381;1433;1485,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,3,6,0
CHEMBL2062264,PHENYLEPHRINE BITARTRATE,CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O,True,True,False,390;1493;1846,853;6515;6715,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0007214,common cold,2,3,3,0
CHEMBL2062266,DIHYDROCODEINE BITARTRATE,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O,True,True,True,288,258;1292;7205,651,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL206253,NETUPITANT,Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,False,False,True,,,531,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL206815,APRATASTAT,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO,True,True,True,624,35;59;90,358,2.0,Completed,MMP13,Activation of Matrix Metalloproteinases;Collagen degradation;Degradation of the extracellular matrix,R-HSA-1442490;R-HSA-1474228;R-HSA-1592389,Matrix metalloproteinase 13 inhibitor,EFO_0000685,rheumatoid arthritis,3,1,3,1
CHEMBL206834,BAFETINIB,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,True,True,False,1217,4308,,2.0,Completed,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000095,chronic lymphocytic leukemia,2,1,1,0
CHEMBL20684,ABT-751,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,True,True,False,845;1580;2014;2252;2358;2422;2730;2793;2855,1558;1622;1686;1750;1814;1878;1942;2107;2171;2235;2299;2363;2427;2491;2555;2619;2683;2747;2811;2875;2939;3003;3073;3137;3201;3265;3329;3393;3457;3521;3585;3676;3740;3804;3868;3932;3996;4063,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000621,neuroblastoma,2,9,38,0
CHEMBL2068724,ACAMPROSATE CALCIUM,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2],True,True,True,505;713;1434;1520;1611;1658;1704;1746;1779;1800;1873;1934;1957;2065;2111;2185;2472;2559;2581;2606;2629;2650;2674,3619;6803;6830;6857;6890;7048;7075;7102;7129,381,4.0,Not yet recruiting,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,MONDO_0007079,alcohol dependence,3,23,9,1
CHEMBL2068839,RISLENEMDAZ,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,True,True,False,726;2619,3632;6816;6843;6870;6903;7061;7088;7115;7142,,2.0,Completed,GRIN1;GRIN2B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0002009,major depressive disorder,2,2,9,0
CHEMBL207433,SB-705498,O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1,True,True,False,696,5722,,2.0,Terminated,TRPV1,TRP channels,R-HSA-3295583,,EFO_0000555,irritable bowel syndrome,2,1,1,0
CHEMBL207538,BREXANOLONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,True,False,True,494;1424;1515;1646;1692;1741;1776;1798;1870;1931;2055;2099;2460;2556;2578;2627,,287,4.0,Completed;Withdrawn,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0007453,postpartum depression,2,16,0,2
CHEMBL2079587,STANOZOLOL,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,True,True,False,564,1987;5902;7806,,2.0,Not yet recruiting,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000198,myelodysplastic syndrome,2,1,3,0
CHEMBL2079588,TELATINIB,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,True,True,False,1134;1174,579;6991;7032;7525,,2.0,Completed;Unknown status,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,MONDO_0001056,gastric cancer,2,2,3,0
CHEMBL20883,TEGAFUR,O=c1[nH]c(=O)n(C2CCCO2)cc1F,False,False,True,,,404,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL2095206,BOSUTINIB MONOHYDRATE,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O,True,True,False,1203;2201,4294,,4.0,,ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000339,chronic myelogenous leukemia,2,2,1,0
CHEMBL2095208,COBICISTAT,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,True,True,True,213;947;1626;1903,7908;7909;7912;7913,398,4.0,Not yet recruiting,CYP3A4;CYP3A43;CYP3A5;CYP3A7,Aflatoxin activation and detoxification;Xenobiotics,R-HSA-211981;R-HSA-5423646,Cytochrome P450 3A inhibitor,EFO_0000180,HIV-1 infection,3,4,2,1
CHEMBL2096631,CLORAZEPATE DIPOTASSIUM,O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],True,False,True,492;1422;1655;1690;2054;2109;2468,,253,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0006788,anxiety disorder,2,7,0,2
CHEMBL2097081,NITROPRUSSIDE,N/A,True,True,False,72,7688,,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,,EFO_0000537,hypertension,2,1,1,0
CHEMBL2103736,FENOPROFEN CALCIUM,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2],True,True,True,112;898,335;4453;5538;5598;5662;6046;6120;6194;6268;6342;6416,115,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL2103738,LITHIUM CITRATE,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+],True,True,False,1179;1226,5493;5496;5501;5504;5507;5512;5515;5518;8090,,4.0,,GSK3A;GSK3B,AKT phosphorylates targets in the cytosol;Constitutive Signaling by AKT1 E17K in Cancer;Maturation of nucleoprotein;Regulation of RUNX2 expression and activity;Suppression of apoptosis;XBP1(S) activates chaperone genes,R-HSA-198323;R-HSA-381038;R-HSA-5674400;R-HSA-8939902;R-HSA-9635465;R-HSA-9683610,,EFO_0009963,bipolar I disorder,2,2,6,0
CHEMBL2103739,EMEDASTINE DIFUMARATE,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O,True,True,False,983,6613,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0007141,allergic conjunctivitis,2,1,1,0
CHEMBL2103743,TOFACITINIB CITRATE,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,True,False,759;782;1185,184;207;403;646;669;782;4236;4267;4415;4521;4556;4579;4604;4635;4658;4683;4714;4737;4762;4783;4803;4821;4844;4869;4890;4913;4938;4956;4979;5004;5022;5045;5070;5089;5114;5132;5155;5180;5210;5230;5260;5280;5298;5321;5346;5364;5387;5412;5428;5458;5478;6911;6934;7468;8297;8325;8353;8387;8415;8443,,4.0,,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000685,rheumatoid arthritis,2,3,28,0
CHEMBL2103744,MORPHINE SULFATE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O,True,True,True,289,259;1293;7206,652,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL2103791,ADIPIPLON,CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12,True,False,False,518;1445;1669;1717;2079;2125;2484,,,2.0,Terminated,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,,EFO_0004698,insomnia,1,7,0,0
CHEMBL2103792,AGATOLIMOD,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O,True,True,False,258,772;7334;7389;7411;7433,,3.0,Terminated,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,EFO_0003060,non-small cell lung carcinoma,2,1,5,0
CHEMBL2103793,AGATOLIMOD SODIUM,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],True,True,False,260,774;7336;7391;7413;7435,,3.0,Terminated,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,EFO_0003060,non-small cell lung carcinoma,2,1,5,0
CHEMBL2103795,AZILSARTAN KAMEDOXOMIL,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+],True,True,True,588,6542;7161;7272;7292,16,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000537,hypertension,3,1,4,1
CHEMBL2103802,DAPAGLIFLOZIN PROPANEDIOL,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1.C[C@H](O)CO.O,False,False,True,,,591,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL2103826,DAVUNETIDE,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O,True,True,False,855;1588;2023;2261;2367;2431;2737;2802;2865,1568;1632;1696;1760;1824;1888;1952;2117;2181;2245;2309;2373;2437;2501;2565;2629;2693;2757;2821;2885;2949;3013;3083;3147;3211;3275;3339;3403;3467;3531;3595;3686;3750;3814;3878;3942;4006;4073,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,HP_0100543,Cognitive impairment,2,9,38,0
CHEMBL2103827,DROXIDOPA,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,True,True,False,368;1310;1360;1470;1815;2509,831;881;931;985;1035;1089;1141;1191;1373;1423;1477;6493;6693,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL2103828,ELINOGREL,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,True,True,False,474,1359,,2.0,Terminated,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0000612,myocardial infarction,2,1,1,0
CHEMBL2103829,FAXELADOL,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1,True,True,True,338;1294,308;1342;7255,669,2.0,Completed,OPRM1;SLC6A4,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0005687,fibromyalgia,3,2,3,1
CHEMBL2103831,NAPROXCINOD,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1,True,True,True,156;936,379;4497;5576;5636;5706;6090;6164;6238;6312;6386;6460,157,3.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL2103836,IMAGABALIN,CCC[C@@H](C)C[C@H](N)CC(=O)O,True,False,False,1908;2495,,,3.0,Terminated,CACNA1A;CACNA2D1,,,,EFO_0005230,anxiety,1,2,0,0
CHEMBL2103838,DILMAPIMOD,Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2c1ccc(=O)n2-c1c(F)cccc1F,False,False,True,,,98,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL2103849,UDENAFIL,CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1,True,True,True,877,7677;7704;7717,453,3.0,Unknown status,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,EFO_0001361,pulmonary arterial hypertension,3,1,3,1
CHEMBL2103851,AMUVATINIB,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,True,True,False,1172,577;6989;7523,,2.0,Completed,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000702,small cell lung carcinoma,2,1,3,0
CHEMBL2103852,CROLIBULIN,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC,True,True,True,867;1599;2034;2274;2378;2443;2749;2813;2877,1580;1644;1708;1772;1836;1900;1964;2129;2193;2257;2321;2385;2449;2513;2577;2641;2705;2769;2833;2897;2961;3025;3095;3159;3223;3287;3351;3415;3479;3543;3607;3698;3762;3826;3890;3954;4018;4085,62,1.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,MONDO_0002108;MONDO_0004992,cancer;thyroid cancer,3,9,38,1
CHEMBL2103854,OMADACYCLINE TOSYLATE,CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cc1ccc(S(=O)(=O)O)cc1,False,False,True,,,345,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2103873,MACITENTAN,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,True,False,False,1912,,,4.0,,EDNRA,,,,EFO_0000537,hypertension,1,1,0,0
CHEMBL2103876,MAPRACORAT,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1,True,True,True,57,749;2058;5973;7877;8014;8080;8151;8217;8283,233,3.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,MONDO_0005129,cataract,3,1,9,1
CHEMBL2103878,ODELEPRAN,NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1,True,True,False,343,313;1347;7260,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,MONDO_0007079,alcohol dependence,2,1,3,0
CHEMBL2103879,GANETESPIB,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,False,False,True,,,585,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL2103881,DEXMECAMYLAMINE,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C,True,True,False,441;2137,7921;7935;7949,,3.0,Completed,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,MONDO_0002009,major depressive disorder,2,2,3,0
CHEMBL2104745,PAGOCLONE,CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1,True,False,True,519;1447;1672;1720;2077;2127;2482,,290,2.0,Completed,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0803321,premature ejaculation,2,7,0,2
CHEMBL2104927,FIGOPITANT,CN(CCc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)[C@H](c1ccccc1)N1CCN(CC2CC2)CC1,False,False,True,,,537,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL2104955,BECOCALCIDIOL,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O,True,True,True,251,6004;7781;7899,29,2.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000676,psoriasis,3,1,3,1
CHEMBL2104964,TEBANICLINE TOSYLATE,Cc1ccc(S(=O)(=O)O)cc1.Clc1ccc(OC[C@H]2CCN2)cn1,False,False,True,,,538,,,,,,Neuronal acetylcholine receptor; alpha4/beta2 agonist,,,1,0,0,2
CHEMBL2104986,TEDATIOXETINE,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1,True,True,True,405;1296,868;6530;6730,703,2.0,Completed,ADRA1A;SLC6A4,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,Serotonin 2a (5-HT2a) receptor antagonist,MONDO_0002009,major depressive disorder,3,2,3,1
CHEMBL2104991,VABICASERIN HYDROCHLORIDE,Cl.c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2,False,False,True,,,704,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL2104992,VESTIPITANT MESYLATE,CS(=O)(=O)O.Cc1cc(F)ccc1[C@H]1CNCCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,False,False,True,,,539,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL2104993,VORTIOXETINE,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,True,False,False,1291,,,3.0,Terminated,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL2105107,INECALCITOL,C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C,True,True,True,250,6003;7780;7898,30,2.0,Unknown status,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000222,acute myeloid leukemia,3,1,3,1
CHEMBL2105395,OSPEMIFENE,OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,True,False,False,2295,,,4.0,,ESR1,,,,EFO_1001271,Atrophic Vaginitis,1,1,0,0
CHEMBL2105458,THENALIDINE,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1,True,True,False,986,6616,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL2105527,TETRAZEPAM,CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21,False,False,True,,,291,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL2105629,VINFLUNINE DITARTRATE,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,False,False,True,,,68,,,,,,Tubulin inhibitor,,,1,0,0,1
CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO,True,True,False,854;1587;2022;2262;2366;2430;2738;2801;2866,1567;1631;1695;1759;1823;1887;1951;2116;2180;2244;2308;2372;2436;2500;2564;2628;2692;2756;2820;2884;2948;3012;3082;3146;3210;3274;3338;3402;3466;3530;3594;3685;3749;3813;3877;3941;4005;4072,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_1001901,neuroendocrine neoplasm,2,9,38,0
CHEMBL2105648,PALOVAROTENE,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,True,True,False,188,5990;6016;6025,,4.0,,RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,,MONDO_0007606,fibrodysplasia ossificans progressiva,2,1,3,0
CHEMBL2105665,ELACYTARABINE,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O,False,False,True,,,421,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL2105667,ORVEPITANT,Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,False,False,True,,,540,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL2105669,TEDIZOLID PHOSPHATE,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1,False,False,True,,,329,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2105682,EDOXABAN TOSYLATE,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1,True,True,True,451,7531;7560,470,4.0,,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,Coagulation factor X inhibitor,EFO_0000275,atrial fibrillation,3,1,2,1
CHEMBL2105683,NAPROXEN ETEMESIL,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1,True,True,True,164;940,387;4505;5580;5640;5714;6098;6172;6246;6320;6394;6468,158,2.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,MONDO_0005178,osteoarthritis,3,2,10,1
CHEMBL2105705,LUNACALCIPOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,252,6005;7782;7900,31,2.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000676,psoriasis,3,1,3,1
CHEMBL2105708,PONATINIB HYDROCHLORIDE,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl,True,True,False,1200;2198,4291,,4.0,,ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000220,acute lymphoblastic leukemia,2,2,1,0
CHEMBL2105711,TOFOGLIFLOZIN,CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O,False,False,True,,,592,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL2105728,CRENOLANIB,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,True,True,False,1115,7013,,3.0,Recruiting,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000222,acute myeloid leukemia,2,1,1,0
CHEMBL2105732,LEVOMILNACIPRAN HYDROCHLORIDE,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN.Cl,True,False,False,1247,,,4.0,,SLC6A4,,,,EFO_0005687,fibromyalgia,1,1,0,0
CHEMBL2105738,GALETERONE,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,True,True,True,563,1986;5901;7805,81,3.0,Terminated,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,MONDO_0008315,prostate cancer,3,1,3,1
CHEMBL2105740,SITAXENTAN SODIUM,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+],True,False,False,1915,,,4.0,,EDNRA,,,,MONDO_0005149,pulmonary hypertension,1,1,0,0
CHEMBL2105749,SAMIDORPHAN L-MALATE,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O,True,True,False,318,288;1322;7235,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0009963,bipolar I disorder,2,1,3,0
CHEMBL2105754,TRELAGLIPTIN SUCCINATE,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O.O=C(O)CCC(=O)O,True,False,True,669,,522,3.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0000400,diabetes mellitus,2,1,0,1
CHEMBL2105755,NALDEMEDINE,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1,True,True,False,319,289;1323;7236,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0002019,Constipation,2,1,3,0
CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O,True,True,False,1105;1151,556;6968;7003;7502,,4.0,,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000681,renal cell carcinoma,2,2,3,0
CHEMBL2105759,BARICITINIB,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,True,True,True,757;777,182;202;644;664;4234;4413;4554;4574;4633;4653;4712;4732;4781;4819;4839;4888;4908;4954;4974;5020;5040;5084;5130;5150;5208;5258;5296;5316;5362;5382;5456;6909;6929;7463;8292;8320;8348;8382;8410;8438,480,4.0,,JAK1;JAK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,EFO_0000540,immune system disease,3,2,27,1
CHEMBL2105760,BREXPIPRAZOLE,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,False,False,True,,,705,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL2105762,OMARIGLIPTIN,CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,True,False,True,666,,523,3.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0000400,diabetes mellitus,2,1,0,1
CHEMBL2105842,CORTIVAZOL,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,True,True,True,63,755;2064;5979;7883;8020;8086;8157;8223;8289,234,2.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0003843,pain,3,1,9,1
CHEMBL2106068,ATRASENTAN HYDROCHLORIDE,CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1.Cl,True,False,False,1922,,,3.0,Completed,EDNRA,,,,MONDO_0008315,prostate cancer,1,1,0,0
CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,True,True,False,1343;1395;2542,914;966;1018;1070;1122;1174;1226;1406;1458;1510,,3.0,Completed,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0001422;EFO_0003843,cirrhosis of liver;pain,2,3,6,0
CHEMBL2106227,ETIFOXINE,CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1,True,False,False,511;1439;1529;1664;1710;1752;1784;1804;1877;1939;2074;2117;2478;2563;2591;2635,,,3.0,,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,,EFO_0005230,anxiety,1,16,0,0
CHEMBL2106309,HYDROCORTISONE ACEPONATE,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,False,False,True,,,235,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL2106468,TRICETAMIDE,CCN(CC)C(=O)CNC(=O)c1cc(OC)c(OC)c(OC)c1,False,False,True,,,471,,,,,,Tyrosine-protein kinase JAK1 inhibitor,,,1,0,0,1
CHEMBL2106615,BAZEDOXIFENE ACETATE,CC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,True,False,False,2285,,,4.0,,ESR1,,,,EFO_0003854,postmenopausal osteoporosis,1,1,0,0
CHEMBL2106798,NERAMEXANE MESYLATE,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,True,True,True,718;1617;1963;2190;2611;2659;2680,3624;6808;6835;6862;6895;7053;7080;7107;7134,399,3.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,HP_0000360,Tinnitus,3,7,9,1
CHEMBL2106829,METHAQUALONE HYDROCHLORIDE,Cc1ccccc1-n1c(C)nc2ccccc2c1=O.Cl,False,False,True,,,292,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL2107067,TESTOSTERONE UNDECANOATE,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,True,True,False,546,1969;5884;7788,,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL2107186,RESOCORTOL BUTYRATE,CCCC(=O)O[C@]1(C(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,False,False,True,,,236,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL2107339,ESMIRTAZAPINE MALEATE,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O,True,True,True,1028;1344;1396;2544,915;967;1019;1071;1123;1175;1227;1407;1459;1511;6658,706,3.0,Completed,ADRA2A;ADRA2B;ADRA2C;HRH1,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,Serotonin 2a (5-HT2a) receptor antagonist,EFO_0004698,insomnia,3,4,7,1
CHEMBL2107341,FISPEMIFENE,OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,True,False,False,2311,,,2.0,Completed,ESR1,,,,EFO_0004234,erectile dysfunction,1,1,0,0
CHEMBL2107342,GAMITHROMYCIN,CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C,False,False,True,,,363,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2107360,PALIPERIDONE PALMITATE,CCCCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(CCN1CCC(c3noc4cc(F)ccc34)CC1)c2=O,False,False,True,,,691,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL2107384,VICRIVIROC MALEATE,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O,True,True,True,224,1266;4383;6765;6789,505,2.0,Completed,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 5 antagonist,EFO_0000764,HIV infection,3,1,4,1
CHEMBL2107387,VORTIOXETINE HYDROBROMIDE,Br.Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,True,False,False,1276,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL2107455,IGURATIMOD,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,True,True,False,151,374;4492;5701;6085;6159;6233;6307;6381;6455,,3.0,Completed,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL2107546,BUCINDOLOL HYDROCHLORIDE,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl,True,True,False,400;1503;1860,863;6525;6725,,2.0,Completed,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000275,atrial fibrillation,2,3,3,0
CHEMBL2107729,ATACIGUAT,O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1,True,True,True,75,7691,254,2.0,Completed,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000266,aortic stenosis,3,1,1,1
CHEMBL2107759,MILATAXEL,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C,True,True,True,844;1576;2011;2250;2355;2420;2727;2790;2854,1557;1621;1685;1749;1813;1877;1941;2106;2170;2234;2298;2362;2426;2490;2554;2618;2682;2746;2810;2874;2938;3002;3072;3136;3200;3264;3328;3392;3456;3520;3584;3675;3739;3803;3867;3931;3995;4062,66,2.0,Unknown status,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000588,mesothelioma,3,9,38,1
CHEMBL2107760,NEBENTAN,COc1ccccc1Oc1c(NS(=O)(=O)/C=C/c2ccccc2)nc(-c2ncccn2)nc1OC,True,False,False,1924,,,2.0,Terminated,EDNRA,,,,EFO_0000673,prostate adenocarcinoma,1,1,0,0
CHEMBL2107771,RALFINAMIDE,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,True,True,True,717;1616;1962;2189;2610;2655;2679,3623;6807;6834;6861;6894;7052;7079;7106;7133,400,3.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,EFO_0003843,pain,3,7,9,1
CHEMBL2107779,SEMAPIMOD,C/C(=N\NC(=N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(/C(C)=N/NC(=N)N)cc(/C(C)=N/NC(=N)N)c2)cc(/C(C)=N/NC(=N)N)c1,False,False,True,,,99,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL2107801,RESEQUINIL,COc1cccc(-c2nccc3[nH]c(=O)c(-c4noc(C)n4)cc23)c1,True,False,False,522;1448;1673;1721;2081;2128;2486,,,2.0,Completed,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,,MONDO_0004975,Alzheimer disease,1,7,0,0
CHEMBL2107823,GANDOTINIB,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1,True,True,True,796,221;683;4593;4672;4751;4858;4927;4993;5059;5103;5169;5335;5401;6948;7482;8311;8339;8367;8401;8429;8457,481,2.0,"Active, not recruiting",JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000616,neoplasm,3,1,21,1
CHEMBL2107830,EMPAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,False,False,True,,,593,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL2107834,RIOCIGUAT,COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,True,True,False,73,7689,,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,,EFO_0000537,hypertension,2,1,1,0
CHEMBL2107842,ALBINTERFERON ALFA-2B,N/A,False,True,False,,632;4217;5204;5254;5452,,3.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL2107911,ONERCEPT,N/A,True,True,False,85,394;4148;4163;4512,,3.0,Terminated,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0003778,psoriatic arthritis,2,1,4,0
CHEMBL2107979,PEXELIZUMAB,N/A,False,True,False,,1238;7175;7736;7748;7760,,3.0,Completed,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0001645,coronary artery disease,1,1,5,0
CHEMBL2108080,PARNAPARIN SODIUM,N/A,True,True,False,174,146;7552;7581;7603,,3.0,Terminated,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0000545,infertility,2,1,4,0
CHEMBL2108147,STREPTOKINASE,N/A,True,True,False,681,74;105;132;455,,4.0,,PLG,Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Platelet degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-114608;R-HSA-1474228;R-HSA-1592389;R-HSA-381426,,HP_0004419,Recurrent thrombophlebitis,2,1,4,0
CHEMBL2108222,ALOXIPRIN,N/A,True,True,False,138;919,361;4479;5559;5619;5688;6072;6146;6220;6294;6368;6442,,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0003843,pain,2,2,10,0
CHEMBL2108250,ANISTREPLASE,N/A,True,True,False,682,75;106;133;456,,4.0,,PLG,Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Platelet degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-114608;R-HSA-1474228;R-HSA-1592389;R-HSA-381426,,HP_0004419,Recurrent thrombophlebitis,2,1,4,0
CHEMBL2108313,CONBERCEPT,N/A,False,True,False,,424;468;480;492;504;516;528;540;590;803,,3.0,Terminated,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0001365,age-related macular degeneration,1,1,10,0
CHEMBL2108508,INTERFERON ALFA-2A,N/A,False,True,False,,629;4214;5201;5251;5449,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL2108589,CLAZAKIZUMAB,N/A,False,True,False,,121;171;4407;4543;4622;4701;7591,,2.0,Terminated,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,EFO_0000384,Crohn's disease,1,1,7,0
CHEMBL2108628,PACLITAXEL POLIGLUMEX,N/A,True,True,False,828;1561;1996;2235;2340;2404;2711;2775;2839,1541;1605;1669;1733;1797;1861;1925;2090;2154;2218;2282;2346;2410;2474;2538;2602;2666;2730;2794;2858;2922;2986;3056;3120;3184;3248;3312;3376;3440;3504;3568;3659;3723;3787;3851;3915;3979;4046,,3.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL2108677,PEGINTERFERON BETA-1A,N/A,False,True,False,,630;4215;5202;5252;5450,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL2108718,SEMULOPARIN SODIUM,N/A,True,True,False,177,149;7555;7584;7606,,3.0,Terminated,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0004286,venous thromboembolism,2,1,4,0
CHEMBL2108723,PEGINTERFERON LAMBDA-1A,N/A,False,True,False,,4394;4777;4884,,3.0,Completed,IL10RB,Interleukin-10 signaling;Interleukin-20 family signaling;Other interleukin signaling,R-HSA-449836;R-HSA-6783783;R-HSA-8854691,,EFO_0003047,hepatitis C virus infection,1,1,3,0
CHEMBL2108730,SARILUMAB,N/A,False,True,False,,175;637;4547;4626;4705;7146,,4.0,,IL6R,Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Transcriptional regulation of granulopoiesis,R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-6785807;R-HSA-9616222;R-HSA-9679191,,EFO_0000540,immune system disease,1,1,6,0
CHEMBL2108739,PLACULUMAB,N/A,True,True,False,90,399;4153;4168;4517,,2.0,Completed,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000685,rheumatoid arthritis,2,1,4,0
CHEMBL2108752,PEGAPTANIB OCTASODIUM,N/A,False,True,False,,427;471;483;495;507;519;531;543;593;806,,3.0,Completed,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,MONDO_0810000,choroidal neovascularization,1,1,10,0
CHEMBL2108806,BEMIPARIN SODIUM,N/A,True,True,False,175,147;7553;7582;7604,,3.0,Completed,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0003907,deep vein thrombosis,2,1,4,0
CHEMBL2108887,AFELIMOMAB,N/A,True,True,False,86,395;4149;4164;4513,,2.0,,TNF,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807,,EFO_0000540,immune system disease,2,1,4,0
CHEMBL2109047,INTERFERON ALFA-N3,N/A,False,True,False,,633;4218;5205;5255;5453,,2.0,Completed,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000694,severe acute respiratory syndrome,1,1,5,0
CHEMBL2109084,DESMOTEPLASE,N/A,True,True,False,686,79;110;137;460,,3.0,Completed,PLG,Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Platelet degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-114608;R-HSA-1474228;R-HSA-1592389;R-HSA-381426,,EFO_0000712,stroke,2,1,4,0
CHEMBL2109204,NADROPARIN CALCIUM,N/A,True,True,False,176,148;7554;7583;7605,,3.0,Completed,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0003907,deep vein thrombosis,2,1,4,0
CHEMBL2109325,AMG-191,N/A,True,True,False,1177,582;6994;7528,,1.0,Recruiting,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,MONDO_0015974,severe combined immunodeficiency,2,1,3,0
CHEMBL2109341,CCR5MAB004,N/A,True,True,False,227,1269;4386;6768;6792,,1.0,Completed,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000764,HIV infection,2,1,4,0
CHEMBL2109342,HGS-1025,N/A,True,True,False,226,1268;4385;6767;6791,,1.0,Withdrawn,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000729,ulcerative colitis,2,1,4,0
CHEMBL2109343,LERONLIMAB,N/A,True,True,False,219,1261;4378;6760;6784,,3.0,Suspended,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,,MONDO_0100096,COVID-19,2,1,4,0
CHEMBL2109430,GIMSILUMAB,N/A,False,True,False,,4392;6879;8381,,2.0,Completed,CSF2,"Interleukin-10 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;RAF/MAP kinase cascade",R-HSA-512988;R-HSA-5673001;R-HSA-6783783,,MONDO_0100096,COVID-19,1,1,3,0
CHEMBL2109433,OTILIMAB,N/A,False,True,False,,4388;6875;8377,,3.0,Completed,CSF2,"Interleukin-10 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;RAF/MAP kinase cascade",R-HSA-512988;R-HSA-5673001;R-HSA-6783783,,EFO_0000685,rheumatoid arthritis,1,1,3,0
CHEMBL2109458,AMG-108,N/A,False,True,False,,635;4193;4401,,2.0,Withdrawn,IL1R1,Interleukin-1 signaling;Interleukin-10 signaling;Potential therapeutics for SARS,R-HSA-6783783;R-HSA-9020702;R-HSA-9679191,,EFO_0000400,diabetes mellitus,1,1,3,0
CHEMBL2109470,PERAKIZUMAB,N/A,False,True,False,,162;4231;7311,,1.0,Completed,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_0003778,psoriatic arthritis,1,1,3,0
CHEMBL2109574,ASG-5ME,N/A,True,True,False,864;1597;2032;2270;2375;2439;2748;2811;2874,1577;1641;1705;1769;1833;1897;1961;2126;2190;2254;2318;2382;2446;2510;2574;2638;2702;2766;2830;2894;2958;3022;3092;3156;3220;3284;3348;3412;3476;3540;3604;3695;3759;3823;3887;3951;4015;4082,,1.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0001663,prostate carcinoma,2,9,38,0
CHEMBL2109607,MEDI-8968,N/A,False,True,False,,636;4194;4402,,2.0,Completed,IL1R1,Interleukin-1 signaling;Interleukin-10 signaling;Potential therapeutics for SARS,R-HSA-6783783;R-HSA-9020702;R-HSA-9679191,,EFO_0000341,chronic obstructive pulmonary disease,1,1,3,0
CHEMBL2109613,PF-04236921,N/A,False,True,False,,120;170;4406;4542;4621;4700;7590,,2.0,Completed,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,EFO_0000384,Crohn's disease,1,1,7,0
CHEMBL2109614,MEDI-5117,N/A,False,True,False,,122;172;4408;4544;4623;4702;7592,,1.0,Terminated,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,EFO_0000685,rheumatoid arthritis,1,1,7,0
CHEMBL2109615,MRA 003 US,N/A,False,True,False,,124;174;4410;4546;4625;4704;7594,,1.0,Completed,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,MONDO_0007915,systemic lupus erythematosus,1,1,7,0
CHEMBL2109636,VILOBELIMAB,N/A,False,True,False,,1243;7180;7741;7753;7765,,3.0,Recruiting,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,HP_0000999,Pyoderma,1,1,5,0
CHEMBL2110372,RANITIDINE HYDROCHLORIDE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl,True,True,True,747,5816,731,4.0,,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,EFO_0004607,duodenal ulcer,3,1,1,1
CHEMBL2110581,BEVASIRANIB,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O,False,True,False,,425;469;481;493;505;517;529;541;591;804,,3.0,Withdrawn,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0001365,age-related macular degeneration,1,1,10,0
CHEMBL2110725,VINFLUNINE,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,True,True,True,827;1559;1994;2233;2338;2403;2710;2773;2837,1540;1604;1668;1732;1796;1860;1924;2089;2153;2217;2281;2345;2409;2473;2537;2601;2665;2729;2793;2857;2921;2985;3055;3119;3183;3247;3311;3375;3439;3503;3567;3658;3722;3786;3850;3914;3978;4045,63,3.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000294,bladder tumor,3,9,38,1
CHEMBL2110727,CENICRIVIROC,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1,True,True,True,218;228,1246;1260;4363;4377;6759;6769;6783,506,3.0,Terminated,CCR2;CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 2 antagonist | C-C chemokine receptor type 5 antagonist,EFO_1001249,non-alcoholic steatohepatitis,3,2,4,1
CHEMBL2110774,CHLORPHENOXAMINE,CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1,True,True,False,987,6617,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL2110814,DELUCEMINE,CNCCC(c1cccc(F)c1)c1cccc(F)c1,False,False,True,,,401,,,,,,Glutamate [NMDA] receptor antagonist,,,1,0,0,1
CHEMBL2110900,DAPOXETINE,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,True,False,False,1287,,,3.0,Completed,SLC6A4,,,,EFO_0004234,erectile dysfunction,1,1,0,0
CHEMBL2110954,NERAMEXANE,CC1(C)CC(C)(C)CC(C)(N)C1,True,True,False,720;1618;1964;2191;2614;2656;2681,3626;6810;6837;6864;6897;7055;7082;7109;7136,,3.0,Completed;Terminated,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,HP_0000360,Tinnitus,2,7,9,0
CHEMBL2111286,RANITIDINE BISMUTH CITRATE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3],True,True,True,751,5820,732,4.0,,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,EFO_0003948,gastroesophageal reflux disease,3,1,1,1
CHEMBL211456,EPHEDRINE,CN[C@@H](C)[C@H](O)c1ccccc1,True,True,False,352;1301;1361;1460;1830;2500,815;872;932;976;1036;1080;1132;1192;1364;1424;1468;6477;6677,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL21333,PRANLUKAST,O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1,True,True,False,1231,621;6578,,3.0,Completed,CYSLTR1,G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-416476;R-HSA-9679191,,EFO_0003956,seasonal allergic rhinitis,2,1,2,0
CHEMBL2146063,CHLORTETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl,False,False,True,,,330,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,CN[C@@H](C)[C@H](O)c1ccccc1.Cl,True,True,False,380;1325;1378;1484;1840;2523,843;896;949;1000;1053;1104;1156;1209;1388;1441;1492;6505;6705,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0003956,seasonal allergic rhinitis,2,6,8,0
CHEMBL2146123,METHACYCLINE HYDROCHLORIDE,C=C1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.Cl,False,False,True,,,312,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2147777,TENELIGLIPTIN,Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,True,False,True,676,,524,3.0,Recruiting,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL214796,NGD-8243,FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1,True,True,False,699,5725,,2.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0003843,pain,2,1,1,0
CHEMBL2159122,ELUXADOLINE,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O,True,True,True,266,236;1270;7183,670,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0000555,irritable bowel syndrome,3,1,3,1
CHEMBL2160007,PSI-352938,CCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F,False,False,True,,,437,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL2165326,APROCITENTAN,NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,True,False,False,1918,,,3.0,Completed,EDNRA,,,,EFO_0000537,hypertension,1,1,0,0
CHEMBL217092,SARACATINIB,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,True,True,False,1218,4309,,2.0,Terminated,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000365,colorectal adenocarcinoma,2,1,1,0
CHEMBL2178570,AZD4818,CC(=O)Nc1ccc(O)cc1OC[C@@](C)(O)CNC1CCN(Cc2ccc(Cl)cc2)CC1,True,False,False,1790,,,2.0,Completed,CCR1,,,,EFO_0000341,chronic obstructive pulmonary disease,1,1,0,0
CHEMBL2178573,ILACIRNON,Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1,True,True,True,231,1249;4366;6772,507,2.0,Completed,CCR2,Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 2 antagonist,EFO_0000401,diabetic nephropathy,3,1,3,1
CHEMBL217899,TOFIMILAST,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2,True,True,True,425;1058;1087;2165,4338;5747;5775;5804;5842;5871,621,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL2179529,AZD1446,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1,True,True,True,446;2142,7926;7940;7954,541,2.0,Completed,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,Neuronal acetylcholine receptor; alpha4/beta2 agonist,EFO_0003888,attention deficit hyperactivity disorder,3,2,3,2
CHEMBL2180604,TAK-593,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,True,True,False,1139,7037,,1.0,Completed,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000616,neoplasm,2,1,1,0
CHEMBL2204263,JNJ-41443532,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,True,True,True,237,1255;4372;6778,508,2.0,Completed,CCR2,Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 2 antagonist,MONDO_0005148,type 2 diabetes mellitus,3,1,3,1
CHEMBL220492,TOPIRAMATE,CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1,True,False,False,479;1408;1512;1630;1677;1735;1771;1794;1866;1927;2038;2083;2447;2553;2572;2625,,,4.0,Completed;Unknown status,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,,EFO_0000474,epilepsy,1,16,0,0
CHEMBL2206196,PAROMOMYCIN SULFATE,NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,False,False,True,,,331,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL22108,DIMETHINDENE,CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,True,True,False,1039,6669,,2.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL221722,FAVIPIRAVIR,NC(=O)c1nc(F)cnc1O,False,False,True,,,412,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL221886,SISOMICIN,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,False,False,True,,,338,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2218877,ERYTHROMYCIN ESTOLATE,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C.CCCCCCCCCCCCOS(=O)(=O)O,False,False,True,,,332,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2218894,FLUVASTATIN SODIUM,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+],True,True,True,741,7620;7635;7650;7665,32,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,EFO_0004911,familial hypercholesterolemia,3,1,4,1
CHEMBL2219414,ERAVACYCLINE DIHYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12.Cl.Cl,False,False,True,,,346,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2219416,NALOXEGOL OXALATE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O,True,True,False,290,260;1294;7207,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL2219418,NALOXEGOL,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5,True,True,False,314,284;1318;7231,,4.0,Terminated,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0002019,Constipation,2,1,3,0
CHEMBL2219425,ARIPIPRAZOLE LAUROXIL,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,False,False,True,,,707,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL221959,TOFACITINIB,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,True,True,False,765;791;1191,190;216;409;652;678;788;4242;4273;4421;4527;4562;4588;4610;4641;4667;4689;4720;4746;4768;4789;4809;4827;4853;4875;4896;4922;4944;4962;4988;5010;5028;5054;5076;5098;5120;5138;5164;5186;5216;5236;5266;5286;5304;5330;5352;5370;5396;5418;5434;5464;5484;6917;6943;7477;8306;8334;8362;8396;8424;8452,,3.0,Recruiting,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000519,glioblastoma multiforme,2,3,28,0
CHEMBL2220442,FLUVASTATIN,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,True,True,False,737,7616;7631;7646;7661,,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL222559,TIPRANAVIR,CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,False,False,True,,,411,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL223360,LINIFANIB,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,True,True,False,1112,7010,,3.0,Terminated,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000182,hepatocellular carcinoma,2,1,1,0
CHEMBL224436,JOSAMYCIN,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1OC(C)=O,False,False,True,,,339,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL226267,ARZOXIFENE,COc1ccc(-c2sc3cc(O)ccc3c2Oc2ccc(OCCN3CCCCC3)cc2)cc1,True,False,False,2302,,,3.0,Completed,ESR1,,,,EFO_0003869,breast neoplasm,1,1,0,0
CHEMBL2263632,ASLAN-003,COc1cccc(-c2cc(F)c(Nc3ncccc3C(=O)O)c(F)c2)c1,False,False,True,,,733,,,,,,Dihydroorotate dehydrogenase inhibitor,,,1,0,0,1
CHEMBL227529,ALOGLIPTIN BENZOATE,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O.O=C(O)c1ccccc1,True,False,True,662,,514,4.0,,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL2304041,SAGOPILONE,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O,True,True,False,839;1571;2006;2245;2350;2414;2721;2787;2849,1552;1616;1680;1744;1808;1872;1936;2101;2165;2229;2293;2357;2421;2485;2549;2613;2677;2741;2805;2869;2933;2997;3067;3131;3195;3259;3323;3387;3451;3515;3579;3670;3734;3798;3862;3926;3990;4057,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000519,glioblastoma multiforme,2,9,38,0
CHEMBL2311030,ERGOLOID MESYLATES,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O,True,True,False,353;1311;1362;1461;1816;2501,816;882;933;986;1037;1090;1142;1193;1374;1425;1478;6478;6678,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL2316582,OLVEREMBATINIB,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1,True,True,False,1211;2207,4302,,3.0,Recruiting,ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000220,acute lymphoblastic leukemia,2,2,1,0
CHEMBL231779,APIXABAN,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,True,True,True,450,7530;7559,464,4.0,,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,Coagulation factor X inhibitor,EFO_0000275,atrial fibrillation,3,1,2,1
CHEMBL23261,DARUSENTAN,COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1,True,False,False,1919,,,3.0,Completed,EDNRA,,,,EFO_0000537,hypertension,1,1,0,0
CHEMBL2346976,AZD3514,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,True,True,False,577,2000;5915;7819,,1.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,MONDO_0008315,prostate cancer,2,1,3,0
CHEMBL2348780,VAMOROLONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO,False,False,True,,,237,,,,,,Glucocorticoid receptor agonist,,,1,0,0,1
CHEMBL2355051,CLOMIPHENE,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,True,False,False,2298,,,3.0,Not yet recruiting,ESR1,,,,EFO_0000279,azoospermia,1,1,0,0
CHEMBL2356023,DIHYDROTACHYSTEROL,CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3\C[C@@H](O)CC[C@@H]3C)CCC[C@]12C,False,False,True,,,33,,,,,,Vitamin D receptor agonist,,,1,0,0,1
CHEMBL2358147,CARPHENAZINE MALEATE,CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,False,False,True,,,692,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL2359966,QUININE SULFATE,C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O,False,False,True,,,454,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL2364574,DOXYCYCLINE CALCIUM,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2],True,True,True,613;619;626;632,30;37;42;48;54;61;66;72;85;92;97;103;116;130;235;3032,364,0.5,Terminated,MMP1;MMP13;MMP7;MMP8,Activation of Matrix Metalloproteinases;Basigin interactions;Collagen degradation;Degradation of the extracellular matrix;Interleukin-4 and Interleukin-13 signaling;Neutrophil degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1442490;R-HSA-1474228;R-HSA-1592389;R-HSA-381426;R-HSA-6785807;R-HSA-6798695,Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 7 inhibitor | Matrix metalloproteinase 8 inhibitor | Matrix metalloproteinase-1 inhibitor,EFO_0003102,osteomyelitis,3,4,7,1
CHEMBL2364605,CEBRANOPADOL,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12,True,True,False,328,298;1332;7245,,3.0,Not yet recruiting,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl,True,True,False,708;1608;1953;2181;2603;2647;2670,3614;6798;6825;6852;6885;7043;7070;7097;7124,,4.0,,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0002009;MONDO_0002050,depressive disorder;major depressive disorder,2,7,9,0
CHEMBL2364611,GALUNISERTIB,Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,True,False,False,1971,,,2.0,Completed,TGFBR1,,,,EFO_0000182,hepatocellular carcinoma,1,1,0,0
CHEMBL2364614,LIAFENSINE,CN1Cc2cc(-c3ccc(N)nn3)ccc2[C@H](c2ccc3ccccc3c2)C1,True,False,False,1295,,,2.0,Completed,SLC6A4,,,,EFO_0009854,treatment resistant depression,1,1,0,0
CHEMBL2364618,MAVATREP,CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1,True,True,False,702,5728,,1.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0004616,"osteoarthritis, knee",2,1,1,0
CHEMBL2364619,METHYLSAMIDORPHAN,C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13,True,True,False,340,310;1344;7257,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0002019,Constipation,2,1,3,0
CHEMBL2364623,PLAZOMICIN SULFATE,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O.O=S(=O)(O)O,False,False,True,,,347,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL2364626,RALIMETINIB,CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21,False,False,True,,,116,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL2364653,ANIFROLUMAB,N/A,False,True,False,,622;4207;5194;5244;5442,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000540,immune system disease,1,1,5,0
CHEMBL2364968,ERGOLOID,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,True,True,False,403;1348;1400;1506;1864;2547,866;919;971;1023;1075;1127;1179;1231;1411;1463;1515;6528;6728,,2.0,Completed,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0004718,vascular dementia,2,6,8,0
CHEMBL2368861,BUPRENORPHINE HYDROCHLORIDE,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl,True,True,True,300,270;1304;7217,653,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003890,drug dependence,3,1,3,1
CHEMBL237500,LINAGLIPTIN,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,True,False,True,659,,515,4.0,,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0000400,diabetes mellitus,2,1,0,1
CHEMBL238465,SOFINICLINE,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl,True,True,True,442;2138,7922;7936;7950,533,2.0,Completed,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,Neuronal acetylcholine receptor; alpha4/beta2 agonist,EFO_0000401,diabetic nephropathy,3,2,3,2
CHEMBL2403318,DELEOBUVIR,Cn1c(C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Br)cn5)n(C)c4c3)CCC2)nc2ccc(/C=C/C(=O)O)cc21,False,False,True,,,438,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL2424780,VESATOLIMOD,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2,True,True,False,601,761;4257;7323;7345;7356;7367;7378;7400;7422;7444;7455,,2.0,"Active, not recruiting",TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0000180,HIV-1 infection,2,1,11,0
CHEMBL2443262,OLICERIDINE,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,True,True,True,291,261;1295;7208,671,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL24441,BETAHISTINE,CNCCc1ccccn1,True,True,False,990,6620,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0002321,Vertigo,2,1,1,0
CHEMBL2448612,ERGOTAMINE TARTRATE,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O,True,True,False,392;1336;1388;1494;1854;2534,855;907;959;1011;1063;1115;1167;1219;1399;1451;1503;6517;6717,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,HP_0002315,Headache,2,6,8,0
CHEMBL24778,SILODOSIN,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,True,True,False,346,809;6471;6671,,4.0,,ADRA1A,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,1,3,0
CHEMBL24828,VANDETANIB,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,True,False,False,1770,,,4.0,,EPHA7,,,,EFO_0000616,neoplasm,1,1,0,0
CHEMBL25,ASPIRIN,CC(=O)Oc1ccccc1C(=O)O,True,True,True,94;884,317;4435;5524;5584;5644;6028;6102;6176;6250;6324;6398,122,4.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000612,myocardial infarction,3,2,10,1
CHEMBL25202,TAMIBAROTENE,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,True,False,False,1768;1895,,,3.0,Recruiting,RARA;RARB,,,,EFO_0000198,myelodysplastic syndrome,1,2,0,0
CHEMBL252164,LUMINESPIB,CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,False,False,True,,,581,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL254328,ABIRATERONE,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,True,True,True,553,1976;5891;7795,77,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000616,neoplasm,3,1,3,1
CHEMBL255863,NILOTINIB,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,True,True,False,1214;2208,4305,,3.0,"Active, not recruiting;Terminated",ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000339,chronic myelogenous leukemia,2,2,1,0
CHEMBL256907,MARAVIROC,Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,False,False,True,,,500,,,,,,C-C chemokine receptor type 5 antagonist,,,1,0,0,1
CHEMBL256997,ATALUREN,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,True,False,False,1729,,,4.0,,RPS27,,,,MONDO_0010679,Duchenne muscular dystrophy,1,1,0,0
CHEMBL257704,EPLIVANSERIN,CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F,False,False,True,,,698,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL259209,MILNACIPRAN,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,True,False,False,1263,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL261244,REGRELOR DISODIUM,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21.[Na+].[Na+],True,True,False,476,1361,,2.0,Terminated,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0001645,coronary artery disease,2,1,1,0
CHEMBL261772,MECLOCYCLINE SULFOSALICYLATE,C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.O=C(O)c1cc(S(=O)(=O)O)ccc1O,False,False,True,,,321,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL262075,INDIPLON,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,True,False,False,512,,,3.0,Terminated,GABRA1,,,,EFO_0004698,insomnia,1,1,0,0
CHEMBL270190,ALVIMOPAN,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1,True,True,False,315,285;1319;7232,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0002019,Constipation,2,1,3,0
CHEMBL272621,HYODEOXYCHOLIC_ACID,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,True,False,False,1728,,,1.0,Unknown status,NR1H2,,,,HP_0003124,Hypercholesterolemia,1,1,0,0
CHEMBL273575,NOMIFENSINE,CN1Cc2c(N)cccc2C(c2ccccc2)C1,True,False,False,1264,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL274654,ORANTINIB,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,True,True,False,1110,7008,,3.0,Terminated,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000182,hepatocellular carcinoma,2,1,1,0
CHEMBL276711,SEMAXANIB,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,True,True,False,1167,572;6984;7518,,3.0,Completed,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,MONDO_0005575,colorectal cancer,2,1,3,0
CHEMBL277062,BROMAZEPAM,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,True,False,False,1700,,,4.0,,GABRA2,,,,EFO_0005230,anxiety,1,1,0,0
CHEMBL277474,ANTIPYRINE,Cc1cc(=O)n(-c2ccccc2)n1C,True,True,False,905,5545;5605,,4.0,,PTGS1,COX reactions;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2162123,,EFO_0003843,pain,2,1,2,0
CHEMBL277535,BIFONAZOLE,c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1,False,False,True,,,41,,,,,,HMG-CoA reductase inhibitor,,,1,0,0,1
CHEMBL27810,CELIPROLOL,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,True,True,False,1302;1353;2502,873;924;977;1028;1081;1133;1184;1365;1416;1469,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,3,6,0
CHEMBL278398,PHENINDAMINE,CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12,True,True,False,1016,6646,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL279785,MARIMASTAT,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,True,True,True,612;630,28;41;52;65;83;96;114;128;233,355,3.0,Completed,MMP1;MMP7,Activation of Matrix Metalloproteinases;Basigin interactions;Collagen degradation;Degradation of the extracellular matrix;Interleukin-4 and Interleukin-13 signaling;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1442490;R-HSA-1474228;R-HSA-1592389;R-HSA-381426;R-HSA-6785807,Matrix metalloproteinase 7 inhibitor | Matrix metalloproteinase-1 inhibitor,MONDO_0007254;MONDO_0008903,breast cancer;lung cancer,3,2,6,1
CHEMBL282042,SAQUINAVIR MESYLATE,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1.CS(=O)(=O)O,False,False,True,,,388,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL282052,METHAQUALONE,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,False,False,True,,,279,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL282724,SITAXENTAN,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,True,False,False,1913,,,4.0,,EDNRA,,,,EFO_0000537,hypertension,1,1,0,0
CHEMBL284121,ILX23-7553,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,254,6007;7784;7902,19,1.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000616,neoplasm,3,1,3,1
CHEMBL285674,ESTAZOLAM,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,True,False,True,488;1428;1649;1687;2049;2094;2455,,264,4.0,Completed,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004698,insomnia,2,7,0,2
CHEMBL288441,BOSUTINIB,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,True,True,False,1215;2209,4306,,3.0,"Active, not recruiting",ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000339,chronic myelogenous leukemia,2,2,1,0
CHEMBL289351,FOSBRETABULIN DISODIUM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+],True,True,True,843;1579;2015;2253;2357;2419;2726;2791;2856,1556;1620;1684;1748;1812;1876;1940;2105;2169;2233;2297;2361;2425;2489;2553;2617;2681;2745;2809;2873;2937;3001;3071;3135;3199;3263;3327;3391;3455;3519;3583;3674;3738;3802;3866;3930;3994;4061,57,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000616,neoplasm,3,9,38,1
CHEMBL294199,CAPSAICIN,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,True,True,True,691,5717,164,4.0,,TRPV1,TRP channels,R-HSA-3295583,Vanilloid receptor opener,EFO_0003843,pain,3,1,1,1
CHEMBL296419,ASTEMIZOLE,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,True,True,False,1005,6635,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL296913,PARECOXIB SODIUM,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+],True,True,False,139,362;4480;5689;6073;6147;6221;6295;6369;6443,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0003843,pain,2,1,9,0
CHEMBL299400,BUTORPHANOL TARTRATE,O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,True,True,False,312,282;1316;7229,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003890,drug dependence,2,1,3,0
CHEMBL3,NICOTINE,CN1CCC[C@H]1c1cccnc1,True,True,True,436;2132,7916;7930;7944,528,4.0,,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,Neuronal acetylcholine receptor; alpha4/beta2 agonist,EFO_0003768,nicotine dependence,3,2,3,2
CHEMBL30,CIMETIDINE,CN/C(=N\CCSCc1nc[nH]c1C)NC#N,True,True,True,748,5817,715,4.0,,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,EFO_0004607,duodenal ulcer,3,1,1,1
CHEMBL30219,METHOHEXITAL SODIUM,C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+],False,False,True,,,263,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL303933,PIPERAQUINE,Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,False,False,True,,,446,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL3039504,NINTEDANIB ESYLATE,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,True,True,False,1107,7005,,4.0,,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000717,systemic scleroderma,2,1,1,0
CHEMBL3039507,SOTAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,False,False,True,,,594,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL3039508,NALDEMEDINE TOSYLATE,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1,True,True,False,307,277;1311;7224,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL3039509,TILDIPIROSIN,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN2CCCCC2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CN1CCCCC1,False,False,True,,,365,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3039511,BEVENOPRAN,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1,True,True,False,331,301;1335;7248,,3.0,Terminated,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0002019,Constipation,2,1,3,0
CHEMBL3039547,PEXASTIMOGENE DEVACIREPVEC,N/A,False,True,False,,4387;6874;8376,,3.0,Completed,CSF2,"Interleukin-10 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;RAF/MAP kinase cascade",R-HSA-512988;R-HSA-5673001;R-HSA-6783783,,EFO_0000182,hepatocellular carcinoma,1,1,3,0
CHEMBL3039596,FOSINOPRIL SODIUM,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C.[Na+],True,True,True,651,447,382,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000537,hypertension,3,1,1,1
CHEMBL3039598,FOSINOPRIL,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,True,True,False,642,438,,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL304087,MERIMEPODIB,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,False,False,True,,,406,,,,,,Inosine-5'-monophosphate dehydrogenase 1 inhibitor,,,1,0,0,1
CHEMBL305660,EBASTINE,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,True,True,False,1023,6653,,3.0,Recruiting,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000555,irritable bowel syndrome,2,1,1,0
CHEMBL3113974,TRANIMILAST,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1,True,True,True,421;1052;1081;2157,4332;5743;5769;5798;5838;5865,610,3.0,Recruiting,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL3121539,RADALBUVIR,CC1=CC[C@H](C(=O)N(c2cc(C#CC(C)(C)C)sc2C(=O)O)[C@H]2CC[C@](O)(CO[C@H]3CCOC3)CC2)CC1,False,False,True,,,439,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL312443,GABOXADOL,Oc1noc2c1CCNC2,True,False,False,513;1526;1711;1753;1785;1940;2071;2118;2590,,,3.0,Completed;Terminated,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3,,,,EFO_0004698,insomnia,1,9,0,0
CHEMBL312448,XYLOMETAZOLINE,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,True,True,False,389;1328;1382;1488;1850;2525,852;899;953;1003;1057;1107;1159;1213;1391;1445;1495;6514;6714,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0005751,eye allergy,2,6,8,0
CHEMBL313006,DALCETRAPIB,CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1,True,False,False,1896,,,3.0,Completed,CETP,,,,EFO_0000319,cardiovascular disease,1,1,0,0
CHEMBL3137308,PEFICITINIB,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2,True,True,False,766;790;1190,191;215;408;653;677;787;4243;4272;4422;4526;4563;4587;4609;4642;4666;4688;4721;4745;4767;4790;4808;4828;4852;4874;4897;4921;4943;4963;4987;5009;5029;5053;5075;5097;5119;5139;5163;5185;5217;5235;5267;5285;5305;5329;5351;5371;5395;5417;5433;5465;5483;6918;6942;7476;8305;8333;8361;8395;8423;8451,,3.0,,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000540,immune system disease,2,3,28,0
CHEMBL3137310,BENZHYDROCODONE HYDROCHLORIDE,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl,True,True,False,292,262;1296;7209,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL3137313,AXELOPRAN,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1,True,True,False,341,311;1345;7258,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0002019,Constipation,2,1,3,0
CHEMBL3137316,FOSDAGROCORAT,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1,True,True,False,61,753;2062;5977;7881;8018;8084;8155;8221;8287,,2.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL313971,ZUCAPSAICIN,COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O,True,True,False,693,5719,,3.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0003843,pain,2,1,1,0
CHEMBL314437,MEPTAZINOL,CCC1(c2cccc(O)c2)CCCCN(C)C1,True,True,False,308,278;1312;7225,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL314854,FINGOLIMOD,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,True,False,False,1882,,,4.0,,S1PR4,,,,EFO_0000540,immune system disease,1,1,0,0
CHEMBL315795,CLOMETHIAZOLE,Cc1ncsc1CCCl,True,False,True,1525;1755;2587,,284,3.0,Terminated,GABRB1;GABRB2;GABRB3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230,anxiety,2,3,0,2
CHEMBL317094,IMIDAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O,True,True,True,643,439,367,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL3181947,BROMFENAC SODIUM,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+],True,True,True,140;906,363;4481;5546;5606;5690;6074;6148;6222;6296;6370;6444,136,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL3183075,NIZATIDINE,CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,True,True,True,749,5818,734,4.0,,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,EFO_0004607,duodenal ulcer,3,1,1,1
CHEMBL3183409,APALUTAMIDE,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,True,True,True,554,1977;5892;7796,82,4.0,"Active, not recruiting",AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000673,prostate adenocarcinoma,3,1,3,1
CHEMBL3183740,TRELANSERIN,NC(=O)Cn1c(=O)cc(CCN2CCN(c3nccc4sccc34)CC2)c2ccc(F)cc21,False,False,True,,,708,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL3184512,CLINDAMYCIN PHOSPHATE,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1,False,False,True,,,313,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3184791,STREPTOMYCIN SULFATE,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,False,False,True,,,314,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3185958,CLOMIPHENE CITRATE,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,False,False,2278,,,4.0,,ESR1,,,,EFO_0000545,infertility,1,1,0,0
CHEMBL3187812,ILEPATRIL,CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C,True,True,True,657,453,383,2.0,Completed,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000537,hypertension,3,1,1,1
CHEMBL3188034,TRIPROLIDINE HYDROCHLORIDE,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1.Cl.O,True,True,False,961,6591,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL3188576,DIHYDROSTREPTOMYCIN SULFATE,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,False,False,True,,,333,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3188993,QUETIAPINE FUMARATE,O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,False,False,True,,,693,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL321582,BUCINDOLOL,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N,True,True,False,401;1504;1861,864;6526;6726,,2.0,Completed,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000275,atrial fibrillation,2,3,3,0
CHEMBL3219616,CP-866087,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21,True,True,False,337,307;1341;7254,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0001073,obesity,2,1,3,0
CHEMBL322241,TELINAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1)C(=O)NC(C)(C)C,False,False,True,,,407,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL3260567,VACTOSERTIB,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,True,False,False,1972,,,2.0,Recruiting,TGFBR1,,,,EFO_0003060,non-small cell lung carcinoma,1,1,0,0
CHEMBL3264610,SEVITERONEL,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1,True,True,True,567,1990;5905;7809,83,2.0,Terminated,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000616,neoplasm,3,1,3,1
CHEMBL328190,LASOFOXIFENE,Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1,True,False,False,2303,,,3.0,Completed,ESR1,,,,EFO_0003882,osteoporosis,1,1,0,0
CHEMBL328560,SULTHIAME,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,True,False,False,1235,,,4.0,,CA6,,,,EFO_0000474,epilepsy,1,1,0,0
CHEMBL3287379,CONTEZOLID,O=C1C=CN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)c(F)c2F)CC1,False,False,True,,,348,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3301582,POLATUZUMAB VEDOTIN,N/A,True,True,False,812;1545;1980;2219;2324;2388;2695;2759;2823,1525;1589;1653;1717;1781;1845;1909;2074;2138;2202;2266;2330;2394;2458;2522;2586;2650;2714;2778;2842;2906;2970;3040;3104;3168;3232;3296;3360;3424;3488;3552;3643;3707;3771;3835;3899;3963;4030,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000403,diffuse large B-cell lymphoma,2,9,38,0
CHEMBL3301585,PINATUZUMAB VEDOTIN,N/A,True,True,False,860;1593;2028;2267;2372;2436;2743;2807;2871,1573;1637;1701;1765;1829;1893;1957;2122;2186;2250;2314;2378;2442;2506;2570;2634;2698;2762;2826;2890;2954;3018;3088;3152;3216;3280;3344;3408;3472;3536;3600;3691;3755;3819;3883;3947;4011;4078,,1.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000095,chronic lymphocytic leukemia,2,9,38,0
CHEMBL3301589,ENFORTUMAB VEDOTIN,N/A,True,True,False,817;1547;1982;2221;2330;2389;2696;2760;2829,1530;1594;1658;1722;1786;1850;1914;2079;2143;2207;2271;2335;2399;2463;2527;2591;2655;2719;2783;2847;2911;2975;3045;3109;3173;3237;3301;3365;3429;3493;3557;3648;3712;3776;3840;3904;3968;4035,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL3301595,DASOTRALINE,N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,True,False,False,1286,,,3.0,Completed,SLC6A4,,,,EFO_0003888,attention deficit hyperactivity disorder,1,1,0,0
CHEMBL3301600,SPEBRUTINIB BESYLATE,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1,True,True,True,205,611;4106;6568;6748,551,2.0,Completed,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000685,rheumatoid arthritis,3,1,4,1
CHEMBL3301606,SOLCITINIB,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1,True,True,True,773,198;660;4250;4429;4570;4649;4728;4797;4835;4904;4970;5036;5146;5224;5274;5312;5378;5472;6925,482,2.0,Completed,JAK1,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;RAF/MAP kinase cascade;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor,EFO_0000676,psoriasis,3,1,19,1
CHEMBL3301607,FILGOTINIB,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,True,True,True,756;778;1183,181;203;401;643;665;780;4233;4265;4412;4519;4553;4575;4602;4632;4654;4681;4711;4733;4760;4780;4801;4818;4840;4867;4887;4909;4936;4953;4975;5002;5019;5041;5068;5085;5112;5129;5151;5178;5207;5228;5257;5278;5295;5317;5344;5361;5383;5410;5426;5455;5476;6908;6930;7464;8293;8321;8349;8383;8411;8439,472,4.0,,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,EFO_0000540,immune system disease,3,3,28,1
CHEMBL3301621,CENTANAFADINE,c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1,True,False,False,1288,,,3.0,Completed,SLC6A4,,,,EFO_0003888,attention deficit hyperactivity disorder,1,1,0,0
CHEMBL3301625,SPEBRUTINIB,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,True,True,False,206,612;4107;6569;6749,,2.0,Completed,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,,EFO_0000685,rheumatoid arthritis,2,1,4,0
CHEMBL3305901,MK-0812,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)(C(C)C)C1,False,False,True,,,509,,,,,,C-C chemokine receptor type 2 antagonist,,,1,0,0,1
CHEMBL3306803,LUMATEPERONE,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12,True,False,True,1249,,709,4.0,Terminated,SLC6A4,,,Serotonin 2a (5-HT2a) receptor antagonist,EFO_0005407,psychosis,2,1,0,1
CHEMBL332750,TETOMILAST,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,True,True,True,422;1055;1083;2160,4334;5744;5772;5800;5839;5867,619,3.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000729,ulcerative colitis,3,4,3,1
CHEMBL3334824,BMS-817399,CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(c2ccc(Cl)cc2)C(C)(C)C1,True,False,False,1791,,,2.0,Completed,CCR1,,,,EFO_0000685,rheumatoid arthritis,1,1,0,0
CHEMBL334966,CANGRELOR,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O,True,True,False,472,1357,,3.0,Recruiting,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0000556,ischemia,2,1,1,0
CHEMBL3358920,ETRASIMOD,O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,True,False,False,1885,,,3.0,Recruiting,S1PR4,,,,EFO_0000384,Crohn's disease,1,1,0,0
CHEMBL3360975,BMS-779788,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,True,False,False,1726,,,1.0,Completed,NR1H2,,,,EFO_0003914,atherosclerosis,1,1,0,0
CHEMBL33986,BUTORPHANOL,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,True,True,False,309,279;1313;7226,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL3402567,ITX-5061,COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O.Cl,False,False,True,,,100,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL341812,IBUFENAC,CC(C)Cc1ccc(CC(=O)O)cc1,False,False,True,,,152,,,,,,Cyclooxygenase inhibitor,,,1,0,0,1
CHEMBL3542265,LY2452473,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,True,True,False,566,1989;5904;7808,,2.0,Terminated,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000284,benign prostatic hyperplasia,2,1,3,0
CHEMBL3544909,CALCIFEDIOL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O,True,True,True,242,5995;7772;7890,34,4.0,,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0003884,chronic kidney disease,3,1,3,1
CHEMBL3544917,RAPASTINEL,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O,True,True,False,719;1619;1966;2193;2613;2658;2683,3625;6809;6836;6863;6896;7054;7081;7108;7135,,3.0,Completed;Terminated,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0002009,major depressive disorder,2,7,9,0
CHEMBL3544945,SAR-113945,N/A,True,True,False,1234,4022;4089;4115;4118;4121;4124;4127;4130;4133;4136;4139;4142;4157;4172;4175;4178;4181;4184;4187;4197;4200;4203;4206;4221;4283;4286;4289;4318;4350,,2.0,Completed,IKBKB,"Activation of NF-kappaB in B cells;CLEC7A (Dectin-1) signaling;Downstream TCR signaling;ER-Phagosome pathway;FCERI mediated NF-kB activation;IKBKB deficiency causes SCID;IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR);IKK complex recruitment mediated by RIP1;IRAK1 recruits IKK complex;IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation;IkBA variant leads to EDA-ID;Interleukin-1 signaling;MAP3K8 (TPL2)-dependent MAPK1/3 activation;Modulation of host responses by IFN-stimulated genes;NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10;NF-kB is activated and signals survival;NOD1/2 Signaling Pathway;PKR-mediated signaling;RIP-mediated NFkB activation via ZBP1;Regulation of NF-kappa B signaling;Regulation of TNFR1 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;SLC15A4:TASL-dependent IRF5 activation;TAK1-dependent IKK and NF-kappa-B activation;TICAM1, RIP1-mediated IKK complex recruitment;TNFR1-induced NF-kappa-B signaling pathway;TRAF6 mediated NF-kB activation;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;p75NTR recruits signalling complexes",R-HSA-112409;R-HSA-1169091;R-HSA-1236974;R-HSA-168638;R-HSA-168927;R-HSA-1810476;R-HSA-202424;R-HSA-209543;R-HSA-209560;R-HSA-2871837;R-HSA-445989;R-HSA-5357905;R-HSA-5357956;R-HSA-5602636;R-HSA-5603027;R-HSA-5603029;R-HSA-5607764;R-HSA-9020702;R-HSA-933542;R-HSA-937039;R-HSA-937041;R-HSA-9705671;R-HSA-975144;R-HSA-9758274;R-HSA-9833482;R-HSA-9860276;R-HSA-9860927;R-HSA-9909505,,EFO_0004616,"osteoarthritis, knee",2,1,29,0
CHEMBL3544947,BURAPITANT,CC(C)(C(N)=O)C1CCN(CCC2(c3ccc(Cl)c(Cl)c3)CN(C(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CCO2)CC1,False,False,True,,,552,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL3544953,SAF312,N/A,True,True,False,697,5723,,2.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0003843,pain,2,1,1,0
CHEMBL3544974,ASENAPINE MALEATE,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,False,False,True,,,694,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL3544984,TRADIPITANT,O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1,False,False,True,,,553,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL3544985,DASABUVIR SODIUM MONOHYDRATE,COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[n-]c2=O)cc1C(C)(C)C.O.[Na+],False,False,True,,,422,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL3544986,PERINDOPRIL ARGININE,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC.N=C(N)NCCC[C@H](N)C(=O)O,True,True,True,652,448,384,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000537,hypertension,3,1,1,1
CHEMBL3545017,GTX-758,O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,True,False,False,2313,,,2.0,Completed,ESR1,,,,MONDO_0008315,prostate cancer,1,1,0,0
CHEMBL3545039,AZD1386,Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O,True,True,False,698,5724,,2.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0003843,pain,2,1,1,0
CHEMBL3545046,GSK2849466,N/A,True,True,False,573,1996;5911;7815,,1.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,HP_0004326,Cachexia,2,1,3,0
CHEMBL3545060,ERYTHROMYCIN GLUCEPTATE,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,False,False,True,,,315,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3545085,XL-228,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,True,True,False,946;1221,4312,,1.0,Terminated,ABL1;BLK,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000220,acute lymphoblastic leukemia,2,2,1,0
CHEMBL3545092,CR 1447,N/A,True,True,False,565,1988;5903;7807,,2.0,Terminated,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000304,breast adenocarcinoma,2,1,3,0
CHEMBL3545094,ELOCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@@H](C)C/C=C/C(O)(CC)CC)=CCC23)C[C@@H](O)C[C@@H]1O,False,False,True,,,35,,,,,,Vitamin D receptor agonist,,,1,0,0,1
CHEMBL3545125,MIROGABALIN,CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O,True,False,False,2496,,,3.0,Completed,CACNA2D1,,,,EFO_0005687,fibromyalgia,1,1,0,0
CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,N/A,True,True,False,822;1555;1990;2229;2334;2398;2705;2769;2833,1535;1599;1663;1727;1791;1855;1919;2084;2148;2212;2276;2340;2404;2468;2532;2596;2660;2724;2788;2852;2916;2980;3050;3114;3178;3242;3306;3370;3434;3498;3562;3653;3717;3781;3845;3909;3973;4040,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_1001100,peritoneal neoplasm,2,9,38,0
CHEMBL3545155,JI-101,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1,True,True,False,1138,7036,,1.0,Completed,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000616,neoplasm,2,1,1,0
CHEMBL3545157,TIDEGLUSIB,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,True,True,False,1182,5499;5510;5521;8093,,2.0,Completed,GSK3B,AKT phosphorylates targets in the cytosol;Constitutive Signaling by AKT1 E17K in Cancer;Maturation of nucleoprotein;Regulation of RUNX2 expression and activity,R-HSA-198323;R-HSA-5674400;R-HSA-8939902;R-HSA-9683610,,EFO_0003756,autism spectrum disorder,2,1,4,0
CHEMBL3545168,IMD-1041,N/A,True,True,False,1233,4021;4088;4114;4117;4120;4123;4126;4129;4132;4135;4138;4141;4156;4171;4174;4177;4180;4183;4186;4196;4199;4202;4205;4220;4282;4285;4288;4317;4349,,2.0,Unknown status,IKBKB,"Activation of NF-kappaB in B cells;CLEC7A (Dectin-1) signaling;Downstream TCR signaling;ER-Phagosome pathway;FCERI mediated NF-kB activation;IKBKB deficiency causes SCID;IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR);IKK complex recruitment mediated by RIP1;IRAK1 recruits IKK complex;IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation;IkBA variant leads to EDA-ID;Interleukin-1 signaling;MAP3K8 (TPL2)-dependent MAPK1/3 activation;Modulation of host responses by IFN-stimulated genes;NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10;NF-kB is activated and signals survival;NOD1/2 Signaling Pathway;PKR-mediated signaling;RIP-mediated NFkB activation via ZBP1;Regulation of NF-kappa B signaling;Regulation of TNFR1 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;SLC15A4:TASL-dependent IRF5 activation;TAK1-dependent IKK and NF-kappa-B activation;TICAM1, RIP1-mediated IKK complex recruitment;TNFR1-induced NF-kappa-B signaling pathway;TRAF6 mediated NF-kB activation;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;p75NTR recruits signalling complexes",R-HSA-112409;R-HSA-1169091;R-HSA-1236974;R-HSA-168638;R-HSA-168927;R-HSA-1810476;R-HSA-202424;R-HSA-209543;R-HSA-209560;R-HSA-2871837;R-HSA-445989;R-HSA-5357905;R-HSA-5357956;R-HSA-5602636;R-HSA-5603027;R-HSA-5603029;R-HSA-5607764;R-HSA-9020702;R-HSA-933542;R-HSA-937039;R-HSA-937041;R-HSA-9705671;R-HSA-975144;R-HSA-9758274;R-HSA-9833482;R-HSA-9860276;R-HSA-9860927;R-HSA-9909505,,EFO_0000341,chronic obstructive pulmonary disease,2,1,29,0
CHEMBL3545174,GSK2881078,N/A,True,True,False,572,1995;5910;7814,,2.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,HP_0004326,Cachexia,2,1,3,0
CHEMBL3545193,MSC-2364447,N/A,True,True,False,211,617;4112;6574;6754,,1.0,Completed,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,,MONDO_0007915,systemic lupus erythematosus,2,1,4,0
CHEMBL3545210,SR16234,CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,False,False,2314,,,2.0,Completed,ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL3545211,SR16234,CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1,True,False,False,2312,,,2.0,Completed,ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL3545215,BMS-911543,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,True,True,True,804,229;691;4601;4680;4759;4866;4935;5001;5067;5111;5177;5343;5409;6956;7490;8319;8347;8375;8409;8437;8465,483,1.0,Terminated,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,MONDO_0004992,cancer,3,1,21,1
CHEMBL3545221,AZD2423,N/A,True,True,False,229,1247;4364;6770,,2.0,Completed,CCR2,Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000341,chronic obstructive pulmonary disease,2,1,3,0
CHEMBL3545225,INCB-047986,N/A,True,True,False,774,199;661;4251;4430;4571;4650;4729;4798;4836;4905;4971;5037;5147;5225;5275;5313;5379;5473;6926,,2.0,Terminated,JAK1,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;RAF/MAP kinase cascade;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,,EFO_0000685,rheumatoid arthritis,2,1,19,0
CHEMBL3545237,HE3235,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C,True,True,False,575,1998;5913;7817,,1.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,MONDO_0008315,prostate cancer,2,1,3,0
CHEMBL3545241,AC-430,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,True,True,True,801,226;688;4598;4677;4756;4863;4932;4998;5064;5108;5174;5340;5406;6953;7487;8316;8344;8372;8406;8434;8462,484,1.0,Completed,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000685,rheumatoid arthritis,3,1,21,1
CHEMBL3545252,DOCETAXEL,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O,True,True,True,807;1543;1977;2216;2321;2383;2690;2754;2818,1520;1584;1648;1712;1776;1840;1904;2069;2133;2197;2261;2325;2389;2453;2517;2581;2645;2709;2773;2837;2901;2965;3035;3099;3163;3227;3291;3355;3419;3483;3547;3638;3702;3766;3830;3894;3958;4025,53,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000228;EFO_0000305,adenocarcinoma;breast carcinoma,3,9,38,1
CHEMBL3545259,VANUCIZUMAB,N/A,False,True,False,,428;472;484;496;508;520;532;544;594;807,,2.0,Terminated,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,MONDO_0005575,colorectal cancer,1,1,10,0
CHEMBL3545309,LEFAMULIN ACETATE,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O.CC(=O)O,False,False,True,,,349,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3545316,RINUCUMAB,N/A,True,True,False,1131,7029,,2.0,Terminated,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0001365,age-related macular degeneration,2,1,1,0
CHEMBL3545328,XL-019,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,True,True,True,800,225;687;4597;4676;4755;4862;4931;4997;5063;5107;5173;5339;5405;6952;7486;8315;8343;8371;8405;8433;8461,485,1.0,Terminated,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000479,essential thrombocythemia,3,1,21,1
CHEMBL3545333,MK-0773,N/A,True,True,False,571,1994;5909;7813,,2.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_1000653,sarcopenia,2,1,3,0
CHEMBL3545350,EVT-101,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1,True,True,False,729;2622,3635;6819;6846;6873;6906;7064;7091;7118;7145,,2.0,Terminated,GRIN1;GRIN2B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0002050,depressive disorder,2,2,9,0
CHEMBL3545351,AV-101,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O,True,True,True,716;1615;1961;2188;2609;2654;2678,3622;6806;6833;6860;6893;7051;7078;7105;7132,402,3.0,"Active, not recruiting",GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,Glutamate [NMDA] receptor antagonist,EFO_0001361,pulmonary arterial hypertension,3,7,9,1
CHEMBL3545372,SOFITUZUMAB VEDOTIN,N/A,True,True,False,865;1598;2033;2272;2376;2441;2747;2812;2876,1578;1642;1706;1770;1834;1898;1962;2127;2191;2255;2319;2383;2447;2511;2575;2639;2703;2767;2831;2895;2959;3023;3093;3157;3221;3285;3349;3413;3477;3541;3605;3696;3760;3824;3888;3952;4016;4083,,1.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0002618,pancreatic carcinoma,2,9,38,0
CHEMBL3545391,ORG-34517,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C,True,True,False,59,751;2060;5975;7879;8016;8082;8153;8219;8285,,2.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0000677,mental or behavioural disorder,2,1,9,0
CHEMBL3545401,X-82,N/A,True,True,False,1129,7027,,2.0,Terminated,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0001365,age-related macular degeneration,2,1,1,0
CHEMBL3545402,XL-820,N/A,True,True,False,1136;1175,580;6992;7034;7526,,2.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,MONDO_0011719,gastrointestinal stromal tumor,2,2,3,0
CHEMBL3545413,FLUMATINIB,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,True,True,False,1212,4303,,3.0,Recruiting,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000220,acute lymphoblastic leukemia,2,1,1,0
CHEMBL3545427,CM-082,N/A,True,True,False,1122;1163,568;6980;7020;7514,,3.0,Unknown status,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000681,renal cell carcinoma,2,2,3,0
CHEMBL3559672,RAUWOLFIA SERPENTINA,N/A,True,True,False,375;1319;1371;1479;1838;2518,838;890;942;994;1046;1098;1150;1202;1382;1434;1486;6500;6700,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,6,8,0
CHEMBL356388,ETAZOLATE,CCOC(=O)c1cnc2c(cnn2CC)c1NN=C(C)C,True,False,False,1532,,,2.0,Completed,GABRB3,,,,MONDO_0004975,Alzheimer disease,1,1,0,0
CHEMBL3581693,BRILANESTRANT,CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,True,False,False,2315,,,2.0,Terminated,ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL3590187,CLASCOTERONE,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,True,True,True,556,1979;5894;7798,84,4.0,"Active, not recruiting",AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0003894,acne,3,1,3,1
CHEMBL3622820,ITACITINIB,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,True,True,True,767,192;654;4244;4423;4564;4643;4722;4791;4829;4898;4964;5030;5140;5218;5268;5306;5372;5466;6919,486,3.0,,JAK1,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;RAF/MAP kinase cascade;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor,EFO_0000540,immune system disease,3,1,19,1
CHEMBL3622821,UPADACITINIB,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,True,True,False,763;789;1188,188;214;406;650;676;785;4240;4270;4419;4524;4560;4586;4607;4639;4665;4686;4718;4744;4765;4787;4806;4825;4851;4872;4894;4920;4941;4960;4986;5007;5026;5052;5073;5096;5117;5136;5162;5183;5214;5233;5264;5283;5302;5328;5349;5368;5394;5415;5431;5462;5481;6915;6941;7475;8304;8332;8360;8394;8422;8450,,3.0,"Active, not recruiting;Completed;Enrolling by invitation",JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000274,atopic eczema,2,3,28,0
CHEMBL362558,LY-2090314,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,True,True,False,1180;1227,5494;5497;5502;5505;5508;5513;5516;5519;8091,,2.0,Completed,GSK3A;GSK3B,AKT phosphorylates targets in the cytosol;Constitutive Signaling by AKT1 E17K in Cancer;Maturation of nucleoprotein;Regulation of RUNX2 expression and activity;Suppression of apoptosis;XBP1(S) activates chaperone genes,R-HSA-198323;R-HSA-381038;R-HSA-5674400;R-HSA-8939902;R-HSA-9635465;R-HSA-9683610,,EFO_0000565,leukemia,2,2,6,0
CHEMBL363295,TERODILINE,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,True,False,False,1906;2494,,,4.0,,CACNA1A;CACNA2D1,,,,HP_0000020;HP_0000103,Polyuria;Urinary incontinence,1,2,0,0
CHEMBL363648,TAK-715,CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1,False,False,True,,,105,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL3647536,DARIGABAT,CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21,True,False,False,520;1443;1530;1668;1718;1757;1787;1806;1879;1942;2075;2122;2483;2565;2592;2636,,,2.0,Recruiting,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,,EFO_0004262,panic disorder,1,16,0,0
CHEMBL364804,GW-406381,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1,True,True,False,152,375;4493;5702;6086;6160;6234;6308;6382;6456,,3.0,Completed,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL3655081,ABROCITINIB,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,True,True,True,755,180;642;4232;4411;4552;4631;4710;4779;4817;4886;4952;5018;5128;5206;5256;5294;5360;5454;6907,473,4.0,,JAK1,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;RAF/MAP kinase cascade;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor,EFO_0000274,atopic eczema,3,1,19,1
CHEMBL3666807,VELSECORAT,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2,True,True,False,64,756;2065;5980;7884;8021;8087;8158;8224;8290,,2.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,MONDO_0004979,asthma,2,1,9,0
CHEMBL3678958,RUSERONTINIB,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21,True,True,False,1213,4304,,3.0,Recruiting,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000222,acute myeloid leukemia,2,1,1,0
CHEMBL3702854,RILZABRUTINIB,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,True,True,True,201,607;4102;6564;6744,560,3.0,Recruiting,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0007160,autoimmune thrombocytopenic purpura,3,1,4,1
CHEMBL3707226,DEFIBROTIDE SODIUM,N/A,True,True,False,685,78;109;136;459,,4.0,,PLG,Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Platelet degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-114608;R-HSA-1474228;R-HSA-1592389;R-HSA-381426,,MONDO_0019514,hepatic veno-occlusive disease,2,1,4,0
CHEMBL3707228,PLOZALIZUMAB,N/A,True,True,False,230,1248;4365;6771,,2.0,Withdrawn,CCR2,Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000319,cardiovascular disease,2,1,3,0
CHEMBL3707235,GEMIGLIPTIN,N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,True,False,True,670,,525,3.0,,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0000400,diabetes mellitus,2,1,0,1
CHEMBL3707250,CP-601927,N/A,True,True,False,447;2143,7927;7941;7955,,2.0,Terminated,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,MONDO_0002009,major depressive disorder,2,2,3,0
CHEMBL3707293,XEN-D0501,N/A,True,True,False,695,5721,,2.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0000341,chronic obstructive pulmonary disease,2,1,1,0
CHEMBL3707311,VAMOROLONE,N/A,True,True,False,48,740;2049;5964;7868;8005;8071;8142;8208;8274,,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,MONDO_0010679,Duchenne muscular dystrophy,2,1,9,0
CHEMBL3707313,TRIFAROTENE,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1,True,True,False,186,5988;6014;6023,,4.0,Completed,RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,,EFO_0003894,acne,2,1,3,0
CHEMBL3707325,LENZILUMAB,N/A,False,True,False,,4389;6876;8378,,3.0,"Active, not recruiting",CSF2,"Interleukin-10 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;RAF/MAP kinase cascade",R-HSA-512988;R-HSA-5673001;R-HSA-6783783,,EFO_0003106,pneumonia,1,1,3,0
CHEMBL3707330,ROLAPITANT HYDROCHLORIDE,C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.O,False,False,True,,,542,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL3707348,ACALABRUTINIB,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,True,True,True,190,596;4091;6553;6733,561,4.0,,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000095,chronic lymphocytic leukemia,3,1,4,1
CHEMBL3707356,TIVANISIRAN,N/A,True,True,False,694,5720,,3.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_1000906,dry eye syndrome,2,1,1,0
CHEMBL3707357,BROLUCIZUMAB,N/A,False,True,False,,420;464;476;488;500;512;524;536;586;799,,4.0,Withdrawn,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0004683,wet macular degeneration,1,1,10,0
CHEMBL3707365,BEMIPARIN,N/A,True,True,False,460,7540;7569,,3.0,Unknown status,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,EFO_0001422,cirrhosis of liver,2,1,2,0
CHEMBL3707374,AMISELIMOD HYDROCHLORIDE,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F.Cl,True,False,False,1886,,,2.0,Completed,S1PR4,,,,EFO_0000384,Crohn's disease,1,1,0,0
CHEMBL3707375,AMISELIMOD,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F,True,False,False,1887,,,2.0,Completed,S1PR4,,,,EFO_0000384,Crohn's disease,1,1,0,0
CHEMBL3707376,CADAZOLID,O=C(O)c1cn(C2CC2)c2cc(N3CCC(O)(COc4ccc(N5C[C@H](CO)OC5=O)cc4F)CC3)c(F)cc2c1=O,False,False,True,,,350,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3707398,PAC-14028,N/A,True,True,False,692,5718,,3.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,EFO_0000274,atopic eczema,2,1,1,0
CHEMBL3707400,INDANTADOL,N/A,True,True,False,725;1622;1968;2194;2617;2661;2685,3631;6815;6842;6869;6902;7060;7087;7114;7141,,2.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,EFO_0003843;EFO_0005762,neuropathic pain;pain,2,7,9,0
CHEMBL376140,TIGECYCLINE,CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,False,False,True,,,299,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL376359,ALOGLIPTIN,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,True,False,False,671,,,3.0,,DPP4,,,,EFO_0000400,diabetes mellitus,1,1,0,0
CHEMBL37676,APC-100,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,True,True,True,576,1999;5914;7818,74,1.0,Unknown status,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,MONDO_0008315,prostate cancer,3,1,3,1
CHEMBL377559,RETASPIMYCIN HYDROCHLORIDE,C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2.Cl,False,False,True,,,580,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL3785197,OBICETRAPIB,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ncc(OCCCC(=O)O)cn2)C[C@H]1CC,True,False,False,1899,,,3.0,"Active, not recruiting",CETP,,,,EFO_0003914,atherosclerosis,1,1,0,0
CHEMBL378544,VINBLASTINE SULFATE,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,True,True,True,806;1539;1974;2213;2318;2382;2689;2752;2817,1519;1583;1647;1711;1775;1839;1903;2068;2132;2196;2260;2324;2388;2452;2516;2580;2644;2708;2772;2836;2900;2964;3034;3098;3162;3226;3290;3354;3418;3482;3546;3637;3701;3765;3829;3893;3957;4024,45,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000183,Hodgkins lymphoma,3,9,38,1
CHEMBL38,TRETINOIN,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,True,True,True,180;1761;1888,5982;6008;6017,616,4.0,,RARA;RARB;RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,Retinoic acid receptor agonist,EFO_0000224,acute promyelocytic leukemia,3,3,3,1
CHEMBL3813873,PEXIDARTINIB,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,True,True,False,1143,548;6960;7494,,4.0,,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL383322,RESIQUIMOD,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,True,True,False,605,765;4261;7327;7349;7360;7371;7382;7404;7426;7448;7459,,2.0,"Active, not recruiting",TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0000632,oligodendroglioma,2,1,11,0
CHEMBL3833306,VANDORTUZUMAB VEDOTIN,N/A,True,True,False,868;1601;2036;2275;2380;2444;2751;2815;2879,1581;1645;1709;1773;1837;1901;1965;2130;2194;2258;2322;2386;2450;2514;2578;2642;2706;2770;2834;2898;2962;3026;3096;3160;3224;3288;3352;3416;3480;3544;3608;3699;3763;3827;3891;3955;4019;4086,,1.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,MONDO_0008315,prostate cancer,2,9,38,0
CHEMBL3833307,SATRALIZUMAB,N/A,False,True,False,,176;638;4548;4627;4706;7147,,4.0,,IL6R,Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Transcriptional regulation of granulopoiesis,R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-6785807;R-HSA-9616222;R-HSA-9679191,,EFO_0000540,immune system disease,1,1,6,0
CHEMBL3833330,CINPANEMAB,N/A,True,False,False,2568,,,2.0,Terminated,SNCA,,,,MONDO_0005180,Parkinson disease,1,1,0,0
CHEMBL3833343,VOBARILIZUMAB,N/A,False,True,False,,179;641;4551;4630;4709;7150,,2.0,Completed,IL6R,Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Transcriptional regulation of granulopoiesis,R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-6785807;R-HSA-9616222;R-HSA-9679191,,EFO_0000685,rheumatoid arthritis,1,1,6,0
CHEMBL3833357,BEGELOMAB,N/A,True,False,False,672,,,3.0,,DPP4,,,,EFO_0000540,immune system disease,1,1,0,0
CHEMBL3833371,UPRIFOSBUVIR,CC(C)OC(=O)[C@@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1,False,False,True,,,440,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL3833389,DEXTROMORAMIDE,C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1,True,True,False,293,263;1297;7210,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL3833393,EMICIZUMAB,N/A,True,True,False,456,7536;7565,,4.0,"Active, not recruiting",F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,MONDO_0010602,hemophilia A,2,1,2,0
CHEMBL383824,ALVESPIMYCIN,CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,False,False,True,,,579,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL38434,BREQUINAR,Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O,False,False,True,,,735,,,,,,Dihydroorotate dehydrogenase inhibitor,,,1,0,0,1
CHEMBL384467,DEXAMETHASONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,True,True,True,12,704;2013;5928;7832;7969;8035;8106;8172;8238,222,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL385517,SAXAGLIPTIN ANHYDROUS,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,True,False,False,667,,,3.0,,DPP4,,,,EFO_0000400,diabetes mellitus,1,1,0,0
CHEMBL386630,TESTOSTERONE,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,True,True,False,551,1974;5889;7793,,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL38827,LUMEFANTRINE,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,False,False,True,,,445,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL389621,HYDROCORTISONE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,True,True,True,5,697;2006;5921;7825;7962;8028;8099;8165;8231,168,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL3900409,BRENSOCATIB,Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21,False,False,True,,,562,,,,,,Dipeptidyl peptidase I inhibitor,,,1,0,0,1
CHEMBL3900554,BMS-986142,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,True,True,True,208,614;4109;6571;6751,563,2.0,Completed,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000685,rheumatoid arthritis,3,1,4,1
CHEMBL393220,ATORVASTATIN CALCIUM,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],True,True,True,739,7618;7633;7648;7663,46,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,EFO_0000373,congestive heart failure,3,1,4,1
CHEMBL3936761,ZANUBRUTINIB,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,True,True,True,192,598;4093;6555;6735,564,4.0,,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000616,neoplasm,3,1,4,1
CHEMBL393820,VALOPICITABINE,CC(C)[C@H](N)C(=O)O[C@@H]1[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@]1(C)O,False,False,True,,,424,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL3945199,BMS-852927,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,True,False,False,1727,,,1.0,Terminated,NR1H2,,,,HP_0003124,Hypercholesterolemia,1,1,0,0
CHEMBL3948730,UMBRALISIB,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,True,True,False,1205,4296,,4.0,,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000616,neoplasm,2,1,1,0
CHEMBL395091,ESKETAMINE,CN[C@]1(c2ccccc2Cl)CCCCC1=O,True,True,False,707;1606;1954;2180;2601;2646;2671,3613;6797;6824;6851;6884;7042;7069;7096;7123,,4.0,Recruiting,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0002050,depressive disorder,2,7,9,0
CHEMBL39541,DOLASTATIN-10,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,True,True,True,841;1574;2009;2249;2354;2418;2723;2789;2853,1554;1618;1682;1746;1810;1874;1938;2103;2167;2231;2295;2359;2423;2487;2551;2615;2679;2743;2807;2871;2935;2999;3069;3133;3197;3261;3325;3389;3453;3517;3581;3672;3736;3800;3864;3928;3992;4059,64,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000565;EFO_0000574,leukemia;lymphoma,3,9,38,1
CHEMBL398435,TICAGRELOR,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,True,True,True,467,1352,559,4.0,Unknown status,P2RY12,G alpha (i) signalling events,R-HSA-418594,Purinergic receptor P2Y12 negative allosteric modulator,EFO_0000612,myocardial infarction,3,1,1,1
CHEMBL398707,HYDROMORPHONE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,True,True,False,294,264;1298;7211,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL3989406,ENALAPRILAT,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,True,True,True,655,451,385,3.0,Completed,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000407,dilated cardiomyopathy,3,1,1,1
CHEMBL3989408,IBUPROFEN SODIUM,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+],True,True,True,154;934,377;4495;5574;5634;5704;6088;6162;6236;6310;6384;6458,117,3.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL3989410,INDOMETHACIN SODIUM,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+],True,True,True,165;941,388;4506;5581;5641;5715;6099;6173;6247;6321;6395;6469,137,1.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,MP_0001845,inflammation,3,2,10,1
CHEMBL3989512,SOBLIDOTIN,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,True,True,True,849;1582;2017;2256;2361;2425;2732;2796;2860,1562;1626;1690;1754;1818;1882;1946;2111;2175;2239;2303;2367;2431;2495;2559;2623;2687;2751;2815;2879;2943;3007;3077;3141;3205;3269;3333;3397;3461;3525;3589;3680;3744;3808;3872;3936;4000;4067,69,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000691,sarcoma,3,9,38,1
CHEMBL3989519,DOXAPRAM HYDROCHLORIDE,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O,True,True,False,531;536,16;21;7723;7728,,4.0,,KCNK3;KCNK9,Phase 4 - resting membrane potential;TWIK-releated acid-sensitive K+ channel (TASK),R-HSA-1299316;R-HSA-5576886,,EFO_0003818,lung disease,2,2,2,0
CHEMBL3989555,MECLIZINE HYDROCHLORIDE,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1.Cl.Cl.O,True,True,False,981,6611,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0006928,motion sickness,2,1,1,0
CHEMBL3989562,TERAZOSIN HYDROCHLORIDE,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O,True,True,False,361;1465;1823,824;6486;6686,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,3,3,0
CHEMBL3989568,OXYTETRACYCLINE CALCIUM,CN(C)[C@@H]1C([O-])=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.CN(C)[C@@H]1C([O-])=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.[Ca+2],False,False,True,,,316,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3989571,SPECTINOMYCIN HYDROCHLORIDE,CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@@]3(O)C(=O)C[C@@H](C)O[C@H]3O[C@@H]2[C@H]1O.Cl.Cl.O.O.O.O.O,False,False,True,,,334,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3989676,OXYPHENBUTAZONE,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O,True,True,True,124;920,347;4465;5560;5620;5674;6058;6132;6206;6280;6354;6428,138,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005752,eye inflammation,3,2,10,1
CHEMBL3989677,HYDROCODONE BITARTRATE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O,True,True,False,295,265;1299;7212,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL3989680,AXOMADOL,COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1,True,True,True,342,312;1346;7259,672,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,HP_0003419,Low back pain,3,1,3,1
CHEMBL3989686,IFERANSERIN,CN1CCCC[C@H]1CCc1ccccc1NC(=O)/C=C/c1ccccc1,False,False,True,,,710,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL3989690,TESOFENSINE,CCOC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,True,False,False,1292,,,2.0,Completed,SLC6A4,,,,EFO_0001073,obesity,1,1,0,0
CHEMBL3989694,OLANZAPINE PAMOATE,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,False,False,True,,,673,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL3989716,PROPOXYPHENE NAPSYLATE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1,True,True,True,310,280;1314;7227,654,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL3989724,FLURAZEPAM HYDROCHLORIDE,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl,True,False,True,490;1429;1650;1695;2057;2095;2456,,293,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004698,insomnia,2,7,0,2
CHEMBL3989740,DOXYCYCLINE HYCLATE,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O,True,True,True,610;615;621;628,26;32;39;44;50;56;63;68;81;87;94;99;112;126;231;3028,351,4.0,Completed,MMP1;MMP13;MMP7;MMP8,Activation of Matrix Metalloproteinases;Basigin interactions;Collagen degradation;Degradation of the extracellular matrix;Interleukin-4 and Interleukin-13 signaling;Neutrophil degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1442490;R-HSA-1474228;R-HSA-1592389;R-HSA-381426;R-HSA-6785807;R-HSA-6798695,Bacterial 70S ribosome inhibitor | Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 7 inhibitor | Matrix metalloproteinase 8 inhibitor | Matrix metalloproteinase-1 inhibitor,EFO_0003894,acne,3,4,7,1
CHEMBL3989754,FLURBIPROFEN SODIUM,CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1.O.O.[Na+],False,False,True,,,139,,,,,,Cyclooxygenase inhibitor,,,1,0,0,1
CHEMBL3989768,LEVORPHANOL TARTRATE,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13.O.O.O=C(O)C(O)C(O)C(=O)O,False,False,True,,,655,,,,,,Mu opioid receptor agonist,,,1,0,0,1
CHEMBL3989803,DIPYRONE,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+],True,True,True,122;907,345;4463;5547;5607;5672;6056;6130;6204;6278;6352;6426,159,4.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0003843,pain,3,2,10,1
CHEMBL3989820,ZOLPIDEM TARTRATE,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O,True,False,False,1642;1738,,,4.0,Completed,GABRB1;GABRG2,,,,EFO_0004698,insomnia,1,2,0,0
CHEMBL3989824,THIOTHIXENE HYDROCHLORIDE,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O,False,False,True,,,711,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL3989826,OXYCODONE TEREPHTHALATE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1,True,True,True,311,281;1315;7228,630,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL3989829,NETILMICIN SULFATE,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,False,False,True,,,335,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3989830,SIBUTRAMINE HYDROCHLORIDE,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1.Cl.O,True,False,False,1284,,,3.0,Completed,SLC6A4,,,,EFO_0001073,obesity,1,1,0,0
CHEMBL3989833,ZIPRASIDONE MESYLATE,CS(=O)(=O)O.O.O.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,False,False,True,,,712,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL3989834,AVOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccncc2)nc1OC,True,False,False,1916,,,3.0,Terminated,EDNRA,,,,EFO_0000401,diabetic nephropathy,1,1,0,0
CHEMBL3989861,DESVENLAFAXINE FUMARATE,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O,True,False,False,1267,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL3989862,PEFCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,247,6000;7777;7895,36,3.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000676,psoriasis,3,1,3,1
CHEMBL3989869,UMBRALISIB TOSYLATE,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1,True,True,False,1208,4299,,4.0,,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_1000630,marginal zone B-cell lymphoma,2,1,1,0
CHEMBL3989872,APIMOSTINEL,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O,True,True,False,727;1624;1970;2196;2620;2663;2687,3633;6817;6844;6871;6904;7062;7089;7116;7143,,2.0,Completed;Withdrawn,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0002009;MONDO_0005090,major depressive disorder;schizophrenia,2,7,9,0
CHEMBL3989904,CETHROMYCIN,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OCC=Cc2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@@]21C,False,False,True,,,352,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3989919,FOSNETUPITANT CHLORIDE HYDROCHLORIDE,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)(O)O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.[Cl-],False,False,True,,,554,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL3989920,PITAVASTATIN SODIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+],True,True,True,744,7623;7638;7653;7668,54,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,HP_0003119,Abnormal circulating lipid concentration,3,1,4,1
CHEMBL3989923,PITAVASTATIN MAGNESIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2],True,True,True,743,7622;7637;7652;7667,55,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,HP_0003119,Abnormal circulating lipid concentration,3,1,4,1
CHEMBL3989932,ANGIOTENSIN II ACETATE,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,True,True,False,590,6544;7163;7274;7294,,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,,EFO_0005251,hypotension,2,1,4,0
CHEMBL3989933,ETRASIMOD ARGININE,N=C(N)NCCC[C@@H](N)C(=O)O.O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,True,False,False,1883,,,4.0,,S1PR4,,,,EFO_0000729,ulcerative colitis,1,1,0,0
CHEMBL3989949,CENOBAMATE,NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl,True,False,True,480;1409;1510;1633;1678;1733;1773;1795;1868;1928;2039;2084;2448;2554;2573;2624,,294,4.0,,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000474,epilepsy,2,16,0,2
CHEMBL3989966,CONTEZOLID ACEFOSAMIL,CC(=O)OP(=O)([O-])N(C[C@H]1CN(c2cc(F)c(N3C=CC(=O)CC3)c(F)c2F)C(=O)O1)c1ccon1.[Na+],False,False,True,,,353,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL3989967,LOTAMILAST,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1,True,True,True,427;1059;1090;2163,4341;5749;5776;5807;5844;5874,631,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000274,atopic eczema,3,4,3,1
CHEMBL3989968,DIFAMILAST,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1,True,True,True,418;1051;1079;2156,4330;5740;5768;5796;5835;5863,611,3.0,"Active, not recruiting;Completed;Recruiting",PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000274,atopic eczema,3,4,3,1
CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,True,True,False,1153,558;6970;7504,,4.0,,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_1000562,Tenosynovial Giant Cell Tumor,2,1,3,0
CHEMBL3989986,RAVULIZUMAB,N/A,False,True,False,,1235;7172;7733;7745;7757,,4.0,,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0000540,immune system disease,1,1,5,0
CHEMBL3989992,PEGILODECAKIN,N/A,False,True,False,,4393;4776;4883,,3.0,Completed,IL10RB,Interleukin-10 signaling;Interleukin-20 family signaling;Other interleukin signaling,R-HSA-449836;R-HSA-6783783;R-HSA-8854691,,EFO_0002618,pancreatic carcinoma,1,1,3,0
CHEMBL3990000,TIBULIZUMAB,N/A,False,True,False,,160;4229;7309,,2.0,Withdrawn,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_0000699,Sjogren syndrome,1,1,3,0
CHEMBL3990025,OLENDALIZUMAB,N/A,False,True,False,,1245;7182;7743;7755;7767,,2.0,Terminated,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0002689,antiphospholipid syndrome,1,1,5,0
CHEMBL3990032,TELISOTUZUMAB VEDOTIN,N/A,True,True,False,831;1564;1998;2237;2343;2407;2714;2778;2841,1544;1608;1672;1736;1800;1864;1928;2093;2157;2221;2285;2349;2413;2477;2541;2605;2669;2733;2797;2861;2925;2989;3059;3123;3187;3251;3315;3379;3443;3507;3571;3662;3726;3790;3854;3918;3982;4049,,3.0,Recruiting;Withdrawn,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0003060,non-small cell lung carcinoma,2,9,38,0
CHEMBL3991932,PEXMETINIB,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,False,False,True,,,85,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL403989,TG100-801,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,True,True,False,944;1133,7031,,2.0,Terminated,BLK;PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0009606,macular degeneration,2,2,1,0
CHEMBL404108,LUMIRACOXIB,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,True,True,False,146,369;4487;5696;6080;6154;6228;6302;6376;6450,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005755,rheumatic disease,2,1,9,0
CHEMBL404849,SULOCTIDIL,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,True,False,False,1904;2488,,,4.0,,CACNA1A;CACNA2D1,,,,EFO_0000319,cardiovascular disease,1,2,0,0
CHEMBL4065122,FENEBRUTINIB,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,True,True,True,196,602;4097;6559;6739,565,3.0,"Active, not recruiting",BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0003840,chronic progressive multiple sclerosis,3,1,4,1
CHEMBL4066936,VERICIGUAT,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N,True,True,True,69,7685,255,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL4068611,RELACORILANT,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1,True,True,False,52,744;2053;5968;7872;8009;8075;8146;8212;8278,,3.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0003099,Cushing syndrome,2,1,9,0
CHEMBL407,FLUMAZENIL,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,True,False,False,516;1442;1667;1714;2076;2121;2480,,,2.0,Completed;Terminated,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,,EFO_0003890;EFO_0004242,drug dependence;obsessive-compulsive disorder,1,7,0,0
CHEMBL4071161,TIRABRUTINIB,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,True,True,True,204,610;4105;6567;6747,566,2.0,Completed,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000095,chronic lymphocytic leukemia,3,1,4,1
CHEMBL4072756,AZD-5423,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1,True,True,False,58,750;2059;5974;7878;8015;8081;8152;8218;8284,,2.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0000341,chronic obstructive pulmonary disease,2,1,9,0
CHEMBL4072833,EVOBRUTINIB,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,True,True,True,202,608;4103;6565;6745,567,3.0,Terminated,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0003929,relapsing-remitting multiple sclerosis,3,1,4,1
CHEMBL4076467,ABT-072,COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,False,False,True,,,441,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL408403,ANGIOTENSIN II,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,True,True,False,581,6535;7154;7265;7285,,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL4085457,RITLECITINIB,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,True,True,False,198,604;4099;6561;6741,,3.0,Recruiting,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,,EFO_0004208,Vitiligo,2,1,4,0
CHEMBL409,BICALUTAMIDE,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,True,True,True,545,1968;5883;7787,71,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000313,carcinoma,3,1,3,1
CHEMBL4094894,CIPEPOFOL,CC(C)c1cccc([C@H](C)C2CC2)c1O,True,False,False,523;1449;1533;1674;1722;1759;1789;1808;1881;1944;2082;2129;2487;2567;2594;2638,,,1.0,Completed,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,,EFO_0003086,kidney disease,1,16,0,0
CHEMBL41,FLUOXETINE,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,True,False,False,1283,,,3.0,Recruiting,SLC6A4,,,,EFO_0000694,severe acute respiratory syndrome,1,1,0,0
CHEMBL4105630,ZURANOLONE,C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1,True,False,True,501;1425;1517;1647;1693;1742;1777;1797;1871;1932;2062;2100;2461;2557;2579;2628,,295,4.0,,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0007453,postpartum depression,2,16,0,2
CHEMBL411,DIETHYLSTILBESTROL,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,True,False,False,2279,,,4.0,,ESR1,,,,EFO_0000616,neoplasm,1,1,0,0
CHEMBL4116008,CERDULATINIB,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,True,True,True,775;1197,200;415;662;794;4252;4279;4431;4533;4572;4616;4651;4695;4730;4774;4799;4815;4837;4881;4906;4950;4972;5016;5038;5082;5126;5148;5192;5226;5242;5276;5292;5314;5358;5380;5424;5440;5474;5490;6927,474,2.0,Completed,JAK1;TYK2,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;RAF/MAP kinase cascade;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor,EFO_0004208,Vitiligo,3,2,21,1
CHEMBL41194,PRATOSARTAN,CCCc1nc2c(n1Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CCCC2,False,False,True,,,0,,,,,,Type-1 angiotensin II receptor antagonist,,,1,0,0,1
CHEMBL4129286,ADAFOSBUVIR,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@@]1(F)O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(O)[C@@H]1O)Oc1ccccc1,False,False,True,,,442,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL4130229,VODOBATINIB,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1,True,True,False,1220;2211,4311,,2.0,Recruiting,ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,HP_0000726,Dementia,2,2,1,0
CHEMBL415,CLOMIPRAMINE,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,True,False,False,1269,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL416146,ETORICOXIB,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,True,True,False,134,357;4475;5684;6068;6142;6216;6290;6364;6438,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005755,rheumatic disease,2,1,9,0
CHEMBL4163691,POSELTINIB,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1,True,True,True,207,613;4108;6570;6750,555,2.0,Terminated,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000685,rheumatoid arthritis,3,1,4,1
CHEMBL419213,LISINOPRIL,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,True,True,True,634,430,369,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL42,CLOZAPINE,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,False,False,True,,,675,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL420,GUANABENZ,N=C(N)N/N=C/c1c(Cl)cccc1Cl,True,True,False,1350;1402;2550,921;973;1025;1077;1129;1181;1233;1413;1465;1517,,1.0,Terminated,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0003929,relapsing-remitting multiple sclerosis,2,3,6,0
CHEMBL4204794,AVAPRITINIB,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,True,True,False,1145,550;6962;7496,,4.0,,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL4208229,ASCIMINIB,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,True,True,False,1206;2204,4297,,4.0,,ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000616,neoplasm,2,2,1,0
CHEMBL4208954,AMIKACIN SULFATE,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O,False,False,True,,,317,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL421,SULFASALAZINE,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,True,True,True,102;890,325;4443;5530;5590;5652;6036;6110;6184;6258;6332;6406,121,4.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL4210847,PF-00489791,CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21,True,True,True,880,7680;7707;7720,455,2.0,Completed,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,EFO_0000401,diabetic nephropathy,3,1,3,1
CHEMBL4216467,RIPRETINIB,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,True,True,False,1146,551;6963;7497,,4.0,,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,1,3,0
CHEMBL42442,OXFENDAZOLE,COC(=O)Nc1nc2cc([S+]([O-])c3ccccc3)ccc2[nH]1,False,False,True,,,65,,,,,,Tubulin inhibitor,,,1,0,0,1
CHEMBL425,OLSALAZINE,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O,True,True,False,162;939,385;4503;5579;5639;5712;6096;6170;6244;6318;6392;6466,,2.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0003898,ankylosing spondylitis,2,2,10,0
CHEMBL426084,SAMIDORPHAN,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3,True,True,False,339,309;1343;7256,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0005203,eating disorder,2,1,3,0
CHEMBL4279455,LAROTAXEL,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,True,True,False,826;1560;1995;2234;2339;2402;2709;2774;2838,1539;1603;1667;1731;1795;1859;1923;2088;2152;2216;2280;2344;2408;2472;2536;2600;2664;2728;2792;2856;2920;2984;3054;3118;3182;3246;3310;3374;3438;3502;3566;3657;3721;3785;3849;3913;3977;4044,,3.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000294,bladder tumor,2,9,38,0
CHEMBL428647,PACLITAXEL,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,True,True,True,810;1544;1978;2218;2322;2384;2691;2758;2819,1523;1587;1651;1715;1779;1843;1907;2072;2136;2200;2264;2328;2392;2456;2520;2584;2648;2712;2776;2840;2904;2968;3038;3102;3166;3230;3294;3358;3422;3486;3550;3641;3705;3769;3833;3897;3961;4028,38,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000305;EFO_0000313,breast carcinoma;carcinoma,3,9,38,1
CHEMBL429,LABETALOL,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1,True,True,False,354;1312;1354;1462;1817;2510,817;883;925;987;1029;1091;1143;1185;1375;1417;1479;6479;6679,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL4296719,DUTOGLIPTIN,O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,True,False,True,673,,526,3.0,Not yet recruiting,DPP4,,,Dipeptidyl peptidase IV inhibitor,EFO_0008585,ST Elevation Myocardial Infarction,2,1,0,1
CHEMBL4297064,MILNACIPRAN HYDROCHLORIDE,CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl,True,False,False,1248,,,4.0,,SLC6A4,,,,EFO_0005687,fibromyalgia,1,1,0,0
CHEMBL4297091,CODEINE SULFATE,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O,True,True,False,296,266;1300;7213,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL4297147,HALOPERIDOL LACTATE,CC(O)C(=O)O.O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,False,False,True,,,713,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL4297163,MUPARFOSTAT,N/A,False,True,False,,423;467;479;491;503;515;527;539;589;802,,3.0,Terminated,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0000182,hepatocellular carcinoma,1,1,10,0
CHEMBL4297185,DAROLUTAMIDE,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,True,True,True,552,1975;5890;7794,86,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000616,neoplasm,3,1,3,1
CHEMBL4297214,PRALICIGUAT,OC(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)(C(F)(F)F)C(F)(F)F,True,True,True,77,7693,256,2.0,Completed,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0003144,heart failure,3,1,1,1
CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O,True,True,True,787,212;674;4584;4663;4742;4849;4918;4984;5050;5094;5160;5326;5392;6939;7473;8302;8330;8358;8392;8420;8448,497,4.0,,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0002430,primary myelofibrosis,3,1,21,1
CHEMBL4297218,ROVAZOLAC,CCOC(=O)Cn1nc(C(F)(F)F)cc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,True,False,False,1724,,,2.0,"Active, not recruiting",NR1H2,,,,EFO_0000274,atopic eczema,1,1,0,0
CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,True,True,False,1204;2202,4295,,4.0,,ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000339,chronic myelogenous leukemia,2,2,1,0
CHEMBL4297268,BMS-275183,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,True,True,False,853;1584;2020;2257;2362;2426;2734;2798;2862,1566;1630;1694;1758;1822;1886;1950;2115;2179;2243;2307;2371;2435;2499;2563;2627;2691;2755;2819;2883;2947;3011;3081;3145;3209;3273;3337;3401;3465;3529;3593;3684;3748;3812;3876;3940;4004;4071,,2.0,Terminated,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0003060,non-small cell lung carcinoma,2,9,38,0
CHEMBL4297287,HT-0712,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1,True,True,True,431;1064;1093;2169,4344;5753;5781;5810;5848;5877,632,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0001072,memory impairment,3,4,3,1
CHEMBL4297294,JNJ-42165279,O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1,True,False,True,689,,118,2.0,Completed,FAAH,,,Anandamide amidohydrolase inhibitor,EFO_0003756,autism spectrum disorder,2,1,0,1
CHEMBL4297296,KOS-1584,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1,True,True,False,851;1585;2018;2258;2363;2429;2735;2799;2864,1564;1628;1692;1756;1820;1884;1948;2113;2177;2241;2305;2369;2433;2497;2561;2625;2689;2753;2817;2881;2945;3009;3079;3143;3207;3271;3335;3399;3463;3527;3591;3682;3746;3810;3874;3938;4002;4069,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0003060,non-small cell lung carcinoma,2,9,38,0
CHEMBL4297312,ORM-12741,COC[C@@]1(C)CCCN2CCc3c(oc4ccccc34)[C@@H]21,True,False,False,2548,,,2.0,Completed,ADRA2C,,,,MONDO_0004975,Alzheimer disease,1,1,0,0
CHEMBL4297356,AZD-8848,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1,True,True,False,607,767;4263;7329;7351;7362;7373;7384;7406;7428;7450;7461,,2.0,Completed,TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0005854,allergic rhinitis,2,1,11,0
CHEMBL4297383,GSK-1521498,Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1,True,True,False,336,306;1340;7253,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0001073,obesity,2,1,3,0
CHEMBL4297385,NS-2359,COC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,True,False,False,1293,,,2.0,Completed,SLC6A4,,,,EFO_0003888,attention deficit hyperactivity disorder,1,1,0,0
CHEMBL4297431,HENAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@]34OC[C@@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1F,False,False,True,,,612,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL4297440,T-900607,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O,True,True,False,836;1569;2004;2243;2348;2412;2719;2783;2847,1549;1613;1677;1741;1805;1869;1933;2098;2162;2226;2290;2354;2418;2482;2546;2610;2674;2738;2802;2866;2930;2994;3064;3128;3192;3256;3320;3384;3448;3512;3576;3667;3731;3795;3859;3923;3987;4054,,2.0,Unknown status,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000182,hepatocellular carcinoma,2,9,38,0
CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1,True,True,False,832;1565;1999;2238;2344;2408;2715;2779;2843,1545;1609;1673;1737;1801;1865;1929;2094;2158;2222;2286;2350;2414;2478;2542;2606;2670;2734;2798;2862;2926;2990;3060;3124;3188;3252;3316;3380;3444;3508;3572;3663;3727;3791;3855;3919;3983;4050,,3.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0003060,non-small cell lung carcinoma,2,9,38,0
CHEMBL4297447,TRV-120027,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O,True,True,False,597,6551;7170;7281;7301,,2.0,Completed,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,,EFO_0003144,heart failure,2,1,4,0
CHEMBL4297452,YM-543,C[N+](C)(C)CCO.[O-]c1ccc(Cc2cc3cccccc-3c2)cc1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,False,False,True,,,613,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL4297460,DOVRAMILAST,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC,True,True,True,432;1065;1094;2170,4345;5754;5782;5811;5849;5878,614,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0003834,cutaneous lupus erythematosus,3,4,3,1
CHEMBL4297477,BREPOCITINIB,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,True,True,True,764;1189,189;407;651;786;4241;4271;4420;4525;4561;4608;4640;4687;4719;4766;4788;4807;4826;4873;4895;4942;4961;5008;5027;5074;5118;5137;5184;5215;5234;5265;5284;5303;5350;5369;5416;5432;5463;5482;6916,487,3.0,Recruiting,JAK1;TYK2,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;RAF/MAP kinase cascade;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor,EFO_0000398,dermatomyositis,3,2,21,1
CHEMBL4297492,GSK-2245035,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1,True,True,False,606,766;4262;7328;7350;7361;7372;7383;7405;7427;7449;7460,,2.0,Completed,TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0010638,atopic asthma,2,1,11,0
CHEMBL4297502,AVORALSTAT,C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC,False,False,True,,,556,,,,,,Plasma kallikrein inhibitor,,,1,0,0,1
CHEMBL4297507,DELGOCITINIB,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2,True,True,False,769;793;1193,194;218;411;656;680;790;4246;4275;4425;4529;4566;4590;4612;4645;4669;4691;4724;4748;4770;4793;4811;4831;4855;4877;4900;4924;4946;4966;4990;5012;5032;5056;5078;5100;5122;5142;5166;5188;5220;5238;5270;5288;5308;5332;5354;5374;5398;5420;5436;5468;5486;6921;6945;7479;8308;8336;8364;8398;8426;8454,,3.0,Completed;Recruiting,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,HP_0000964,Eczematoid dermatitis,2,3,28,0
CHEMBL4297509,ELACESTRANT,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1,True,False,False,2305,,,3.0,Recruiting,ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL4297519,NAFITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2[C@H](/C(N)=N/O[C@@H](C)c3nnc(-c4ccccn4)s3)C(=O)O[C@@]21C,False,False,True,,,354,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL4297520,OGLEMILAST,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,True,True,True,428;1060;1088;2164,4339;5750;5777;5805;5845;5872,633,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL4297521,PADSEVONIL,COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(C(F)(F)F)nc2s1,True,False,False,517;1444;1670;1715;2078;2123;2481,,,2.0,Completed;Terminated,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,,EFO_0004263,partial epilepsy,1,7,0,0
CHEMBL4297524,RADOTINIB,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,True,True,False,1216;2210,4307,,3.0,"Active, not recruiting",ABL1;BCR,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000339,chronic myelogenous leukemia,2,2,1,0
CHEMBL4297526,REMIMAZOLAM,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21,True,False,False,506;1435;1659;1705;2067;2113;2473,,,3.0,Recruiting,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,,EFO_0000275,atrial fibrillation,1,7,0,0
CHEMBL4297527,REVAMILAST,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12,True,True,True,430;1063;1092;2168,4343;5752;5780;5809;5847;5876,634,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000685,rheumatoid arthritis,3,4,3,1
CHEMBL4297538,MK-0812,N/A,True,True,False,234,1252;4369;6775,,2.0,Completed,CCR2,Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000685,rheumatoid arthritis,2,1,3,0
CHEMBL4297564,COBITOLIMOD,N/A,True,True,False,257,771;7333;7388;7410;7432,,3.0,Completed,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,EFO_0000729,ulcerative colitis,2,1,5,0
CHEMBL4297572,ABBV-3373,N/A,True,True,False,60;88,397;752;2061;4151;4166;4515;5976;7880;8017;8083;8154;8220;8286,,2.0,Completed,NR3C1;TNF,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;Regulation of TNFR1 signaling;SUMOylation of intracellular receptors;TNFR1-induced NF-kappa-B signaling pathway",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0000685,rheumatoid arthritis,2,2,13,0
CHEMBL4297589,SELATOGREL,CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1,True,True,False,473,1358,,3.0,Enrolling by invitation,P2RY12,G alpha (i) signalling events,R-HSA-418594,,EFO_0008583,acute myocardial infarction,2,1,1,0
CHEMBL4297601,ROCACETRAPIB,COc1cc(F)c(C(C)C)cc1C1=C(CN2C(=O)O[C@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H]2C)CC(C)(C)CC1,True,False,False,1901,,,1.0,Completed,CETP,,,,Orphanet_309005,Disorder of lipid metabolism,1,1,0,0
CHEMBL4297608,ELDECALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O,True,True,True,249,6002;7779;7897,37,3.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0003882,osteoporosis,3,1,3,1
CHEMBL4297616,OLINCIGUAT,NC(=O)[C@](O)(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)C(F)(F)F,True,True,False,79,7695,,2.0,Terminated,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,,HP_0002571,Achalasia,2,1,1,0
CHEMBL4297624,BISEGLIPTIN,CCOC(=O)C12CCC(NCC(=O)N3C[C@@H](F)C[C@H]3C#N)(CC1)CC2,True,False,True,679,,527,2.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL4297625,LICOGLIFLOZIN,CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,False,False,True,,,595,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL4297631,TELRATOLIMOD,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21,True,True,False,608,768;4264;7330;7352;7363;7374;7385;7407;7429;7451;7462,,1.0,"Active, not recruiting",TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0000180,HIV-1 infection,2,1,11,0
CHEMBL4297632,OXYCODEGOL,COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5,True,True,True,332,302;1336;7249,674,3.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,HP_0003419,Low back pain,3,1,3,1
CHEMBL4297636,PLOCABULIN,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O,True,True,True,856;1592;2027;2263;2368;2434;2741;2803;2867,1569;1633;1697;1761;1825;1889;1953;2118;2182;2246;2310;2374;2438;2502;2566;2630;2694;2758;2822;2886;2950;3014;3084;3148;3212;3276;3340;3404;3468;3532;3596;3687;3751;3815;3879;3943;4007;4074,70,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,MONDO_0005575,colorectal cancer,3,9,38,1
CHEMBL4297640,VECABRUTINIB,NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O,False,False,True,,,568,,,,,,Tyrosine-protein kinase BTK inhibitor,,,1,0,0,1
CHEMBL4297658,IPRAGLIFLOZIN L-PROLINE,O=C(O)[C@@H]1CCCN1.OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,False,False,True,,,596,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL4297674,BRANEBRUTINIB,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,True,True,True,210,616;4111;6573;6753,569,1.0,Completed,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000685,rheumatoid arthritis,3,1,4,1
CHEMBL4297680,1018 ISS,N/A,True,True,False,261,775;7337;7392;7414;7436,,3.0,Terminated,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,MONDO_0100096,COVID-19,2,1,5,0
CHEMBL4297684,ABICIPAR PEGOL,N/A,False,True,False,,426;470;482;494;506;518;530;542;592;805,,3.0,,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0005753,ocular vascular disease,1,1,10,0
CHEMBL4297686,IZOKIBEP,N/A,False,True,False,,158;4227;7307,,3.0,"Active, not recruiting",IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_1000710,hidradenitis suppurativa,1,1,3,0
CHEMBL4297700,BIMEKIZUMAB,N/A,False,True,False,,155;4224;7304,,4.0,,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_0000540,immune system disease,1,1,3,0
CHEMBL4297722,CEMDISIRAN,N/A,False,True,False,,1241;7178;7739;7751;7763,,3.0,Recruiting,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0004991,Myasthenia gravis,1,1,5,0
CHEMBL4297732,ZILTIVEKIMAB,N/A,False,True,False,,123;173;4409;4545;4624;4703;7593,,1.0,Completed,IL6,Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-381426;R-HSA-6783783;R-HSA-6785807;R-HSA-8957275,,EFO_0003884,chronic kidney disease,1,1,7,0
CHEMBL4297736,PRALUZATAMAB RAVTANSINE,N/A,True,True,False,859;1590;2024;2265;2370;2432;2740;2805;2869,1572;1636;1700;1764;1828;1892;1956;2121;2185;2249;2313;2377;2441;2505;2569;2633;2697;2761;2825;2889;2953;3017;3087;3151;3215;3279;3343;3407;3471;3535;3599;3690;3754;3818;3882;3946;4010;4077,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,MONDO_0007254,breast cancer,2,9,38,0
CHEMBL4297744,ELX-02,N/A,True,False,False,1731,,,2.0,Completed,RPS27,,,,MONDO_0009061,cystic fibrosis,1,1,0,0
CHEMBL4297750,FARICIMAB,N/A,False,True,False,,421;465;477;489;501;513;525;537;587;800,,4.0,,VEGFA,Interleukin-4 and Interleukin-13 signaling;Platelet degranulation;Potential therapeutics for SARS;Regulation of gene expression by Hypoxia-inducible Factor;Signaling by VEGF;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;VEGF binds to VEGFR leading to receptor dimerization;VEGF ligand-receptor interactions;VEGFA-VEGFR2 Pathway;VEGFR2 mediated cell proliferation,R-HSA-114608;R-HSA-1234158;R-HSA-194138;R-HSA-194313;R-HSA-195399;R-HSA-4420097;R-HSA-5218921;R-HSA-6785807;R-HSA-8866910;R-HSA-9679191,,EFO_0010977,macrovascular complications of diabetes,1,1,10,0
CHEMBL4297754,FITUSIRAN,N/A,True,True,False,178,150;7556;7585;7607,,3.0,Completed,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,MONDO_0010602,hemophilia A,2,1,4,0
CHEMBL4297768,IDRABIOTAPARINUX SODIUM,N/A,True,True,False,457,7537;7566,,3.0,Terminated,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,EFO_0000275,atrial fibrillation,2,1,2,0
CHEMBL4297776,LEFITOLIMOD,N/A,True,True,False,262,776;7338;7393;7415;7437,,2.0,Completed,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,EFO_0000180,HIV-1 infection,2,1,5,0
CHEMBL4297789,MT-3724,N/A,True,False,False,1730,,,2.0,Terminated,RPS27,,,,EFO_0000403,diffuse large B-cell lymphoma,1,1,0,0
CHEMBL4297813,PRI-724,N/A,True,False,False,2551,,,2.0,Withdrawn,CREBBP,,,,EFO_0000365,colorectal adenocarcinoma,1,1,0,0
CHEMBL4297819,ROPEGINTERFERON ALFA-2B,N/A,False,True,False,,631;4216;5203;5253;5451,,4.0,,IFNAR1,Evasion by RSV of host interferon responses;Interferon alpha/beta signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-909733;R-HSA-912694;R-HSA-9679191;R-HSA-9705671;R-HSA-9833109,,EFO_0000616,neoplasm,1,1,5,0
CHEMBL4297838,TILSOTOLIMOD,N/A,True,True,False,259,773;7335;7390;7412;7434,,3.0,Terminated,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,EFO_0002617,metastatic melanoma,2,1,5,0
CHEMBL4297841,TISOTUMAB VEDOTIN,N/A,True,True,False,819;1553;1986;2224;2326;2396;2699;2766;2830,1532;1596;1660;1724;1788;1852;1916;2081;2145;2209;2273;2337;2401;2465;2529;2593;2657;2721;2785;2849;2913;2977;3047;3111;3175;3239;3303;3367;3431;3495;3559;3650;3714;3778;3842;3906;3970;4037,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,N/A,True,True,False,863;1596;2031;2271;2377;2440;2746;2810;2875,1576;1640;1704;1768;1832;1896;1960;2125;2189;2253;2317;2381;2445;2509;2573;2637;2701;2765;2829;2893;2957;3021;3091;3155;3219;3283;3347;3411;3475;3539;3603;3694;3758;3822;3886;3950;4014;4081,,1.0,Terminated;Withdrawn,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0001378,multiple myeloma,2,9,38,0
CHEMBL4297863,REMTOLUMAB,N/A,True,True,False,91,159;400;4154;4169;4228;4518;7308,,2.0,Completed,IL17A;TNF,Interleukin-10 signaling;Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;Regulation of TNFR1 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TNFR1-induced NF-kappa-B signaling pathway,R-HSA-448424;R-HSA-5357905;R-HSA-5357956;R-HSA-6783783;R-HSA-6785807;R-HSA-9705671,,EFO_0000685,rheumatoid arthritis,2,2,6,0
CHEMBL4297865,ABIVERTINIB,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,True,True,True,197,603;4098;6560;6740,570,3.0,Not yet recruiting,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0003060,non-small cell lung carcinoma,3,1,4,1
CHEMBL4297866,ABIVERTINIB MALEATE,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O,True,True,True,199,605;4100;6562;6742,571,3.0,Not yet recruiting,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0003060,non-small cell lung carcinoma,3,1,4,1
CHEMBL4297886,ASUNERCEPT,N/A,False,True,False,,152;7312;7313;7314;7315;7316;7317;7318;7319,,3.0,Terminated,FASLG,CASP8 activity is inhibited;Caspase activation via Death Receptors in the presence of ligand;Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models;Dimerization of procaspase-8;FOXO-mediated transcription of cell death genes;FasL/ CD95L signaling;Interleukin-4 and Interleukin-13 signaling;RIPK1-mediated regulated necrosis;Regulation by c-FLIP,R-HSA-140534;R-HSA-3371378;R-HSA-5213460;R-HSA-5218900;R-HSA-6785807;R-HSA-69416;R-HSA-75157;R-HSA-8862803;R-HSA-9614657,,MONDO_0100096,COVID-19,1,1,9,0
CHEMBL4297892,ANVATABART OPADOTIN,N/A,True,True,False,846;1578;2013;2251;2356;2423;2729;2792;2857,1559;1623;1687;1751;1815;1879;1943;2108;2172;2236;2300;2364;2428;2492;2556;2620;2684;2748;2812;2876;2940;3004;3074;3138;3202;3266;3330;3394;3458;3522;3586;3677;3741;3805;3869;3933;3997;4064,,2.0,Withdrawn,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL4297919,PAROXETINE HYDROCHLORIDE HEMIHYDRATE,N/A,True,False,False,1289,,,3.0,Completed,SLC6A4,,,,EFO_1001917,social anxiety disorder,1,1,0,0
CHEMBL4297926,CJM-112,N/A,False,True,False,,161;4230;7310,,2.0,Completed,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_0003894,acne,1,1,3,0
CHEMBL4297928,NOMACOPAN,N/A,False,True,False,,1242;7179;7740;7752;7764,,3.0,Withdrawn,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0007187,bullous pemphigoid,1,1,5,0
CHEMBL4297935,RG-7841,N/A,True,True,False,862;1595;2030;2269;2374;2438;2744;2808;2873,1575;1639;1703;1767;1831;1895;1959;2124;2188;2252;2316;2380;2444;2508;2572;2636;2700;2764;2828;2892;2956;3020;3090;3154;3218;3282;3346;3410;3474;3538;3602;3693;3757;3821;3885;3949;4013;4080,,1.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL4297938,LIFASTUZUMAB VEDOTIN,N/A,True,True,False,857;1591;2025;2266;2371;2435;2742;2806;2870,1570;1634;1698;1762;1826;1890;1954;2119;2183;2247;2311;2375;2439;2503;2567;2631;2695;2759;2823;2887;2951;3015;3085;3149;3213;3277;3341;3405;3469;3533;3597;3688;3752;3816;3880;3944;4008;4075,,2.0,Terminated,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,MONDO_0008170,ovarian cancer,2,9,38,0
CHEMBL4297951,COAGULATION FACTOR X HUMAN,N/A,True,True,False,454,7534;7563,,4.0,,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,MONDO_0002247,factor X deficiency,2,1,2,0
CHEMBL4297993,EMD-1201081,N/A,True,True,False,264,778;7340;7395;7417;7439,,2.0,Completed,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,EFO_0000681,renal cell carcinoma,2,1,5,0
CHEMBL4297994,TILSOTOLIMOD SODIUM,N/A,True,True,False,265,779;7341;7396;7418;7440,,2.0,Completed,TLR9,MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-9679191;R-HSA-975110;R-HSA-975138;R-HSA-975155,,EFO_0002617,metastatic melanoma,2,1,5,0
CHEMBL4297995,BAZLITORAN,N/A,True,True,False,263;604,764;777;4260;7326;7339;7348;7359;7370;7381;7394;7403;7416;7425;7438;7447;7458,,2.0,Completed,TLR7;TLR9,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0000398,dermatomyositis,2,2,11,0
CHEMBL4298012,TESIDOLUMAB,N/A,False,True,False,,1244;7181;7742;7754;7766,,2.0,Completed,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0001365,age-related macular degeneration,1,1,5,0
CHEMBL4298023,M-1095,N/A,False,True,False,,157;4226;7306,,3.0,Recruiting,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_1000710,hidradenitis suppurativa,1,1,3,0
CHEMBL4298045,INDUSATUMAB VEDOTIN,N/A,True,True,False,837;1570;2005;2248;2353;2417;2720;2788;2852,1550;1614;1678;1742;1806;1870;1934;2099;2163;2227;2291;2355;2419;2483;2547;2611;2675;2739;2803;2867;2931;2995;3065;3129;3193;3257;3321;3385;3449;3513;3577;3668;3732;3796;3860;3924;3988;4055,,2.0,Terminated,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000503,gastric adenocarcinoma,2,9,38,0
CHEMBL4298077,PRASINEZUMAB,N/A,True,False,False,2569,,,2.0,"Active, not recruiting",SNCA,,,,MONDO_0005180,Parkinson disease,1,1,0,0
CHEMBL4298086,POZELIMAB,N/A,False,True,False,,1237;7174;7735;7747;7759,,4.0,,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,HP_0002243,Protein-losing enteropathy,1,1,5,0
CHEMBL4298098,TUSAMITAMAB RAVTANSINE,N/A,True,True,False,833;1566;2001;2240;2345;2409;2716;2780;2844,1546;1610;1674;1738;1802;1866;1930;2095;2159;2223;2287;2351;2415;2479;2543;2607;2671;2735;2799;2863;2927;2991;3061;3125;3189;3253;3317;3381;3445;3509;3573;3664;3728;3792;3856;3920;3984;4051,,3.0,"Active, not recruiting",TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0003060,non-small cell lung carcinoma,2,9,38,0
CHEMBL4298101,LADIRATUZUMAB VEDOTIN,N/A,True,True,False,852;1586;2021;2260;2365;2427;2736;2800;2863,1565;1629;1693;1757;1821;1885;1949;2114;2178;2242;2306;2370;2434;2498;2562;2626;2690;2754;2818;2882;2946;3010;3080;3144;3208;3272;3336;3400;3464;3528;3592;3683;3747;3811;3875;3939;4003;4070,,2.0,Recruiting,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0003869;EFO_0003968,angiosarcoma;breast neoplasm,2,9,38,0
CHEMBL4298102,VUNAKIZUMAB,N/A,False,True,False,,156;4225;7305,,3.0,Not yet recruiting,IL17A,Interleukin-17 signaling;Interleukin-4 and Interleukin-13 signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses,R-HSA-448424;R-HSA-6785807;R-HSA-9705671,,EFO_0000676,psoriasis,1,1,3,0
CHEMBL4298167,FILGOTINIB MALEATE,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O,True,True,True,760;783;1187,185;208;405;647;670;784;4237;4269;4416;4523;4557;4580;4606;4636;4659;4685;4715;4738;4764;4784;4805;4822;4845;4871;4891;4914;4940;4957;4980;5006;5023;5046;5072;5090;5116;5133;5156;5182;5211;5232;5261;5282;5299;5322;5348;5365;5388;5414;5430;5459;5480;6912;6935;7469;8298;8326;8354;8388;8416;8444,488,4.0,,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,EFO_0000685,rheumatoid arthritis,3,3,28,1
CHEMBL4298207,ZILUCOPLAN,N/A,False,True,False,,1239;7176;7737;7749;7761,,3.0,Completed,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0004991,Myasthenia gravis,1,1,5,0
CHEMBL4298209,BELANTAMAB MAFODOTIN,N/A,True,True,False,820;1551;1987;2225;2332;2390;2703;2767;2831,1533;1597;1661;1725;1789;1853;1917;2082;2146;2210;2274;2338;2402;2466;2530;2594;2658;2722;2786;2850;2914;2978;3048;3112;3176;3240;3304;3368;3432;3496;3560;3651;3715;3779;3843;3907;3971;4038,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL429910,DAPAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,False,False,True,,,586,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL4303201,CATEQUENTINIB,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,True,True,False,1111;1155,560;6972;7009;7506,,3.0,Not yet recruiting;Recruiting,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000182,hepatocellular carcinoma,2,2,3,0
CHEMBL4303389,NS-018,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1,True,True,True,802,227;689;4599;4678;4757;4864;4933;4999;5065;5109;5175;5341;5407;6954;7488;8317;8345;8373;8407;8435;8463,498,1.0,Completed,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0002430,primary myelofibrosis,3,1,21,1
CHEMBL4303403,LOREDIPLON,CC(=O)N(C)c1cc(-c2ccnc3c(C(=O)c4cccs4)cnn23)ccc1F,False,False,True,,,296,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL43064,CINNARIZINE,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,True,True,False,994,6624,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0002321,Vertigo,2,1,1,0
CHEMBL431,SPIRAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2,True,True,False,635,431,,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL432162,TASOSARTAN,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,True,True,True,596,6550;7169;7280;7300,3,2.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL435298,ESFLURBIPROFEN,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,True,True,True,160;938,383;4501;5578;5638;5710;6094;6168;6242;6316;6390;6464,167,3.0,Completed,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,HP_0030839,Knee pain,3,2,10,1
CHEMBL435381,CIMICOXIB,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F,True,True,False,163,386;4504;5713;6097;6171;6245;6319;6393;6467,,2.0,Completed,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,MONDO_0002050,depressive disorder,2,1,9,0
CHEMBL439849,VILAZODONE,N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,True,False,False,1270,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL440498,CTS-1027,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,True,True,True,618;625,36;47;60;71;91;102;3031,357,2.0,Completed;Terminated,MMP13;MMP8,Activation of Matrix Metalloproteinases;Collagen degradation;Degradation of the extracellular matrix;Neutrophil degranulation,R-HSA-1442490;R-HSA-1474228;R-HSA-1592389;R-HSA-6798695,Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 8 inhibitor,EFO_0003047,hepatitis C virus infection,3,2,4,1
CHEMBL441,THIOPENTAL,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,True,False,False,1527;1754;2588,,,3.0,Completed,GABRB1;GABRB2;GABRB3,,,,EFO_0006834,septic shock,1,3,0,0
CHEMBL442,ERGOTAMINE,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,True,True,False,396;1339;1391;1497;1856;2538,859;910;962;1014;1066;1118;1170;1222;1402;1454;1506;6521;6721,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,MONDO_0005277,migraine disorder,2,6,8,0
CHEMBL4435170,DEUCRAVACITINIB,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,True,True,False,1184,402;781;4266;4520;4603;4682;4761;4802;4868;4937;5003;5069;5113;5179;5229;5279;5345;5411;5427;5477,,4.0,Completed,TYK2,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000676,psoriasis,2,1,20,0
CHEMBL4444976,CCX354,COc1cc(N2CCN(C(=O)Cn3nc(-c4ncc[nH]4)c4cccnc43)CC2)ccc1Cl,True,False,False,1792,,,2.0,Completed,CCR1,,,,EFO_0000685,rheumatoid arthritis,1,1,0,0
CHEMBL445,NORTRIPTYLINE,CNCCC=C1c2ccccc2CCc2ccccc21,True,False,False,1262,,,4.0,Terminated,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL4457723,BMS-741672,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1,True,True,True,236,1254;4371;6777,510,2.0,Completed,CCR2,Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 2 antagonist,EFO_0005762,neuropathic pain,3,1,3,1
CHEMBL4459585,ROPSACITINIB,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1,True,True,False,1196,414;793;4278;4532;4615;4694;4773;4814;4880;4949;5015;5081;5125;5191;5241;5291;5357;5423;5439;5489,,2.0,Completed,TYK2,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000676,psoriasis,2,1,20,0
CHEMBL4475463,AMCENESTRANT,O=C(O)c1ccc2c(c1)CCCC(c1ccc(Cl)cc1Cl)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1,True,False,False,2306,,,3.0,Terminated,ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL447955,SERLOPITANT,C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,False,False,True,,,534,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL448,PENTOBARBITAL,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,True,False,True,1516;1739;2576,,258,4.0,,GABRB1;GABRB2;GABRB3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004698,insomnia,2,3,0,2
CHEMBL450,METHARBITAL,CCC1(CC)C(=O)NC(=O)N(C)C1=O,True,False,True,1511;1734;2574,,259,4.0,,GABRB1;GABRB2;GABRB3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000474,epilepsy,2,3,0,2
CHEMBL450044,SERGLIFLOZIN ETABONATE,CCOC(=O)OC[C@H]1O[C@@H](Oc2ccccc2Cc2ccc(OC)cc2)[C@H](O)[C@@H](O)[C@@H]1O,False,False,True,,,587,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL451,CHLORDIAZEPOXIDE,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,True,False,True,500;1414;1645;1683;2046;2092;2453,,240,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230;EFO_0006788,anxiety;anxiety disorder,2,7,0,2
CHEMBL451930,PLITIDEPSIN,CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,False,False,True,,,601,,,,,,Elongation factor 1-alpha 2 inhibitor,,,1,0,0,1
CHEMBL452,CLONAZEPAM,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,True,False,True,481;1410;1631;1679;2042;2085;2449,,241,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000474,epilepsy,2,7,0,2
CHEMBL452461,PERZINFOTEL,O=c1c2c(c1=O)N(CCP(=O)(O)O)CCCN2,False,False,True,,,394,,,,,,Glutamate [NMDA] receptor antagonist,,,1,0,0,1
CHEMBL453514,SPIRAMYCIN,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O,False,False,True,,,342,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL454,BUTALBITAL,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,True,False,True,1519;1744;2582,,242,4.0,,GABRB1;GABRB2;GABRB3,,,GABA-A receptor; anion channel positive allosteric modulator,MONDO_0005277,migraine disorder,2,3,0,2
CHEMBL4541964,ZATOLMILAST,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1,True,True,False,1086,4337;5803;5870,,3.0,Enrolling by invitation,PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,,MONDO_0010383,fragile X syndrome,2,1,3,0
CHEMBL454950,TETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.Cl,False,False,True,,,303,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL455461,RADEZOLID,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(CNCc4cnn[nH]4)cc3)c(F)c2)C(=O)O1,False,False,True,,,341,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL4577523,GOLIDOCITINIB,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1,True,True,True,770,195;657;4247;4426;4567;4646;4725;4794;4832;4901;4967;5033;5143;5221;5271;5309;5375;5469;6922,489,2.0,Recruiting,JAK1,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;RAF/MAP kinase cascade;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor,EFO_0000211,unspecified peripheral T-cell lymphoma,3,1,19,1
CHEMBL459,METHYLDOPA,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,True,True,False,1320;1372;2519,891;943;995;1047;1099;1151;1203;1383;1435;1487,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,3,6,0
CHEMBL459324,DIACETYLMORPHINE,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,True,True,True,329,299;1333;7246,662,3.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0005611,opioid dependence,3,1,3,1
CHEMBL4594217,CANAGLIFLOZIN,Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,False,False,True,,,597,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL4594254,SIMPINICLINE,C(=C/[C@H]1CCNC1)\c1cncnc1,True,True,True,443;2139,7923;7937;7951,543,2.0,Completed,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,Neuronal acetylcholine receptor; alpha4/beta2 agonist,EFO_0000555,irritable bowel syndrome,3,2,3,2
CHEMBL4594273,ELACESTRANT HYDROCHLORIDE,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1.Cl.Cl,True,False,False,2287,,,4.0,,ESR1,,,,EFO_0003869,breast neoplasm,1,1,0,0
CHEMBL4594275,GUSACITINIB,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1,True,True,False,771;794;1194,196;219;412;658;681;791;4248;4276;4427;4530;4568;4591;4613;4647;4670;4692;4726;4749;4771;4795;4812;4833;4856;4878;4902;4925;4947;4968;4991;5013;5034;5057;5079;5101;5123;5144;5167;5189;5222;5239;5272;5289;5310;5333;5355;5376;5399;5421;5437;5470;5487;6923;6946;7480;8309;8337;8365;8399;8427;8455,,2.0,Completed,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000274,atopic eczema,2,3,28,0
CHEMBL4594287,ENSIFENTRINE,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2,True,True,True,419;1054;1082;2158,4333;5741;5771;5799;5836;5866,635,3.0,Completed;Recruiting,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL4594293,ACALABRUTINIB MALEATE,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O,True,True,True,191,597;4092;6554;6734,572,4.0,,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000095,chronic lymphocytic leukemia,3,1,4,1
CHEMBL4594301,REMIMAZOLAM BESYLATE,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21.O=S(=O)(O)c1ccccc1,True,False,True,502;1426;1648;1701;2056;2101;2469,,297,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0009868,sedation,2,7,0,2
CHEMBL4594316,CROVALIMAB,N/A,False,True,False,,1240;7177;7738;7750;7762,,3.0,Withdrawn,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0007292,Guillain-Barre syndrome,1,1,5,0
CHEMBL4594348,ELSUBRUTINIB,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1,True,True,True,209,615;4110;6572;6752,573,2.0,Completed,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000685,rheumatoid arthritis,3,1,4,1
CHEMBL4594382,DEURUXOLITINIB PHOSPHATE,O=P(O)(O)O.[2H]C1([2H])C([C@@H](CC#N)n2cc(-c3ncnc4[nH]ccc34)cn2)C([2H])([2H])C([2H])([2H])C1([2H])[2H],False,False,True,,,490,,,,,,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,,,1,0,0,1
CHEMBL4594402,ORP-101,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,True,True,False,335,305;1339;7252,,2.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0000555,irritable bowel syndrome,2,1,3,0
CHEMBL4594417,PRUXELUTAMIDE,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1,True,True,True,560,1983;5898;7802,87,3.0,Withdrawn,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000694,severe acute respiratory syndrome,3,1,3,1
CHEMBL4594419,BMS-813160,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O,True,True,True,220;232,1250;1262;4367;4379;6761;6773;6785,511,2.0,Terminated,CCR2;CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 2 antagonist | C-C chemokine receptor type 5 antagonist,EFO_0000401,diabetic nephropathy,3,2,4,1
CHEMBL4594455,AGS-16C3F,N/A,True,True,False,847;1581;2016;2254;2360;2424;2731;2794;2859,1560;1624;1688;1752;1816;1880;1944;2109;2173;2237;2301;2365;2429;2493;2557;2621;2685;2749;2813;2877;2941;3005;3075;3139;3203;3267;3331;3395;3459;3523;3587;3678;3742;3806;3870;3934;3998;4065,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000681,renal cell carcinoma,2,9,38,0
CHEMBL4594518,LUTIKIZUMAB,N/A,False,True,False,,166;4191;4354;4358;4362;4399;4538,,3.0,Recruiting,IL1B,CLEC7A/inflammasome pathway;Interleukin-1 processing;Interleukin-1 signaling;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Purinergic signaling in leishmaniasis infection;Pyroptosis,R-HSA-448706;R-HSA-5620971;R-HSA-5660668;R-HSA-6783783;R-HSA-6785807;R-HSA-9020702;R-HSA-9660826,,EFO_1000710,hidradenitis suppurativa,1,1,7,0
CHEMBL4594542,EFLEPEDOCOKIN ALFA,N/A,False,True,False,,4395;4778;4885,,2.0,Terminated,IL10RB,Interleukin-10 signaling;Interleukin-20 family signaling;Other interleukin signaling,R-HSA-449836;R-HSA-6783783;R-HSA-8854691,,MONDO_0100096,COVID-19,1,1,3,0
CHEMBL4596392,CRAVACITINIB,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,True,True,False,1192,410;789;4274;4528;4611;4690;4769;4810;4876;4945;5011;5077;5121;5187;5237;5287;5353;5419;5435;5485,,3.0,"Active, not recruiting",TYK2,Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF),R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-449836;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000676,psoriasis,2,1,20,0
CHEMBL461522,METAMIZOLE,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,True,True,False,155;935,378;4496;5575;5635;5705;6089;6163;6237;6311;6385;6459,,3.0,Recruiting;Unknown status,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0003843,pain,2,2,10,0
CHEMBL464,ETRETINATE,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C,True,True,False,184;1764;1892,5986;6012;6021,,4.0,,RARA;RARB;RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,,EFO_0000676,psoriasis,2,3,3,0
CHEMBL4650276,SHR3680,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1,True,True,True,562,1985;5900;7804,88,3.0,"Active, not recruiting",AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,MONDO_0008315,prostate cancer,3,1,3,1
CHEMBL4650293,APRUTUMAB IXADOTIN,N/A,True,True,False,866;1600;2035;2273;2379;2442;2750;2814;2878,1579;1643;1707;1771;1835;1899;1963;2128;2192;2256;2320;2384;2448;2512;2576;2640;2704;2768;2832;2896;2960;3024;3094;3158;3222;3286;3350;3414;3478;3542;3606;3697;3761;3825;3889;3953;4017;4084,,1.0,Terminated,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,MONDO_0004992,cancer,2,9,38,0
CHEMBL4650299,HEPARIN,N/A,True,True,False,173,145;7551;7580;7602,,3.0,Completed,SERPINC1,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation;Post-translational protein phosphorylation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-140837;R-HSA-140875;R-HSA-381426;R-HSA-8957275,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL4650316,GIREDESTRANT,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,True,False,False,2307,,,3.0,"Active, not recruiting",ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL4650321,ORELABRUTINIB,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1,True,True,True,195,601;4096;6558;6738,574,3.0,Recruiting,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000095,chronic lymphocytic leukemia,3,1,4,1
CHEMBL4650322,RUNCACIGUAT,C[C@H]([C@H](C(=O)Nc1cc([C@@H](CC(=O)O)C2CC2)ccc1Cl)c1ccc(Cl)cc1)C(F)(F)F,True,True,True,78,7694,257,2.0,Completed,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0003770,diabetic retinopathy,3,1,1,1
CHEMBL4650323,TOLEBRUTINIB,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1,True,True,True,200,606;4101;6563;6743,575,3.0,Recruiting,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0008520,primary progressive multiple sclerosis,3,1,4,1
CHEMBL4650333,SERALUTINIB,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC,True,True,False,1123;1164,569;6981;7021;7515,,3.0,Not yet recruiting,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0001361,pulmonary arterial hypertension,2,2,3,0
CHEMBL4650336,EMVODODSTAT,COc1ccc([C@H]2c3[nH]c4ccc(Cl)cc4c3CCN2C(=O)Oc2ccc(Cl)cc2)cc1,False,False,True,,,737,,,,,,Dihydroorotate dehydrogenase inhibitor,,,1,0,0,1
CHEMBL4650338,EDRALBRUTINIB,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1,True,True,True,203,609;4104;6566;6746,576,2.0,Recruiting,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_0000096,neoplasm of mature B-cells,3,1,4,1
CHEMBL4650343,IZENCITINIB,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1,True,True,False,772;795;1195,197;220;413;659;682;792;4249;4277;4428;4531;4569;4592;4614;4648;4671;4693;4727;4750;4772;4796;4813;4834;4857;4879;4903;4926;4948;4969;4992;5014;5035;5058;5080;5102;5124;5145;5168;5190;5223;5240;5273;5290;5311;5334;5356;5377;5400;5422;5438;5471;5488;6924;6947;7481;8310;8338;8366;8400;8428;8456,,2.0,Terminated,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0000384,Crohn's disease,2,3,28,0
CHEMBL4650365,CAMIZESTRANT,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F,True,False,False,2308,,,3.0,"Active, not recruiting",ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL4650406,LEVILIMAB,N/A,False,True,False,,178;640;4550;4629;4708;7149,,3.0,"Active, not recruiting",IL6R,Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Transcriptional regulation of granulopoiesis,R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-6785807;R-HSA-9616222;R-HSA-9679191,,EFO_0000685,rheumatoid arthritis,1,1,6,0
CHEMBL4650485,PIRTOBRUTINIB,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1,True,True,True,194,600;4095;6557;6737,577,4.0,,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,Tyrosine-protein kinase BTK inhibitor,EFO_1001469,Mantle cell lymphoma,3,1,4,1
CHEMBL4650501,PF-4136309,N/A,True,True,False,235,1253;4370;6776,,2.0,Terminated,CCR2,Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0004220,chronic hepatitis C virus infection,2,1,3,0
CHEMBL4650518,PLONMARLIMAB,N/A,False,True,False,,4391;6878;8380,,2.0,Completed,CSF2,"Interleukin-10 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;RAF/MAP kinase cascade",R-HSA-512988;R-HSA-5673001;R-HSA-6783783,,MONDO_0100096,COVID-19,1,1,3,0
CHEMBL46618,OTAMIXABAN,COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1,True,True,True,462,7542;7571,461,3.0,Completed,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,Coagulation factor X inhibitor,EFO_0005672,acute coronary syndrome,3,1,2,1
CHEMBL466659,PENTAERYTHRITOL TETRANITRATE,O=[N+]([O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],True,True,True,70,7686,250,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL467084,LANICEMINE,N[C@@H](Cc1ccccn1)c1ccccc1,True,True,False,728;1623;1969;2197;2621;2664;2686,3634;6818;6845;6872;6905;7063;7090;7117;7144,,2.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0002009;MONDO_0002050,depressive disorder;major depressive disorder,2,7,9,0
CHEMBL467399,BIIB021,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C,False,False,True,,,582,,,,,,Heat shock protein HSP90 inhibitor,,,1,0,0,1
CHEMBL46740,BAZEDOXIFENE,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,True,False,False,2301,,,3.0,Completed,ESR1,,,,EFO_0003882,osteoporosis,1,1,0,0
CHEMBL469,KETOROLAC,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,True,True,False,125;909,348;4466;5549;5609;5675;6059;6133;6207;6281;6355;6429,,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005752,eye inflammation,2,2,10,0
CHEMBL473159,PHLOROGLUCINOL,Oc1cc(O)cc(O)c1,True,False,False,1907;2493,,,4.0,,CACNA1A;CACNA2D1,,,,EFO_0010282,gastrointestinal disease,1,2,0,0
CHEMBL477772,PAZOPANIB,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,True,True,False,1116;1158,563;6975;7014;7509,,3.0,"Active, not recruiting",KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000349,clear cell renal carcinoma,2,2,3,0
CHEMBL479,THIORIDAZINE,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,False,False,True,,,656,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL479527,TORCETRAPIB,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC,True,False,False,1898,,,3.0,Completed,CETP,,,,EFO_0001645,coronary artery disease,1,1,0,0
CHEMBL4802157,ELINZANETANT,Cc1cc(F)ccc1-c1cc(N2C[C@H]3COCCN3C[C@H]2CO)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,False,False,True,,,557,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL4802159,ENPATORAN,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12,True,True,True,602,762;4258;7324;7346;7357;7368;7379;7401;7423;7445;7456,456,2.0,Recruiting,TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,Toll-like receptor 7 antagonist,EFO_0000398,dermatomyositis,3,1,11,1
CHEMBL4802163,NEZULCITINIB,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1,True,True,False,776;803;1198,201;228;416;663;690;795;4253;4280;4432;4534;4573;4600;4617;4652;4679;4696;4731;4758;4775;4800;4816;4838;4865;4882;4907;4934;4951;4973;5000;5017;5039;5066;5083;5110;5127;5149;5176;5193;5227;5243;5277;5293;5315;5342;5359;5381;5408;5425;5441;5475;5491;6928;6955;7489;8318;8346;8374;8408;8436;8464,,1.0,Completed,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,,EFO_0004610,acute lung injury,2,3,28,0
CHEMBL482968,ENMD-2076,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,True,True,False,1168,573;6985;7519,,2.0,Completed,KIT,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000182,hepatocellular carcinoma,2,1,3,0
CHEMBL483465,ELRAGLUSIB,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3,True,True,False,1181,5498;5509;5520;8092,,2.0,"Active, not recruiting",GSK3B,AKT phosphorylates targets in the cytosol;Constitutive Signaling by AKT1 E17K in Cancer;Maturation of nucleoprotein;Regulation of RUNX2 expression and activity,R-HSA-198323;R-HSA-5674400;R-HSA-8939902;R-HSA-9683610,,EFO_0000691,sarcoma,2,1,4,0
CHEMBL484785,CRISABOROLE,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,True,True,True,407;1040;1068;2145,4319;5729;5757;5785;5824;5852,602,4.0,"Active, not recruiting",PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000274,atopic eczema,3,4,3,1
CHEMBL485,CODEINE,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,True,True,False,297,267;1301;7214,,4.0,Unknown status,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL485629,MK-0873,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,True,True,True,429;1061;1091;2166,4342;5751;5778;5808;5846;5875,624,2.0,Terminated,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL489,AFIMOXIFENE,CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,True,False,False,2310,,,2.0,Completed,ESR1,,,,EFO_0000432,breast ductal carcinoma in situ,1,1,0,0
CHEMBL490,PAROXETINE,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,True,False,False,1265,,,4.0,Completed,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL490672,FILIBUVIR,CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1,False,False,True,,,425,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL491473,CEDIRANIB,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,True,True,False,1118;1160,565;6977;7016;7511,,3.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000519,glioblastoma multiforme,2,2,3,0
CHEMBL492399,VERUBULIN,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,True,True,False,840;1572;2007;2246;2351;2416;2722;2785;2851,1553;1617;1681;1745;1809;1873;1937;2102;2166;2230;2294;2358;2422;2486;2550;2614;2678;2742;2806;2870;2934;2998;3068;3132;3196;3260;3324;3388;3452;3516;3580;3671;3735;3799;3863;3927;3991;4058,,2.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000519,glioblastoma multiforme,2,9,38,0
CHEMBL495727,AT-9283,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,True,True,True,797;1219,222;684;4310;4594;4673;4752;4859;4928;4994;5060;5104;5170;5336;5402;6949;7483;8312;8340;8368;8402;8430;8458,475,2.0,Completed,ABL1;JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9860927,Tyrosine-protein kinase JAK2 inhibitor,EFO_0001378,multiple myeloma,3,2,22,1
CHEMBL49642,INDIBULIN,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,True,True,True,861;1594;2029;2268;2373;2437;2745;2809;2872,1574;1638;1702;1766;1830;1894;1958;2123;2187;2251;2315;2379;2443;2507;2571;2635;2699;2763;2827;2891;2955;3019;3089;3153;3217;3281;3345;3409;3473;3537;3601;3692;3756;3820;3884;3948;4012;4079,58,1.0,Completed;Unknown status,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000616,neoplasm,3,9,38,1
CHEMBL497939,CYTISINICLINE,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1,True,True,False,438;2135,7918;7932;7946,,3.0,,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0003768,nicotine dependence,2,2,3,0
CHEMBL501867,VINCRISTINE SULFATE,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,True,True,True,824;1556;1992;2231;2336;2399;2706;2771;2835,1537;1601;1665;1729;1793;1857;1921;2086;2150;2214;2278;2342;2406;2470;2534;2598;2662;2726;2790;2854;2918;2982;3052;3116;3180;3244;3308;3372;3436;3500;3564;3655;3719;3783;3847;3911;3975;4042,47,3.0,Completed;Terminated,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000095;EFO_0000096,chronic lymphocytic leukemia;neoplasm of mature B-cells,3,9,38,1
CHEMBL502835,NINTEDANIB,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,True,True,False,1120,7018,,3.0,,PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0000616,neoplasm,2,1,1,0
CHEMBL503,LOVASTATIN,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,True,True,True,738,7617;7632;7647;7662,18,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL504652,TC-2216,c1cncc(N2CCC3(CCCN3)C2)c1,True,True,False,448;2144,7928;7942;7956,,1.0,Completed,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0005230,anxiety,2,2,3,0
CHEMBL505,CHLORPHENIRAMINE,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,True,True,False,1006,6636,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL509,MECLOFENAMIC ACID,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,True,True,False,147;928,370;4488;5568;5628;5697;6081;6155;6229;6303;6377;6451,,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0005755,rheumatic disease,2,2,10,0
CHEMBL5095023,LS-104,N#C/C(=C\C=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,False,False,True,,,491,,,,,,Tyrosine-protein kinase JAK2 inhibitor,,,1,0,0,1
CHEMBL5095029,PF-04634817,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1,True,True,True,221;233,1251;1263;4368;4380;6762;6774;6786,512,2.0,Completed,CCR2;CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,C-C chemokine receptor type 2 antagonist | C-C chemokine receptor type 5 antagonist,EFO_0000401,diabetic nephropathy,3,2,4,1
CHEMBL5095049,PACRITINIB CITRATE,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,True,True,785,210;672;4582;4661;4740;4847;4916;4982;5048;5092;5158;5324;5390;6937;7471;8300;8328;8356;8390;8418;8446,499,4.0,,JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0002430,primary myelofibrosis,3,1,21,1
CHEMBL511,PYRILAMINE,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,True,True,False,993,6623,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL511099,BICIFADINE,Cc1ccc(C23CNCC2C3)cc1,True,False,False,1290,,,3.0,Completed,SLC6A4,,,,HP_0003419,Low back pain,1,1,0,0
CHEMBL511115,CILOMILAST,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1,True,True,True,420;1053;1080;2159,4331;5742;5770;5797;5837;5864,622,3.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL511142,BUPRENORPHINE,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,True,True,True,298,268;1302;7215,638,4.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL512351,BETRIXABAN,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1,True,True,True,452,7532;7561,465,4.0,,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,Coagulation factor X inhibitor,EFO_0004286,venous thromboembolism,3,1,2,1
CHEMBL513,CARMUSTINE,O=NN(CCCl)C(=O)NCCCl,False,False,True,,,403,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL514201,TALMAPIMOD,C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl,False,False,True,,,106,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL514800,APREMILAST,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,True,True,True,410;1043;1071;2148,4322;5732;5760;5788;5827;5855,600,4.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000540,immune system disease,3,4,3,1
CHEMBL515387,GOSOGLIPTIN,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1,True,False,True,677,,516,3.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL515606,CILAZAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O,True,True,True,636,432,372,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL515966,EZLOPITANT,COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,False,False,True,,,548,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL516,CYPROHEPTADINE,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,True,True,False,1017,6647,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL5170587,VK5211,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F,True,True,False,569,1992;5907;7811,,2.0,Completed,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,,EFO_0003964,hip fracture,2,1,3,0
CHEMBL521,IBUPROFEN,CC(C)Cc1ccc(C(C)C(=O)O)cc1,True,True,True,92;883,315;4433;5523;5583;5642;6026;6100;6174;6248;6322;6396,123,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000319,cardiovascular disease,3,2,10,1
CHEMBL522302,VOFOPITANT,COc1ccc(-n2nnnc2C(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,False,False,True,,,547,,,,,,Neurokinin 1 receptor antagonist,,,1,0,0,1
CHEMBL522892,DOVITINIB,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,True,True,False,1121;1162,567;6979;7019;7513,,3.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000681,renal cell carcinoma,2,2,3,0
CHEMBL524,METHOXAMINE,COc1ccc(OC)c(C(O)C(C)N)c1,True,True,False,355;1463;1831,818;6480;6680,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000319,cardiovascular disease,2,3,3,0
CHEMBL52440,DEXTROMETHORPHAN,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,True,False,False,2645,,,4.0,,GRIN2A,,,,HP_0012735,Cough,1,1,0,0
CHEMBL526,PROPOFOL,CC(C)c1cccc(C(C)C)c1O,True,False,True,507;1436;1521;1660;1706;1747;1780;1801;1874;1935;2066;2112;2474;2560;2583;2631,,260,3.0,Recruiting,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000275,atrial fibrillation,2,16,0,2
CHEMBL527,PIROXICAM,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,True,True,True,113;899,336;4454;5539;5599;5663;6047;6121;6195;6269;6343;6417,141,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL52885,ENMD-981693,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21,True,True,False,943;1132,7030,,2.0,Completed,BLK;PDGFRB,RAF/MAP kinase cascade,R-HSA-5673001,,EFO_0002618,pancreatic carcinoma,2,2,1,0
CHEMBL529,AZITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,False,False,True,,,318,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL52939,SARPOGRELATE,COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,False,False,True,,,719,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL5303393,VARENICLINE TARTRATE,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,True,True,False,439;2136,7919;7933;7947,,3.0,Completed;Recruiting,CHRNA4;CHRNB2,Highly calcium permeable nicotinic acetylcholine receptors;Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;Highly sodium permeable postsynaptic acetylcholine nicotinic receptors,R-HSA-629587;R-HSA-629594;R-HSA-629597,,EFO_0003768;EFO_0004319,nicotine dependence;smoking cessation,2,2,3,0
CHEMBL5314374,IDRAPARINUX SODIUM,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],True,True,False,458,7538;7567,,3.0,Completed,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,EFO_0000275,atrial fibrillation,2,1,2,0
CHEMBL5314386,ME-344,Cc1c(O)ccc2c1OC[C@@H](c1ccc(O)cc1)[C@H]2c1ccc(O)cc1,True,False,False,1537;1947,,,1.0,Completed,MT-ND4;NDUFA4,,,,EFO_0000616,neoplasm,1,2,0,0
CHEMBL5314391,XL-999,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1,True,True,False,1126;1169,574;6986;7024;7520,,2.0,Terminated,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000222,acute myeloid leukemia,2,2,3,0
CHEMBL5314393,LY2624803,CC(C)(CN1CCN(C2=Nc3ccccc3Oc3ccccc32)CC1)C(=O)O,True,True,False,1037,6667,,2.0,Completed,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0004698,insomnia,2,1,1,0
CHEMBL5314394,SB-773812,COc1cc2c(cc1S(=O)(=O)c1ccc(OCc3ccc(Cl)cc3)cc1)CCN(C)CC2,False,False,True,,,714,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL5314397,ACUMAPIMOD,Cc1ccc(C(=O)NC2CC2)cc1-n1ncc(C(=O)c2cccc(C#N)c2)c1N,False,False,True,,,119,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL5314400,DWP05195,FC(F)(F)c1cccnc1-c1ccc(-c2nc3ccc(Br)cc3[nH]2)nc1,True,True,False,700,5726,,2.0,Completed,TRPV1,TRP channels,R-HSA-3295583,,MONDO_0041052,postherpetic neuralgia,2,1,1,0
CHEMBL5314408,AZD-0424,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1,True,True,False,1224,4315,,1.0,Terminated,ABL1,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,,EFO_0000616,neoplasm,2,1,1,0
CHEMBL5314649,RITLECITINIB TOSYLATE,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1,True,True,False,193,599;4094;6556;6736,,4.0,,BTK,ER-Phagosome pathway;G alpha (12/13) signalling events;G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-1236974;R-HSA-416476;R-HSA-418597;R-HSA-9679191,,EFO_0004192,alopecia areata,2,1,4,0
CHEMBL5314801,IDRAPARINUX,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O,True,True,False,459,7539;7568,,3.0,Completed,F10,Common Pathway of Fibrin Clot Formation;Intrinsic Pathway of Fibrin Clot Formation,R-HSA-140837;R-HSA-140875,,EFO_0000275,atrial fibrillation,2,1,2,0
CHEMBL5315048,ZILUCOPLAN SODIUM,N/A,False,True,False,,1236;7173;7734;7746;7758,,4.0,,C5,Activation of C3 and C5;G alpha (i) signalling events;Peptide ligand-binding receptors;Regulation of Complement cascade;Terminal pathway of complement,R-HSA-166665;R-HSA-174577;R-HSA-375276;R-HSA-418594;R-HSA-977606,,EFO_0004991,Myasthenia gravis,1,1,5,0
CHEMBL5315049,SITAGLIPTIN FUMARATE,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=C(O)/C=C\C(=O)O,True,False,True,663,,544,4.0,,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL5315054,ERTUGLIFLOZIN PIDOLATE,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1.O=C1CC[C@@H](C(=O)O)N1,False,False,True,,,615,,,,,,Sodium/glucose cotransporter 2 inhibitor,,,1,0,0,1
CHEMBL5315055,NALMEFENE HYDROCHLORIDE DIHYDRATE,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O,True,True,False,322,292;1326;7239,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,MONDO_0007079,alcohol dependence,2,1,3,0
CHEMBL5315056,NALOXONE HYDROCHLORIDE DIHYDRATE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O,True,True,False,313,283;1317;7230,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0005611,opioid dependence,2,1,3,0
CHEMBL5315115,LASOFOXIFENE TARTRATE,N/A,True,False,False,2291,,,4.0,,ESR1,,,,EFO_0003854,postmenopausal osteoporosis,1,1,0,0
CHEMBL5315119,UPADACITINIB HEMIHYDRATE,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O,True,True,True,761;784;1186,186;209;404;648;671;783;4238;4268;4417;4522;4558;4581;4605;4637;4660;4684;4716;4739;4763;4785;4804;4823;4846;4870;4892;4915;4939;4958;4981;5005;5024;5047;5071;5091;5115;5134;5157;5181;5212;5231;5262;5281;5300;5323;5347;5366;5389;5413;5429;5460;5479;6913;6936;7470;8299;8327;8355;8389;8417;8445,492,4.0,,JAK1;JAK2;TYK2,"Evasion by RSV of host interferon responses;IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interferon alpha/beta signaling;Interleukin-10 signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Other interleukin signaling;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Regulation of IFNA/IFNB signaling;SARS-CoV-2 activates/modulates innate and adaptive immune responses;Signaling by ALK fusions and activated point mutants;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-449836;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6783783;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-909733;R-HSA-912694;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462;R-HSA-9705671;R-HSA-9725370;R-HSA-9833109,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,EFO_0000685,rheumatoid arthritis,3,3,28,1
CHEMBL532,ERYTHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,False,False,True,,,319,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL53292,ISOXICAM,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1,False,False,True,,,149,,,,,,Cyclooxygenase inhibitor,,,1,0,0,1
CHEMBL534,KETOTIFEN,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,True,True,False,970,6600,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL535,SUNITINIB,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,True,True,False,1100;1144,549;6961;6998;7495,,4.0,Completed,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000616,neoplasm,2,2,3,0
CHEMBL535650,MEFLOQUINE HYDROCHLORIDE,Cl.OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1,False,False,True,,,426,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL538943,VINORELBINE TARTRATE,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,True,True,True,825;1558;1993;2232;2337;2401;2708;2772;2836,1538;1602;1666;1730;1794;1858;1922;2087;2151;2215;2279;2343;2407;2471;2535;2599;2663;2727;2791;2855;2919;2983;3053;3117;3181;3245;3309;3373;3437;3501;3565;3656;3720;3784;3848;3912;3976;4043,48,3.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000183,Hodgkins lymphoma,3,9,38,1
CHEMBL539423,SPARSENTAN,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1,True,True,True,589;1914,6543;7162;7273;7293,9,4.0,,AGTR1;EDNRA,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0004194,IGA glomerulonephritis,3,2,4,1
CHEMBL54,HALOPERIDOL,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,False,False,True,,,676,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL544665,FINGOLIMOD HYDROCHLORIDE,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl,True,False,False,1884,,,4.0,,S1PR4,,,,MONDO_0005301,multiple sclerosis,1,1,0,0
CHEMBL547,ISOTRETINOIN,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,True,True,True,187;1767;1894,5989;6015;6024,618,4.0,Not yet recruiting,RARA;RARB;RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,Retinoic acid receptor agonist,EFO_0003894,acne,3,3,3,1
CHEMBL549,CITALOPRAM,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,True,False,False,1266,,,4.0,Completed,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL549344,CPG-52852,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O,True,True,False,603,763;4259;7325;7347;7358;7369;7380;7402;7424;7446;7457,,2.0,Completed,TLR7,Defective regulation of TLR7 by endogenous ligand;MyD88 dependent cascade initiated on endosome;Potential therapeutics for SARS;RSV-host interactions;Regulation of TLR by endogenous ligand;SARS-CoV-1 activates/modulates innate immune responses;SARS-CoV-2 activates/modulates innate and adaptive immune responses;TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Trafficking and processing of endosomal TLR,R-HSA-1679131;R-HSA-168181;R-HSA-5686938;R-HSA-9679191;R-HSA-9692916;R-HSA-9705671;R-HSA-975110;R-HSA-975138;R-HSA-975155;R-HSA-9824856;R-HSA-9833110,,EFO_0000389,cutaneous melanoma,2,1,11,0
CHEMBL550936,BALAPIRAVIR,CC(C)C(=O)OC[C@@]1(N=[N+]=[N-])O[C@@H](n2ccc(N)nc2=O)[C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C,False,False,True,,,427,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL551978,DROTAVERINE,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC,True,True,True,424;1057;1084;2161,4335;5746;5774;5801;5841;5868,603,3.0,,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0010282,gastrointestinal disease,3,4,3,1
CHEMBL552212,LEXIBULIN,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1,True,True,True,850;1583;2019;2259;2364;2428;2733;2797;2861,1563;1627;1691;1755;1819;1883;1947;2112;2176;2240;2304;2368;2432;2496;2560;2624;2688;2752;2816;2880;2944;3008;3078;3142;3206;3270;3334;3398;3462;3526;3590;3681;3745;3809;3873;3937;4001;4068,60,2.0,Terminated,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0001378,multiple myeloma,3,9,38,1
CHEMBL553025,VINORELBINE,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,True,True,False,818;1548;1983;2222;2331;2394;2702;2764;2824,1531;1595;1659;1723;1787;1851;1915;2080;2144;2208;2272;2336;2400;2464;2528;2592;2656;2720;2784;2848;2912;2976;3046;3110;3174;3238;3302;3366;3430;3494;3558;3649;3713;3777;3841;3905;3969;4036,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL559180,ISOXSUPRINE HYDROCHLORIDE,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl,True,True,False,406;1507;1865,869;6531;6731,,1.0,Completed,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,MONDO_0005301,multiple sclerosis,2,3,3,0
CHEMBL562,GRISEOFULVIN,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,False,False,True,,,40,,,,,,Tubulin inhibitor,,,1,0,0,1
CHEMBL562967,MERICITABINE,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,False,False,True,,,428,,,,,,RNA-directed RNA polymerase inhibitor,,,1,0,0,1
CHEMBL563,FLURBIPROFEN,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,True,True,True,126;910,349;4467;5550;5610;5676;6060;6134;6208;6282;6356;6430,124,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005752,eye inflammation,3,2,10,1
CHEMBL566534,ARTEMETHER,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,False,False,True,,,429,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL568,OXAZEPAM,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,True,False,True,485;1432;1640;1684;2061;2107;2466,,243,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230,anxiety,2,7,0,2
CHEMBL570015,GSK-256066,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1,True,True,True,426;1062;1089;2167,4340;5748;5779;5806;5843;5873,604,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,EFO_0000341,chronic obstructive pulmonary disease,3,4,3,1
CHEMBL571,KETOPROFEN,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,True,True,True,114;891,337;4455;5531;5591;5664;6048;6122;6196;6270;6344;6418,144,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL572284,OMBRABULIN,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO,True,True,True,829;1562;1997;2236;2341;2405;2712;2776;2840,1542;1606;1670;1734;1798;1862;1926;2091;2155;2219;2283;2347;2411;2475;2539;2603;2667;2731;2795;2859;2923;2987;3057;3121;3185;3249;3313;3377;3441;3505;3569;3660;3724;3788;3852;3916;3980;4047,67,3.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,Tubulin inhibitor,EFO_0000691,sarcoma,3,9,38,1
CHEMBL57242,AZILSARTAN,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,True,True,True,595,6549;7168;7279;7299,1,3.0,Completed,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000537,hypertension,3,1,4,1
CHEMBL572881,MOTESANIB,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,True,True,False,1124;1166,571;6983;7022;7517,,3.0,Terminated,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0003060,non-small cell lung carcinoma,2,2,3,0
CHEMBL573677,ABEQUOLIXRON,C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,True,False,False,1725,,,1.0,Recruiting,NR1H2,,,,EFO_0003060,non-small cell lung carcinoma,1,1,0,0
CHEMBL574737,UCN-01,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,True,False,False,1627,,,2.0,Terminated,PDPK1,,,,EFO_0000574,lymphoma,1,1,0,0
CHEMBL576982,QUIZARTINIB,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,True,True,False,1114;1157,562;6974;7012;7508,,3.0,Completed;Withdrawn,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000222,acute myeloid leukemia,2,2,3,0
CHEMBL577,ENALAPRILAT ANHYDROUS,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,True,True,False,656,452,,3.0,Completed,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000407,dilated cardiomyopathy,2,1,1,0
CHEMBL578,ENALAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,True,True,False,644,440,,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL580,LORAZEPAM,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,True,False,True,487;1415;1654;1685;2047;2098;2467,,261,4.0,Completed,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230;EFO_0006788,anxiety;anxiety disorder,2,7,0,2
CHEMBL58510,CHLOROQUINE PHOSPHATE,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O.O=P(O)(O)O,False,False,True,,,423,,,,,,Ferriprotoporphyrin IX inhibitor,,,1,0,0,1
CHEMBL585902,AMG-548,Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,False,False,True,,,78,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL589583,DELAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,True,True,True,654,450,374,3.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,Angiotensin-converting enzyme inhibitor,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL591118,CARMEGLIPTIN,COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2,True,False,True,678,,517,2.0,Completed,DPP4,,,Dipeptidyl peptidase IV inhibitor,MONDO_0005148,type 2 diabetes mellitus,2,1,0,1
CHEMBL591501,PF-03049423,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,True,True,True,881,7681;7708;7721,450,2.0,Terminated,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,HP_0002140,Ischemic stroke,3,1,3,1
CHEMBL592,LEVORPHANOL,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13,True,True,False,344,314;1348;7261,,0.5,"Active, not recruiting",OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL592374,AMITIFADINE,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl,True,False,False,1297,,,2.0,Completed,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL593430,ATAGABALIN,C[C@H]1CC(CN)(CC(=O)O)C[C@@H]1C,True,False,False,1909;2497,,,2.0,Completed,CACNA1A;CACNA2D1,,,,EFO_0004698,insomnia,1,2,0,0
CHEMBL594,EMEDASTINE,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,True,True,False,980,6610,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL596,FENTANYL,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,True,True,True,267,237;1271;7184,636,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL597,PHENTOLAMINE,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,True,True,False,369;1303;1355;1471;1818;2503,832;874;926;978;1030;1082;1134;1186;1366;1418;1470;6494;6694,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL599,MELOXICAM,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,True,True,False,103,326;4444;5653;6037;6111;6185;6259;6333;6407,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL6,INDOMETHACIN,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,True,True,True,93;882,316;4434;5522;5582;5643;6027;6101;6175;6249;6323;6397,120,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000319,cardiovascular disease,3,2,10,1
CHEMBL603,ZAFIRLUKAST,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,True,True,False,1230,620;6577,,4.0,,CYSLTR1,G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-416476;R-HSA-9679191,,HP_0006536,Airway obstruction,2,1,2,0
CHEMBL603469,LESTAURTINIB,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,True,True,True,788,213;675;4585;4664;4743;4850;4919;4985;5051;5095;5161;5327;5393;6940;7474;8303;8331;8359;8393;8421;8449,494,3.0,"Active, not recruiting",JAK2,"IL-6-type cytokine receptor ligand interactions;Inactivation of CSF3 (G-CSF) signaling;Interleukin-12 signaling;Interleukin-20 family signaling;Interleukin-23 signaling;Interleukin-27 signaling;Interleukin-3, Interleukin-5 and GM-CSF signaling;Interleukin-35 Signalling;Interleukin-4 and Interleukin-13 signaling;Interleukin-6 signaling;MAPK1 (ERK2) activation;MAPK3 (ERK1) activation;Potential therapeutics for SARS;Prolactin receptor signaling;RAF activation;RAF/MAP kinase cascade;RMTs methylate histone arginines;Signaling by CSF3 (G-CSF);Signaling by Leptin;Signaling by SCF-KIT;Signaling by moderate kinase activity BRAF mutants",R-HSA-1059683;R-HSA-110056;R-HSA-112411;R-HSA-1170546;R-HSA-1433557;R-HSA-2586552;R-HSA-3214858;R-HSA-512988;R-HSA-5673000;R-HSA-5673001;R-HSA-6785807;R-HSA-6788467;R-HSA-6802946;R-HSA-8854691;R-HSA-8984722;R-HSA-9020591;R-HSA-9020933;R-HSA-9020956;R-HSA-9674555;R-HSA-9679191;R-HSA-9705462,Tyrosine-protein kinase JAK2 inhibitor,EFO_0000220,acute lymphoblastic leukemia,3,1,21,1
CHEMBL605525,DP001,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O,True,True,True,253,6006;7783;7901,21,2.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0003882,osteoporosis,3,1,3,1
CHEMBL6067484,GENTAMICIN SULFATE,N/A,False,False,True,,,336,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL6067972,VARENICLINE TARTRATE,O=C(O)[C@H](O)[C@@H](O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,False,False,True,,,545,,,,,,Neuronal acetylcholine receptor; alpha4/beta2 agonist,,,1,0,0,2
CHEMBL6067973,TULATHROMYCIN,N/A,False,False,True,,,366,,,,,,Bacterial 70S ribosome inhibitor,,,1,0,0,1
CHEMBL6067995,BEROTRALSTAT HYDROCHLORIDE,Cl.Cl.N#Cc1cccc([C@@H](NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1,False,False,True,,,558,,,,,,Plasma kallikrein inhibitor,,,1,0,0,1
CHEMBL6068334,SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE,Cl.N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O,False,False,True,,,546,,,,,,Dipeptidyl peptidase IV inhibitor,,,1,0,0,1
CHEMBL6068336,MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE,Cl.Cl.N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1.O,False,False,True,,,493,,,,,,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,,,1,0,0,1
CHEMBL6068339,IRBESARTAN HYDROCHLORIDE,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1.Cl,False,False,True,,,17,,,,,,Type-1 angiotensin II receptor antagonist,,,1,0,0,1
CHEMBL607,MEPERIDINE,CCOC(=O)C1(c2ccccc2)CCN(C)CC1,True,True,False,268,238;1272;7185,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL608533,MIDOSTAURIN,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,True,True,False,1098;1141,546;6958;6996;7492,,4.0,,KIT;PDGFRB,RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-1433557;R-HSA-5673001;R-HSA-8866910,,EFO_0000222,acute myeloid leukemia,2,2,3,0
CHEMBL61006,PHENYLPROPANOLAMINE,CC(N)C(O)c1ccccc1,True,True,False,391,854;6516;6716,,4.0,,ADRA1A,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,HP_0001742,Nasal congestion,2,1,3,0
CHEMBL611,TERAZOSIN,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,True,True,False,347;1453;1824,810;6472;6672,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,3,3,0
CHEMBL61780,TEZOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO,True,False,False,1921,,,3.0,Completed,EDNRA,,,,EFO_0003144,heart failure,1,1,0,0
CHEMBL621,TRAZODONE,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,True,False,False,1268,,,4.0,Terminated,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL622,ETODOLAC,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,True,True,False,115,338;4456;5665;6049;6123;6197;6271;6345;6419,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL623,NEFAZODONE,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,True,False,False,1275,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL625,THIABENDAZOLE,N/A,False,False,True,,,56,,,,,,Tubulin inhibitor,,,1,0,0,1
CHEMBL628,PENTOXIFYLLINE,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,True,True,True,409;870;1042;1070;2146,4321;5731;5759;5787;5826;5854;7670;7697;7710,716,4.0,,PDE4A;PDE4B;PDE4C;PDE4D;PDE5A,"DARPP-32 events;G alpha (s) signalling events;RHOBTB1 GTPase cycle;Smooth Muscle Contraction;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;cGMP effects",R-HSA-180024;R-HSA-418457;R-HSA-418555;R-HSA-445355;R-HSA-9013422;R-HSA-9860927,"3',5'-cyclic phosphodiesterase inhibitor",EFO_0000319,cardiovascular disease,3,5,6,1
CHEMBL629,AMITRIPTYLINE,CN(C)CCC=C1c2ccccc2CCc2ccccc21,True,False,False,1271,,,4.0,Unknown status,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL63,ROLIPRAM,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,True,True,True,434;1067;1096;2172,4347;5756;5784;5813;5851;5880,617,2.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D,"DARPP-32 events;G alpha (s) signalling events;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-180024;R-HSA-418555;R-HSA-9860927,Phosphodiesterase 4 inhibitor,MONDO_0005301,multiple sclerosis,3,4,3,1
CHEMBL632,BETAMETHASONE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,True,True,True,38,730;2039;5954;7858;7995;8061;8132;8198;8264,162,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0005752,eye inflammation,3,1,9,1
CHEMBL635,PREDNISONE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,True,True,True,6,698;2007;5922;7826;7963;8029;8100;8166;8232,163,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL637,VENLAFAXINE,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,True,False,False,1272,,,4.0,Completed,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL639,AZELASTINE,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,True,True,False,971,6601,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005751,eye allergy,2,1,1,0
CHEMBL643,PROMETHAZINE,CC(CN1c2ccccc2Sc2ccccc21)N(C)C,True,True,False,988,6618,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL644,TRIMIPRAMINE,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21,True,True,False,395;991;1495;1853,858;6520;6621;6720,,4.0,Unknown status,ADRA1A;ADRA1B;ADRA1D;HRH1,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,MONDO_0002009;MONDO_0002050,depressive disorder;major depressive disorder,2,4,3,0
CHEMBL646,TRIAZOLAM,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,True,False,True,496;1420;1644;1696;2053;2103;2457,,244,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004698,insomnia,2,7,0,2
CHEMBL647,APRACLONIDINE,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1,True,True,False,1337;1390;2536,908;961;1012;1065;1116;1168;1221;1400;1453;1504,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,MONDO_0005041,glaucoma,2,3,6,0
CHEMBL648,CYCLIZINE,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,True,True,False,1007,6637,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL650,METHYLPREDNISOLONE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12,True,True,True,7,699;2008;5923;7827;7964;8030;8101;8167;8233,198,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL651,METHADONE,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,True,True,False,269,239;1273;7186,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL654,MIRTAZAPINE,CN1CCN2c3ncccc3Cc3ccccc3C2C1,True,True,True,1332;1379;2530,903;950;1007;1054;1111;1163;1210;1395;1442;1499,678,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,Serotonin 2a (5-HT2a) receptor antagonist,EFO_0004698,insomnia,3,3,6,1
CHEMBL655,MIDAZOLAM,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,True,False,True,482;1411;1634;1680;2040;2086;2450,,281,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000474,epilepsy,2,7,0,2
CHEMBL656,OXYCODONE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,True,True,True,270,240;1274;7187,658,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL657,DIPHENHYDRAMINE,CN(C)CCOC(c1ccccc1)c1ccccc1,True,True,False,989,6619,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,HP_0000989,Pruritus,2,1,1,0
CHEMBL658,SUFENTANIL,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,True,True,False,324,294;1328;7241,,3.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0000546,injury,2,1,3,0
CHEMBL660,AMANTADINE,NC12CC3CC(CC(C3)C1)C2,True,True,False,711;1609;1958;2183;2604;2648;2672,3617;6801;6828;6855;6888;7046;7073;7100;7127,,4.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,MONDO_0005180,Parkinson disease,2,7,9,0
CHEMBL661,ALPRAZOLAM,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,True,False,True,484;1413;1636;1682;2044;2090;2451,,245,4.0,Completed;Terminated,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004262,panic disorder,2,7,0,2
CHEMBL6622,ISOSORBIDE DINITRATE,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],True,True,True,66,7682,238,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL668,PROTRIPTYLINE,CNCCCC1c2ccccc2C=Cc2ccccc21,True,False,False,1277,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
CHEMBL679,EPINEPHRINE,CNC[C@H](O)c1ccc(O)c(O)c1,True,True,False,356;1304;1363;1472;1832;2511,819;875;934;979;1038;1083;1135;1194;1367;1426;1471;6481;6681,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL68055,ACOLBIFENE,CC1=C(c2ccc(O)cc2)[C@H](c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21,True,False,False,2316,,,2.0,Completed,ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL681,ETOMIDATE,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,True,False,False,508;1437;1522;1661;1707;1748;1781;1802;1875;1936;2068;2114;2475;2561;2584;2632,,,3.0,Withdrawn,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,,,,EFO_0000537,hypertension,1,16,0,0
CHEMBL685,MEBENDAZOLE,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,False,False,True,,,42,,,,,,Tubulin inhibitor,,,1,0,0,1
CHEMBL686,MEFENAMIC ACID,Cc1cccc(Nc2ccccc2C(=O)O)c1C,True,True,True,135;929,358;4476;5569;5629;5685;6069;6143;6217;6291;6365;6439,147,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL688,FENTANYL CITRATE,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,True,True,271,241;1275;7188,637,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,Mu opioid receptor agonist,EFO_0003843,pain,3,1,3,1
CHEMBL690,PRAVASTATIN SODIUM,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+],True,True,True,734,7613;7628;7643;7658,43,4.0,,HMGCR,Activation of gene expression by SREBF (SREBP);Cholesterol biosynthesis;EGR2 and SOX10-mediated initiation of Schwann cell myelination;PPARA activates gene expression,R-HSA-191273;R-HSA-1989781;R-HSA-2426168;R-HSA-9619665,HMG-CoA reductase inhibitor,EFO_0000319,cardiovascular disease,3,1,4,1
CHEMBL691,ETHINYL ESTRADIOL,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,True,False,False,2280,,,4.0,,ESR1,,,,EFO_0000616,neoplasm,1,1,0,0
CHEMBL70,MORPHINE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,True,True,False,272,242;1276;7189,,4.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL704,MESALAMINE,Nc1ccc(O)c(C(=O)O)c1,True,True,True,108;895,331;4449;5535;5595;5658;6042;6116;6190;6264;6338;6412,148,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000729,ulcerative colitis,3,2,10,1
CHEMBL70418,CLOBAZAM,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,True,False,True,489;1417;1652;1697;2050;2108;2463,,246,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230,anxiety,2,7,0,2
CHEMBL705,ALITRETINOIN,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,True,True,False,181;1762;1889,5983;6009;6018,,4.0,,RARA;RARB;RARG,Activation of anterior HOX genes in hindbrain development during early embryogenesis;Nuclear Receptor transcription pathway;Signaling by Retinoic Acid,R-HSA-383280;R-HSA-5617472,,EFO_0000558,Kaposi's sarcoma,2,3,3,0
CHEMBL707,DOXAZOSIN,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,True,True,False,376;1480;1839,839;6501;6701,,4.0,Completed;Unknown status,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000537,hypertension,2,3,3,0
CHEMBL709,ALFUZOSIN,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC,True,True,False,362;1454;1825,825;6487;6687,,4.0,Completed,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,3,3,0
CHEMBL71,CHLORPROMAZINE,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,False,False,True,,,657,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL715,OLANZAPINE,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,False,False,True,,,679,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL723,CARVEDILOL,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,True,True,False,370;1473;1820,833;6495;6695,,4.0,,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000319,cardiovascular disease,2,3,3,0
CHEMBL729,LOPINAVIR,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,False,False,True,,,389,,,,,,Human immunodeficiency virus type 1 protease inhibitor,,,1,0,0,1
CHEMBL730,NITROGLYCERIN,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],True,True,True,67,7683,218,4.0,,GUCY1B1,Smooth Muscle Contraction,R-HSA-445355,Soluble guanylate cyclase activator,EFO_0000319,cardiovascular disease,3,1,1,1
CHEMBL73451,MEQUITAZINE,c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2,True,True,False,1018,6648,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL738,THIOPENTAL SODIUM,CCCC(C)C1(CC)C(=O)[N-]C(=S)NC1=O.[Na+],True,False,True,1534;1760;2595,,262,1.0,Completed,GABRB1;GABRB2;GABRB3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_1001454,amnesia,2,3,0,2
CHEMBL742,KETAMINE,CNC1(c2ccccc2Cl)CCCCC1=O,True,True,False,715;1614;1959;2186;2607;2653;2677,3621;6805;6832;6859;6892;7050;7077;7104;7131,,3.0,"Active, not recruiting;Not yet recruiting;Withdrawn",GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,EFO_0000474;EFO_0000546,epilepsy;injury,2,7,9,0
CHEMBL74355,VOLINANSERIN,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,False,False,True,,,696,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL753,PHENOXYBENZAMINE,CC(COc1ccccc1)N(CCCl)Cc1ccccc1,True,True,False,358;1305;1356;1464;1833;2504,821;876;927;980;1031;1084;1136;1187;1368;1419;1472;6483;6683,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,6,8,0
CHEMBL75435,DEXKETOPROFEN,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,True,True,True,136;913,359;4477;5553;5613;5686;6070;6144;6218;6292;6366;6440,165,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL761,NAPHAZOLINE,c1ccc2c(CC3=NCCN3)cccc2c1,True,True,False,384;1329;1385;1491;1851;2532,847;900;956;1004;1060;1108;1160;1216;1392;1448;1496;6509;6709,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0005751,eye allergy,2,6,8,0
CHEMBL762,OXYMETAZOLINE,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,True,True,False,385;1334;1386;1492;1852;2526,848;905;957;1009;1061;1113;1165;1217;1397;1449;1501;6510;6710,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0005751,eye allergy,2,6,8,0
CHEMBL76222,REBIMASTAT,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,True,True,True,617;623;631,29;34;46;53;58;70;84;89;101;115;129;234;3030,356,2.0,Completed,MMP1;MMP13;MMP8,Activation of Matrix Metalloproteinases;Basigin interactions;Collagen degradation;Degradation of the extracellular matrix;Interleukin-4 and Interleukin-13 signaling;Neutrophil degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-1442490;R-HSA-1474228;R-HSA-1592389;R-HSA-381426;R-HSA-6785807;R-HSA-6798695,Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 8 inhibitor | Matrix metalloproteinase-1 inhibitor,EFO_0000673,prostate adenocarcinoma,3,3,7,1
CHEMBL770,TOLAZOLINE,c1ccc(CC2=NCCN2)cc1,True,True,False,359;745;949;1306;1364;1474;1821;2505,822;877;935;981;1039;1085;1137;1195;1369;1427;1473;5814;6484;6579;6684,,4.0,,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;HRH1;HRH2,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (12/13) signalling events;G alpha (i) signalling events;G alpha (q) signalling events;G alpha (s) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-416476;R-HSA-418555;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000319,cardiovascular disease,2,8,9,0
CHEMBL778,DEXMEDETOMIDINE,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,True,True,False,1340;1392;2539,911;963;1015;1067;1119;1171;1223;1403;1455;1507,,3.0,Recruiting,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000546,injury,2,3,6,0
CHEMBL779,TADALAFIL,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O,True,True,True,869,7669;7696;7709,444,4.0,,PDE5A,RHOBTB1 GTPase cycle;Smooth Muscle Contraction;cGMP effects,R-HSA-418457;R-HSA-445355;R-HSA-9013422,Phosphodiesterase 5A inhibitor,EFO_0000284,benign prostatic hyperplasia,3,1,3,1
CHEMBL781,MAZINDOL,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21,True,False,False,1239,,,4.0,,SLC6A4,,,,EFO_0001073,obesity,1,1,0,0
CHEMBL786,TAMOXIFEN CITRATE,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,True,False,False,2297,,,4.0,,ESR1,,,,MONDO_0007254,breast cancer,1,1,0,0
CHEMBL787,MONTELUKAST,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,True,True,False,1228,618;6575,,4.0,Unknown status,CYSLTR1,G alpha (q) signalling events;Potential therapeutics for SARS,R-HSA-416476;R-HSA-9679191,,EFO_0003956,seasonal allergic rhinitis,2,1,2,0
CHEMBL80,NALOXONE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,True,True,False,316,286;1320;7233,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,HP_0002019,Constipation,2,1,3,0
CHEMBL803,CYTARABINE,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,False,False,True,,,405,,,,,,RNA inhibitor,,,1,0,0,1
CHEMBL806,FLUTAMIDE,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,True,True,True,544,1967;5882;7786,73,4.0,,AR,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors,R-HSA-3371497;R-HSA-383280;R-HSA-4090294,Androgen Receptor antagonist,EFO_0000313,carcinoma,3,1,3,1
CHEMBL807,MEMANTINE,CC12CC3CC(C)(C1)CC(N)(C3)C2,True,True,False,709;1607;1952;2179;2600;2644;2669,3615;6799;6826;6853;6886;7044;7071;7098;7125,,4.0,Completed,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,HP_0000726,Dementia,2,7,9,0
CHEMBL809,SERTRALINE,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,True,False,False,1273,,,4.0,Terminated,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL811,BROMPHENIRAMINE,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,True,True,False,1019,6649,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL813,EPROSARTAN,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,True,True,False,582,6536;7155;7266;7286,,4.0,,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,,EFO_0000319,cardiovascular disease,2,1,4,0
CHEMBL814,FLUVOXAMINE,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,True,False,False,1274,,,4.0,Unknown status,SLC6A4,,,,MONDO_0002050,depressive disorder,1,1,0,0
CHEMBL82301,VICRIVIROC,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,True,True,False,217,1259;4376;6758;6782,,3.0,Completed,CCR5,Binding and entry of HIV virion;Chemokine receptors bind chemokines;G alpha (i) signalling events;Interleukin-10 signaling,R-HSA-173107;R-HSA-380108;R-HSA-418594;R-HSA-6783783,,EFO_0000764,HIV infection,2,1,4,0
CHEMBL829,METHYLPROMAZINE,CC(CN(C)C)CN1c2ccccc2Sc2ccccc21,True,True,False,1008,6638,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL83,TAMOXIFEN,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,True,False,False,2281,,,4.0,,ESR1,,,,EFO_0000616,neoplasm,1,1,0,0
CHEMBL831,LOXAPINE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,False,False,True,,,659,,,,,,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL833,TICLOPIDINE,Clc1ccccc1CN1CCc2sccc2C1,True,True,False,470,1355,,4.0,,P2RY12,G alpha (i) signalling events,R-HSA-418594,,HP_0004419,Recurrent thrombophlebitis,2,1,1,0
CHEMBL836,TAMSULOSIN,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,True,True,False,348;1455;1810,811;6473;6673,,4.0,Completed,ADRA1A;ADRA1B;ADRA1D,Adrenoceptors;G alpha (12/13) signalling events;G alpha (q) signalling events,R-HSA-390696;R-HSA-416476;R-HSA-418597,,EFO_0000284,benign prostatic hyperplasia,2,3,3,0
CHEMBL838,BENAZEPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,True,True,False,645,441,,4.0,,ACE,Metabolism of Angiotensinogen to Angiotensins,R-HSA-2022377,,EFO_0000319,cardiovascular disease,2,1,1,0
CHEMBL841,LOPERAMIDE,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,True,True,False,327,297;1331;7244,,3.0,Completed,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003060,non-small cell lung carcinoma,2,1,3,0
CHEMBL844,BRIMONIDINE,Brc1c(NC2=NCCN2)ccc2nccnc12,True,True,False,1330;1383;2533,901;954;1005;1058;1109;1161;1214;1393;1446;1497,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0005751,eye allergy,2,3,6,0
CHEMBL846,CALCITRIOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,True,True,True,238,5991;7768;7886,20,4.0,Completed,VDR,Nuclear Receptor transcription pathway;SUMOylation of intracellular receptors;Vitamin D (calciferol) metabolism,R-HSA-196791;R-HSA-383280;R-HSA-4090294,Vitamin D receptor agonist,EFO_0000676,psoriasis,3,1,3,1
CHEMBL85,RISPERIDONE,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,False,False,True,,,677,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL855,TRIPROLIDINE,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1,True,True,False,1009,6639,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL856,PRIMIDONE,CCC1(c2ccccc2)C(=O)NCNC1=O,True,False,True,1508;1736;2570,,265,4.0,,GABRB1;GABRB2;GABRB3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0000474,epilepsy,2,3,0,2
CHEMBL862,GUANFACINE,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,True,True,False,1313;1365;2512,884;936;988;1040;1092;1144;1196;1376;1428;1480,,4.0,,ADRA2A;ADRA2B;ADRA2C,"Adrenaline signalling through Alpha-2 adrenergic receptor;Adrenaline,noradrenaline inhibits insulin secretion;Adrenoceptors;G alpha (i) signalling events;G alpha (z) signalling events;Surfactant metabolism",R-HSA-390696;R-HSA-392023;R-HSA-400042;R-HSA-418594;R-HSA-418597;R-HSA-5683826,,EFO_0000537,hypertension,2,3,6,0
CHEMBL864,CARBINOXAMINE,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,True,True,False,1010,6640,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL865,VALDECOXIB,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,True,True,False,104,327;4445;5654;6038;6112;6186;6260;6334;6408,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL877,TRANEXAMIC ACID,NC[C@H]1CC[C@H](C(=O)O)CC1,True,True,True,680,73;104;131;454,717,4.0,,PLG,Activation of Matrix Metalloproteinases;Degradation of the extracellular matrix;Platelet degranulation;Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),R-HSA-114608;R-HSA-1474228;R-HSA-1592389;R-HSA-381426,Plasminogen inhibitor,HP_0000132,Menorrhagia,3,1,4,1
CHEMBL895,NALBUPHINE,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,True,True,False,273,243;1277;7190,,4.0,Unknown status,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL896,HYDROXYZINE,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,True,True,False,976,6606,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0005230,anxiety,2,1,1,0
CHEMBL898,DIFLUNISAL,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,True,True,True,116;900,339;4457;5540;5600;5666;6050;6124;6198;6272;6346;6420,126,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0000685,rheumatoid arthritis,3,2,10,1
CHEMBL90,HISTAMINE,NCCc1c[nH]cn1,True,True,False,1022,6652,,3.0,Unknown status,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000389,cutaneous melanoma,2,1,1,0
CHEMBL900,ORPHENADRINE,Cc1ccccc1C(OCCN(C)C)c1ccccc1,True,True,False,721;1033;1620;1965;2192;2612;2657;2682,3627;6663;6811;6838;6865;6898;7056;7083;7110;7137,,3.0,Unknown status,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;HRH1,"Assembly and cell surface presentation of NMDA receptors;EPHB-mediated forward signaling;G alpha (q) signalling events;Long-term potentiation;Negative regulation of NMDA receptor-mediated neuronal transmission;Neurexins and neuroligins;RAF/MAP kinase cascade;Ras activation upon Ca2+ influx through NMDA receptor;Synaptic adhesion-like molecules;Unblocking of NMDA receptors, glutamate binding and activation",R-HSA-3928662;R-HSA-416476;R-HSA-438066;R-HSA-442982;R-HSA-5673001;R-HSA-6794361;R-HSA-8849932;R-HSA-9609736;R-HSA-9617324;R-HSA-9620244,,HP_0003419,Low back pain,2,8,10,0
CHEMBL902,FAMOTIDINE,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,True,True,True,746,5815,718,4.0,,HRH2,G alpha (s) signalling events,R-HSA-418555,Histamine H2 receptor antagonist,EFO_0000685,rheumatoid arthritis,3,1,1,1
CHEMBL90555,VINCRISTINE,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,True,True,False,814;1549;1985;2227;2325;2395;2697;2765;2826,1527;1591;1655;1719;1783;1847;1911;2076;2140;2204;2268;2332;2396;2460;2524;2588;2652;2716;2780;2844;2908;2972;3042;3106;3170;3234;3298;3362;3426;3490;3554;3645;3709;3773;3837;3901;3965;4032,,4.0,,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000616,neoplasm,2,9,38,0
CHEMBL908,CHLORPROTHIXENE,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21,False,False,True,,,680,,,,,,Serotonin 2a (5-HT2a) receptor antagonist,,,1,0,0,1
CHEMBL911,ZOLPIDEM,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,True,False,False,1663;1751,,,3.0,Completed,GABRB1;GABRG2,,,,EFO_0003888,attention deficit hyperactivity disorder,1,2,0,0
CHEMBL91397,RUPATADINE,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,True,True,False,1024,6654,,3.0,Recruiting,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0000685,rheumatoid arthritis,2,1,1,0
CHEMBL914,FEXOFENADINE,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,True,True,False,1011,6641,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL9194,ATRASENTAN,CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,True,False,False,1917,,,3.0,Terminated,EDNRA,,,,EFO_0000401,diabetic nephropathy,1,1,0,0
CHEMBL92,DOCETAXEL ANHYDROUS,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,True,True,False,823;1557;1991;2230;2335;2400;2707;2770;2834,1536;1600;1664;1728;1792;1856;1920;2085;2149;2213;2277;2341;2405;2469;2533;2597;2661;2725;2789;2853;2917;2981;3051;3115;3179;3243;3307;3371;3435;3499;3563;3654;3718;3782;3846;3910;3974;4041,,3.0,"Active, not recruiting;Completed;Not yet recruiting;Recruiting",TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_0000178;EFO_0000181;EFO_0000196;EFO_0000199,gastric carcinoma;head and neck squamous cell carcinoma;metastatic prostate cancer;oral squamous cell carcinoma,2,9,38,0
CHEMBL931,HALOTHANE,FC(F)(F)C(Cl)Br,False,False,True,,,282,,,,,,GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,,,1,0,0,2
CHEMBL932,DIPYRIDAMOLE,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,True,True,True,411;871;1044;1072;2149,4323;5733;5761;5789;5828;5856;7671;7698;7711,720,4.0,Completed,PDE4A;PDE4B;PDE4C;PDE4D;PDE5A,"DARPP-32 events;G alpha (s) signalling events;RHOBTB1 GTPase cycle;Smooth Muscle Contraction;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;cGMP effects",R-HSA-180024;R-HSA-418457;R-HSA-418555;R-HSA-445355;R-HSA-9013422;R-HSA-9860927,"3',5'-cyclic phosphodiesterase inhibitor | Equilibrative nucleoside transporter 1 inhibitor",EFO_0000712,stroke,3,5,6,1
CHEMBL93645,ACECLOFENAC,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,True,True,False,117,340;4458;5667;6051;6125;6199;6273;6347;6421,,4.0,,PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,,EFO_0000685,rheumatoid arthritis,2,1,9,0
CHEMBL940,GABAPENTIN,NCC1(CC(=O)O)CCCCC1,True,False,False,2490,,,4.0,,CACNA2D1,,,,EFO_0000474,epilepsy,1,1,0,0
CHEMBL94081,ALCLOFENAC,C=CCOc1ccc(CC(=O)O)cc1Cl,True,True,False,914,5554;5614,,4.0,,PTGS1,COX reactions;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2162123,,EFO_0005755,rheumatic disease,2,1,2,0
CHEMBL941,IMATINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,True,True,False,1113;1156;1209;2205,561;4300;6973;7011;7507,,3.0,"Active, not recruiting;Recruiting",ABL1;BCR;KIT;PDGFRB,"RAF/MAP kinase cascade;Signaling by SCF-KIT;TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-1433557;R-HSA-5673001;R-HSA-8866910;R-HSA-9860927,,EFO_0000209;EFO_0000220,T-cell acute lymphoblastic leukemia;acute lymphoblastic leukemia,2,4,4,0
CHEMBL94454,MIZOLASTINE,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,True,True,False,1020,6650,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL946,AZATADINE,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,True,True,False,1021,6651,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,MONDO_0005271,allergic disease,2,1,1,0
CHEMBL94657,PATUPILONE,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,True,True,False,835;1568;2003;2241;2346;2410;2717;2781;2845,1548;1612;1676;1740;1804;1868;1932;2097;2161;2225;2289;2353;2417;2481;2545;2609;2673;2737;2801;2865;2929;2993;3063;3127;3191;3255;3319;3383;3447;3511;3575;3666;3730;3794;3858;3922;3986;4053,,3.0,Completed,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,EFO_1001100;MONDO_0002158,fallopian tube cancer;peritoneal neoplasm,2,9,38,0
CHEMBL954,ENCLOMIPHENE,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1,True,False,False,2300,,,3.0,Unknown status,ESR1,,,,EFO_0000660,polycystic ovary syndrome,1,1,0,0
CHEMBL956,SUPROFEN,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1,True,True,True,148;915,371;4489;5555;5615;5698;6082;6156;6230;6304;6378;6452,150,4.0,,PTGS1;PTGS2,Biosynthesis of DHA-derived SPMs;Biosynthesis of DPAn-3 SPMs;Biosynthesis of EPA-derived SPMs;Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives;COX reactions;Interleukin-10 signaling;Interleukin-4 and Interleukin-13 signaling;Nicotinamide salvaging;Synthesis of 15-eicosatetraenoic acid derivatives;Synthesis of Prostaglandins (PG) and Thromboxanes (TX),R-HSA-140180;R-HSA-2142770;R-HSA-2162123;R-HSA-6783783;R-HSA-6785807;R-HSA-73614;R-HSA-9018677;R-HSA-9018679;R-HSA-9025094;R-HSA-9027604,Cyclooxygenase inhibitor,EFO_0005755,rheumatic disease,3,2,10,1
CHEMBL957,BOSENTAN,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,True,False,False,1910,,,4.0,,EDNRA,,,,EFO_0000537,hypertension,1,1,0,0
CHEMBL960,LEFLUNOMIDE,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,False,False,True,,,721,,,,,,Dihydroorotate dehydrogenase inhibitor,,,1,0,0,1
CHEMBL96172,EPOTHILONE D,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1,True,True,False,858;1589;2026;2264;2369;2433;2739;2804;2868,1571;1635;1699;1763;1827;1891;1955;2120;2184;2248;2312;2376;2440;2504;2568;2632;2696;2760;2824;2888;2952;3016;3086;3150;3214;3278;3342;3406;3470;3534;3598;3689;3753;3817;3881;3945;4009;4076,,2.0,Completed;Terminated,TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,AURKA Activation by TPX2;Activation of AMPK downstream of NMDARs;Aggrephagy;Anchoring of the basal body to the plasma membrane;Assembly and cell surface presentation of NMDA receptors;COPI-dependent Golgi-to-ER retrograde traffic;COPI-independent Golgi-to-ER retrograde traffic;COPI-mediated anterograde transport;Carboxyterminal post-translational modifications of tubulin;Cilium Assembly;EML4 and NUDC in mitotic spindle formation;Formation of tubulin folding intermediates by CCT/TriC;Gap junction assembly;HCMV Early Events;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Hedgehog 'off' state;Intraflagellar transport;Kinesins;Loss of Nlp from mitotic centrosomes;Loss of proteins required for interphase microtubule organization from the centrosome;MHC class II antigen presentation;Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;Mitotic Prometaphase;Neutrophil degranulation;PKR-mediated signaling;Post-chaperonin tubulin folding pathway;Prefoldin mediated transfer of substrate to CCT/TriC;RHO GTPases Activate Formins;RHO GTPases activate IQGAPs;Recruitment of NuMA to mitotic centrosomes;Recruitment of mitotic centrosome proteins and complexes;Recycling pathway of L1;Regulation of PLK1 Activity at G2/M Transition;Resolution of Sister Chromatid Cohesion;Sealing of the nuclear envelope (NE) by ESCRT-III;Separation of Sister Chromatids;The role of GTSE1 in G2/M progression after G2 checkpoint;Translocation of SLC2A4 (GLUT4) to the plasma membrane,R-HSA-1445148;R-HSA-190840;R-HSA-190861;R-HSA-2132295;R-HSA-2467813;R-HSA-2500257;R-HSA-2565942;R-HSA-3371497;R-HSA-380259;R-HSA-380270;R-HSA-380284;R-HSA-380320;R-HSA-389957;R-HSA-389960;R-HSA-389977;R-HSA-437239;R-HSA-5610787;R-HSA-5617833;R-HSA-5620912;R-HSA-5620924;R-HSA-5626467;R-HSA-5663220;R-HSA-6798695;R-HSA-6807878;R-HSA-6811434;R-HSA-6811436;R-HSA-68877;R-HSA-8852276;R-HSA-8854518;R-HSA-8955332;R-HSA-9609690;R-HSA-9609736;R-HSA-9619483;R-HSA-9646399;R-HSA-9648025;R-HSA-9668328;R-HSA-983189;R-HSA-9833482,,MONDO_0005575;MONDO_0008315;MONDO_0008903,colorectal cancer;lung cancer;prostate cancer,2,9,38,0
CHEMBL963,OXYMORPHONE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,True,True,False,306,276;1310;7223,,4.0,,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,EFO_0003843,pain,2,1,3,0
CHEMBL967,TEMAZEPAM,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,True,False,True,491;1421;1651;1689;2058;2097;2458,,266,4.0,Completed,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0004698,insomnia,2,7,0,2
CHEMBL968,FLURAZEPAM,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,True,False,False,514;1440;1666;1713;2073;2119;2477,,,3.0,Terminated,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,,EFO_0005230,anxiety,1,7,0,0
CHEMBL969,PRAZEPAM,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,True,False,True,497;1418;1653;1688;2051;2104;2464,,267,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230,anxiety,2,7,0,2
CHEMBL970,HALAZEPAM,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F,True,False,True,498;1419;1643;1698;2052;2096;2465,,283,4.0,,GABRA1;GABRA2;GABRA3;GABRA5;GABRG1;GABRG2;GABRG3,,,GABA-A receptor; anion channel positive allosteric modulator,EFO_0005230,anxiety,2,7,0,2
CHEMBL971,PENTOBARBITAL SODIUM,CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+],False,False,True,,,268,,,,,,GABA-A receptor; anion channel positive allosteric modulator,,,1,0,0,2
CHEMBL973,TERIFLUNOMIDE,C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,False,False,True,,,722,,,,,,Dihydroorotate dehydrogenase inhibitor,,,1,0,0,1
CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O,True,True,False,53,745;2054;5969;7873;8010;8076;8147;8213;8279,,3.0,Completed,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,,EFO_0006834,septic shock,2,1,9,0
CHEMBL979,MEPROBAMATE,CCCC(C)(COC(N)=O)COC(N)=O,True,False,False,493;1514;1691;1740;1774;1930;2059;2105;2577,,,4.0,,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3,,,,EFO_0005230;EFO_0006788,anxiety;anxiety disorder,1,9,0,0
CHEMBL982,NALMEFENE,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,True,True,False,323,293;1327;7240,,4.0,Terminated,OPRM1,G alpha (i) signalling events;Interleukin-4 and Interleukin-13 signaling;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-418594;R-HSA-6785807,,MONDO_0007079,alcohol dependence,2,1,3,0
CHEMBL989,FLUOCINOLONE ACETONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,True,True,True,13,705;2014;5929;7833;7970;8036;8107;8173;8239,219,4.0,,NR3C1,"Circadian Clock;FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;Nuclear Receptor transcription pathway;PTK6 Expression;Potential therapeutics for SARS;Regulation of NPAS4 gene transcription;Regulation of RUNX2 expression and activity;SUMOylation of intracellular receptors",R-HSA-3371497;R-HSA-383280;R-HSA-4090294;R-HSA-8849473;R-HSA-8939902;R-HSA-9615017;R-HSA-9679191;R-HSA-9768777,Glucocorticoid receptor agonist,EFO_0000274,atopic eczema,3,1,9,1
CHEMBL995,LOSARTAN POTASSIUM,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+],True,True,True,586,6540;7159;7270;7290,2,4.0,Completed,AGTR1,Cargo recognition for clathrin-mediated endocytosis;Clathrin-mediated endocytosis;G alpha (q) signalling events;Peptide ligand-binding receptors,R-HSA-375276;R-HSA-416476;R-HSA-8856825;R-HSA-8856828,Type-1 angiotensin II receptor antagonist,EFO_0000537,hypertension,3,1,4,1
CHEMBL9960,AZD-7624,CC[C@H](NC(=O)c1cc(-c2ccccc2)nc2ccccc12)c1ccccc1,False,False,True,,,72,,,,,,MAP kinase p38 alpha inhibitor,,,1,0,0,1
CHEMBL998,LORATADINE,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,True,True,False,962,6592,,4.0,,HRH1,G alpha (q) signalling events,R-HSA-416476,,EFO_0003956,seasonal allergic rhinitis,2,1,1,0
CHEMBL99946,LEVOMILNACIPRAN,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN,True,False,False,1280,,,4.0,,SLC6A4,,,,MONDO_0002009,major depressive disorder,1,1,0,0
